A PRO-INFLAMMATORY PROGRAM DRIVEN BY EGFR ACTIVATION IN EPITHELIAL OVARIAN CANCER by C. Alberti
UNIVERSITÀ DEGLI STUDI DI MILANO 
Scuola di Dottorato in Scienze Biologiche e Molecolari 
XXV Ciclo 
A pro-inflammatory program driven by EGFR activation 
in epithelial ovarian cancer 
SDD: MED16, BIO11 
Chiara Alberti 
PhD Thesis 
Scientific tutor: Dr. Antonella Tomassetti 
Thesis performed at Fondazione IRCCS Istituto Nazionale per lo studio e 
la cura dei tumori di Milano, DipartimentoOncologia sperimentale e 
Medicina Molecolare, Unita’ di Terapie molecolari
Academic year: 2011-2012 

Chiara Alberti 
Contents 
PART I ...................................................................................................... 1
ABSTRACT .............................................................................................. 3
STATE OF ART ....................................................................................... 5
1. CLINICAL MANAGEMENT OF OVARIAN CANCER ............................... 5 
2. TYPE I AND TYPE II OVARIAN CANCER ............................................. 6 
3. HISTOLOGICAL SUBTYPES AND ORIGINS OF EOCS ........................... 7 
3.1 Serous EOCs ................................................................................ 8
3.2 Mucinous EOCs ............................................................................ 8
3.3 Endometrioid EOCs ..................................................................... 8
3.4 Clear Cell EOCs ........................................................................... 9
4. PATTERN OF SPREAD OF EOC ......................................................... 10 
5. INFLAMMATION AND OVARIAN CANCER .......................................... 12 
5.1 IL-6 and cancer .......................................................................... 13
5.2 IL-6 and EOC ............................................................................. 16
6. EPIDERMAL GROWTH FACTOR RECEPTOR .................................... 18 
6.1 EGFR and EOC .......................................................................... 20
6.2 Endocytosis and recycling of EGFR .......................................... 21
6.3 EGFR activation in EOC ............................................................ 23
7. EGFR TARGETED THERAPIES ......................................................... 25 
7.1 Anti-EGFR monoclonal antibodies ............................................ 26
7.2 Tyrosine kinase inibitors ............................................................ 27
AIM OF THE PROJECT ...................................................................... 30
SECTION 1 - THE ROLE OF EGFR IN THE PROGRESSION OF 
EOCS. ...................................................................................................... 31
RESULTS AND DISCUSSION .................................................................. 31 
1.1 IGROV1 and OAW42 EOC cell lines express the highest levels of 
EGFR with the major release of IL-6 ............................................... 31
1.2 EGFR phosphorylation is not a predictor of sensitivity to anti-
EGFR compounds ............................................................................ 33
1.3 EGFR activation induces IL-6 releasing in EOC cell lines ....... 34
1.4 Ligand dependent EGFR activation induce NF-kB 
transcriptional activation ................................................................. 35
1.5 Ligand-dependent EGFR activation induces the release of 
specific inflammatory molecules through NF-kB activation ............ 38
1.6 EGFR silencing inhibits the expression of IL-6 and PAI-1 ........ 40
1.7 The expression of IL-6 and PAI-1 in EOC samples ................... 41
A pro-inflammatory program driven by EGFR activation in the epithelial ovarian cancer
1.8 The analysis of IL-6 and PAI-1 in EOC publicly available 
datasets ............................................................................................. 42
CONCLUSIONS AND FUTURE PROSPECTS ............................................ 43 
SECTION 2 - CHARACTERIZATION OF IL-6 AND EGFR 
EXPRESSING EOCS ............................................................................ 45
RESULTS AND DISCUSSION .................................................................. 45 
2.1 IL-6 correlated genes ................................................................. 45
2.2 Identification of an IL-6 correlated gene signature specific for 
advanced-stage EOCs ...................................................................... 46
2.3 IL-6-correlated gene signature is associated to growth factor 
response in EOC. .............................................................................. 46
2.4 Validation in vitro of some of the 40 IL-6-correlated genes. ..... 47
2.5 The biological role of IL-6 in EOC ............................................ 48
CONCLUSIONS AND FUTURE PROSPECTS ............................................ 50 
SECTION 3 ............................................................................................. 53
RESULTS AND DISCUSSION ................................................................... 53 
3.1 The biological role of PAI-1 in EOC ......................................... 53
CONCLUSIONS AND FUTURE PROSPECTS ............................................ 57 
FIGURES ................................................................................................ 59
REFERENCES ....................................................................................... 83
ACKNOWLEDGEMENTS ................................................................. 100
PART II ................................................................................................. 101
Published PAPER I 
Revised Version Submitted PAPER II  
Chiara Alberti
1 
PART I 
A pro-inflammatory program driven by EGFR activation in the epithelial ovarian cancer
2 
Chiara Alberti
3 
Abstract 
Epithelial Ovarian Cancer (EOC) is the leading cause of death from gynecology 
cancer. Initially EOCs are characterized by local growth mass. In advanced-
stage, EOCs present an increased accumulation of ascites in the peritoneum. 
These ascites contain a variable numbers of tumor cells and inflammatory 
leukocytes, as well as, variable levels of cytokines and chemokines. The 
epidermal growth factor receptor (EGFR), a member of ErbB family of receptor 
tyrosine kinases (RTK), activates multiple signaling cascades that cause growth 
and invasion of tumor cells. In a homeostatic state, EGFR plays a key role in 
normal ovarian follicle development and cell growth regulation of the ovarian 
surface epithelium (OSE), whose cells might give rise to EOC. In EOC 
samples, EGFR is expressed in an estimated 10-70% of EOCs, and its altered 
expression is associated with advanced-stage disease and poor prognosis, but at 
the moment the EGFR signaling cascade has not yet been directly associated 
with induction of an inflammatory network. This thesis is aimed to assess in 
EOC whether the activation of EGFR could induce a pro-inflammatory 
program. High levels of interleukin-6 (IL-6) have been found in the ascites of 
EOC patients and correlate with shorter survival. In vitro analysis of EOC cell 
lines revealed that ligand-stimulated EGFR activated NFkB-dependent 
transcription and induced secretion of IL-6 and plasminogen activator inhibitor 
(PAI-1). Twelve of 23 primary EOC tumors from advanced-stage patients, with 
malignant ascites at surgery, co-expressed membrane EGFR, IL-6, and PAI-1 
by immunohistochemistry (IHC), and both IL-6 and PAI-1 were present in 83% 
of the corresponding ascites. Analysis of a publicly-available gene expression 
dataset from 204 EOCs confirmed a significant correlation between IL-6 and 
PAI-1 expression, and patients with the highest IL-6 and PAI-1 co-expression 
showed a significantly shorter progression-free survival time. All these data 
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suggests that EGFR/NFkB/IL-6-PAI-1 may have a significant impact on the 
therapy of a particular subset of EGFR-expressing EOCs, and that IL-6/PAI-1 
co-expression may be a novel prognostic marker. Subsequently, to analyze the 
role of IL-6 in EOC, we decided to perform a bioinformatic analysis of seven 
publicly available datasets of gene expression profile from EOC patients. We 
identified an IL-6-correlated gene signature in EOCs, containing 40 genes 
mainly associated with proliferation. Thirty-three of 40 genes were also 
significantly correlated in low malignant potential (LMP) EOCs, while 7 genes 
were IL-6-correlated only in advanced stage EOCs. Further analyses allowed us 
to identify, among the 40 genes, a gene set associated with ‘early growth factor 
response’ and a biological network related to ‘thrombosis and cardiovascular 
disease’ for the 7-gene signature. Accordingly, selected genes from the 
identified signatures were validated in vitro by real time RT-PCR in serous 
EOC cell lines upon stimulation with EGF. In vitro analyses to assess the 
biologic role of IL-6 showed that IL-6 produced by EGFR/MEK/NF-kB 
pathway, triggers an autocrine loop of ligand/EGFR activation through 
STAT3/src signalling. Subsequently, the role of PAI-1 in EOC cells has been 
analyzed. Experiments on PAI-1-silenced SKOV3 and OAW42 cells showed 
that the loss of PAI-1 affected cell adhesion to different substrates, as well as 
inhibited cell migration and invasion likely as inducer of epithelial 
mesenchymal transition (EMT) and regulator of EOC cells plasticity. 
Chiara Alberti
5 
State of Art 
EOC is the fifth leading cause of cancer death in women and is the most lethal 
gynaecological malignancy. Although 5-year survival rates can approach 90% 
for women who are diagnosed with tumor confined to the ovaries, 
approximately 70% of patients present disseminated disease. Early detection of 
EOC is limitated by the absence of specific clinical symptoms and diagnostic 
tests. The measurement of circulating levels of the ovarian tumor antigen of 
CA125 (Mucin16) is routinely used to follow the disease, but unfortunately it 
has not a sufficient specificity and sensitivity for population screening [Bast Jr.
et al. 2009]. The standard treatment for EOC is primary surgery, which usually 
includes total abdominal hysterectomy, bilateral salpingoophrectomy, 
omentectomy and lymphadenectomy in some cases, followed by adjuvant 
platinum-based chemotherapy with or without paclitaxel. Surgical debulking is 
an important prognostic factor and it is widely accepted that the volume of 
residual disease after primary surgery influences overall survival (OS). A 
significant contributor to the high mortality rate is that, despite good initial 
responses to chemotherapy, recurrence is common and often fatal. It is, 
therefore, imperative that research into ovarian cancer focuses on better 
treatments for intermediate and late stage disease in addition to identifying 
markers of disease progression. 
1. Clinical management of ovarian cancer 
The majority of women with EOC are diagnosed at advanced stage (III, IV). 
This late diagnosis is due to lack of screening and prognostic biological makers 
specific for this disease. Most patients present advanced-stage disease and 
require aggressive surgical tumor debulking followed by platinum and taxane-
based chemotherapy. Unfortunately, after the first chemotherapy line 70% of 
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patients recur within 12 and 18 months becoming a good candidate for a second 
chemotherapy line treatment. When the disease recurs in less than 6 months the 
patients are defined platinum resistant, and in this settings, other therapeutic 
options, like liposomal doxorubicin [Gordon et al. 2004], topotecan [ten Bokkel
et al. 1997] and paclitaxel [Markman and Walker 2006] could extend the 
progression free survival (PFS) time. A growing number of new molecular 
targeted drugs are now available and used as single agents or in combination 
with standard chemotherapy. At the moment, the most promising agents are 
PARP (Poly ADP-ribose polymerase) inhibitors, monoclonal antibodies and 
small molecules tyrosine kinase inhibitors [Baumann et al. 2012]. 
Unfortunately, the clinical response to these drugs is only partial; therefore new 
approaches to improving the treatment of EOC patients are urgently needed. 
2. Type I and Type II ovarian cancer 
EOC are heterogeneous neoplasms that are divided in: Type I and Type II on 
the basis of their molecular and clinopathologic features (Figure 1). Type I 
tumors comprise low grade serous carcinomas (LGSCs), low-grade 
endometrioid, clear cell and mucinous carcinomas. They originate from 
precursor lesions, endometriosis such as borderline tumors. The borderline 
tumors, identified as low malignant potential (LMP), comprise a group of 
tumors characterized by cellular proliferation and nuclear atypia but without 
stromal invasion [Morice et al. 2012]. Type I tumors, confined to one ovary 
(stage I) are indolents and with a good prognosis. 
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Figure 1. The histologic types of EOC and its associated genetic alterations [Kurman and Shih 
2011] 
They constitute only 25% of ovarian cancer with a 5 year survival of about 
55%. Type I tumors are associated with frequent KRAS, BRAF, CTNNB, 
PTEN and PI3Ca genetic alterations, with rare mutations in TP53 gene. Type II 
tumors comprise high grade serous Carcinomas (HGSCs) that are tumors with 
high cellular proliferation, frequent TP53 mutations and genetic defects as 
mutations and inactivations in BRCA1 and BRCA2 genes. Type II tumors 
represent approximately 75% of all ovarian carcinomas with a five year survival 
of about 30% [Kurman and Shih 2011]. 
3. Histological subtypes and origins of EOCs 
The EOC are primarily classified by cell types in: high grade serous, mucinous, 
endometroid and clear cells corresponding, according to the molecular 
(assessed by gene expression profile) and morphological features similar to 
those of the different epithelia in the organs of the female reproductive tract 
(Figure 2). 
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3.1 Serous EOCs 
Ovarian serous carcinoma is the most common type of EOC (30-70%). It 
derives from the cells that covers the surface of the ovary, named OSE cells, 
and/or from the distal fallopian tube, although the contribution of this two 
compartments to the origin of this type of tumor is not completely understood 
yet [Vaughan et al. 2011]. Serous ovarian carcinoma is widely disseminated at 
the time of diagnosis, often invades through the ovarian capsule and grows on 
the surface of the ovary [Chien et al. 2007]. 
3.2 Mucinous EOCs 
Mucinous tumors are EOCs formed by cells that resemble either those of the 
endocervical epithelium (endocervical or Mullerian type) or, more frequently, 
those of the intestinal epithelium (intestinal type). Malignant mucinous tumors 
represent 5-10% of all malignant ovarian neoplasms and one-third of them are 
bilateral. Late extra-peritoneal recurrences, particularly in the lungs, are 
characteristic of malignant mucinous EOCs [Chien et al. 2007]. 
3.3 Endometrioid EOCs 
Endometrioid tumors are EOCs formed by cells that resemble those of the 
endometrium. They may be associated with the aberrant presence of 
endometrium outside the uterus (endometriosis) and with overgrowth 
(hyperplasia) or cancer of the endometrium. These tumors represent the second 
most common malignant ovarian surface epithelial tumor type and are rarely 
bilateral. Most malignant endometrioid tumors are confined to the ovaries and 
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adjacent pelvic structures. Malignant endometrioid EOCs are considered to 
have a better prognosis than either mucinous or serous EOCs [Aris 2010]. 
3.4 Clear Cell EOCs 
Little is known about the development and progression of this type of EOC. 
Most of them are malignant and studies have shown that 5-10% of cases are 
associated with endometriod lesions. Two-thirds of all women with malignant 
clear cell tumors have never given birth, and 50-70% has endometriosis. They 
can be predominantly solid or cystic with one or more polypoid masses 
protruding into the lumen. Survival rates for clear cell carcinomas are poorer 
than for other surface EOCs [Kajihara et al. 2010]. 
Figure 2. The origins of ovarian cancer [Vaughan et al 2011].
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4. Pattern of spread of EOC
The main characteristic of the EOC progression is not the metastatic 
dissemination through the blood stream, as for other carcinomas, but into the 
peritoneal cavity. During the early stages of EOC metastatization, cells could 
detach from the primary tumor as free floating cells or multi-cellular aggregates 
(MCAs) (Figure 3), and tumor cells, as single cell or MCAs, have been found in 
EOC ascites [Hudson et al. 2008]. Tumor cells shedded from the primary tumor 
could interact with mesothelial cells, placed in the inner surface of the 
peritoneal cavity. Cell-cell and cell-matrix adhesion molecules could facilitate 
floating or anchoring of cells, giving secondary lesions to adjacent pelvic 
organs [Kenny et al. 2007]. 
Figure 3. The metastatization of EOC [Hudson et al 2008] 
In EOC, the peritoneal cavity is the microenvironmental niche in which are 
present tumor cells, inflammatory mediators, such as soluble factors produced 
by or in response to tumor cells. Among these, there are bioactive lipids, growth 
factors and extracellular matrix (ECM) components that together with floating 
Chiara Alberti
11 
and peritoneum attached tumor cells, regulate in a dynamic way the tumor 
microenvironment [Freedman et al. 2004;Mustea et al. 2008]. OSE cell 
integrity, unlike the other epithelia, is maintained by cell-cell adhesion through 
neural cadherins (N-cadherin) expression; however epithelial cadherin (E-
cadherin) is expressed in ovarian carcinoma precursors as well as clefts and 
inclusion cysts [Narod et al. 1991]. In most carcinomas the process of 
dissemination and metastasis is associated with the loss of normal cell-cell 
contacts, most typically characterized by loss of E-cadherin, but most EOCs 
have a behavior different from that of other carcinomas. EOCs rarely 
metastasize to distant sites, but disseminate within the peritoneal cavity. The 
small clusters of cancer cells shedding from the primary site and from 
peritoneal masses overcome anoikis, persist as ascites and attach on the 
abdominal peritoneum or omentum [Hudson et al. 2008]. EOC normally 
displays both epithelial and mesenchymal characteristics retaining a high degree 
of plasticity, expressing vimentin together with cytokeratins 8 and 18 [Ahmed
et al. 2007]. It was demonstrated that in EOC, E-cadherin localization is 
maintained at cell-cell contacts during tumor progression and some advanced 
EOCs concomitantly express both E- and N-cadherin [Tomassetti et al. 2008]. 
EOC cells, purified from ascitic fluids, are found as clumps and the major 
cadherin expressed at cell-cell contact is E-cadherin [Strauss et al. 2011]. In 
addition, while E-cadherin expression is reduced in primary EOC, it could be 
re-expressed in metastatic lesions, where could sustain the survival of 
metastasis inhibiting apoptotic processes [Davidson et al. 2000], suggesting that 
ovarian carcinoma cells undergo incomplete EMT. Interestingly, E-cadherin 
engagement is necessary to the activation of PI3K-AKT-mediated proliferation 
[De Santis et al. 2009], suggesting that E-cadherin downstream signaling 
pathways could be important for ovarian cancer cell growth.  
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5. Inflammation and ovarian cancer 
EOC development is strictly related to the environment in which it spread: the 
peritoneum that is the place that protects the integrity of abdominal organs. 
Indeed, the peritoneum represents the microenvironment in which the tumor 
initiation, progression and differentiation of ovarian cancer take place 
[Freedman et al. 2004]. For a long time two hypothesis have attempted to 
explain the etiology of EOCs: the first one associated to the numbers of 
ovulation events, the ovulation hypothesis, [Murdoch et al. 2002] and the other 
that is associated to the increase of postmenopausal hormones (gonadotropin 
and estrogen) able to stimulate the ovarian surface epithelial cells [Cramer et al.
1983]. For the ovulation theory the process of continuous damage and 
consequent repair of the ovarian epithelium, increase the chance of errors 
during the replication [Fathalla 1971]. Associated to this theory are the events 
of repeated ovulations, endometriosis and pelvic inflammation. Indeed, the 
chronic inflammation could be considered an important and necessary cause to 
make OSE cells prone to transform [Balkwill 2000]. EOCs can be considered 
an inflammatory malignance since the main characteristic of advanced-stage 
EOCs is the development of ascites. Thus, ascites represents the EOC tumor 
microenvironment and play an important role for tumor progression and 
development [Shen-Gunther and Mannel 2002]. Ascites are composed of a 
cellular component, consisting in mesothelial and immune cells, and of an a-
cellular fraction which contains growth factors [Richardson et al. 2002], 
lysophosphatidic acid (LPA) [Yamada et al. 2004], cytokines, chemokine 
[Giuntoli et al. 2009] and ECM components [Ahmed et al. 2005]. EOC growth 
is also regulated by inflammatory factors present in the microenvironment. 
Indeed, the presence in ascites of activated mesothelial and inflammatory cells 
could also contribute to the growth and dissemination of EOC cells. Indeed, in 
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experiments of macrophages depletion, in the peritoneal cavity, the metastases 
were strongly reduced [Robinson-Smith et al. 2007]. Moreover, when 
macrophages were co-coltured with EOC cells, tumor cell invasiveness was 
increased likely due to changes in the expression of cytokines-secreted (IL-6, 
interleukin-10, tumor necrosis factor- ) [Hagemann et al. 2007] suggesting that 
EOC dissemination process is strictly associated to inflammatory pathways and 
regulated by a continuous crosstalk between tumor and stromal cells. High 
levels of many inflammatory cytokines were found in ascites of EOC patients, 
but one the most abudant and associated with EOC tumor progression is IL-6 
[Lane et al. 2011]. 
5.1 IL-6 and cancer 
IL-6 is a 26 kD glycopeptide produced by immune cells, such as dendritic cells, 
B-cells and macrophages, as well non-hematopoietic cells, such as fibroblasts 
and cancer cells. IL-6 is a pleiotropic inflammatory cytokine whose release 
could be induced upon many stimuli as bacterial endotoxin and other 
inflammatory cytokines, such as tumor necrosis factor- (TNF-), interleukin-1 
(IL-1) and interferons (IFNs). IL-6 is involved in many biological processes as 
response to infection, hematopoiesis, and immune response [Sehgal et al.
1995]. The inflammatory cytokines, like IL-6, TGF- (transforming growth 
factor beta) and TNF- are some of the hallmarks of cancer–related 
inflammation that regulate the tumor microenvironment. IL-6 has been 
implicated in several human malignancies such as multiple myeloma [Shain et 
al. 2009] and hepatocellular carcinomas [Soresi et al. 2006]. Production of IL-6 
by inflammatory cells is regulated by different transcription factors, primarily 
NF-B [Karin 2009], C/EPB (CAAT/enhancer-binding protein beta, formerly 
NF-IL6) and AP-1 (activator protein 1) [Das et al. 2011]. IL-6, upon induction, 
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by inflammatory cells like monocytes or macrophages can act on other cells, 
such as tumor cells and other inflammatory cells to up-regulate the transcription 
of the IL-6 gene. Both paracrine and autocrine IL-6 signaling pathway acts 
through a membrane receptor consisting of the ligand binding protein IL-6R
and the signal-transducing component named gp130 [Guo et al. 2012]. The 
binding of IL-6 to its receptor complex at the membrane induces the activation 
of Janus kinase (JAK) followed by tyrosine phosphoryation of Signal 
transducer and activator of transcription 3 (STAT3) [Scheller et al. 2006]. 
STAT3 phosphorylated could translocate as dimer from the cytoplasm to 
nucleus [Levy et al. 2002] where, upon binding to a specific consensus DNA 
sequences, could induce the transcription of many genes involved in apoptosis, 
proliferation and survival pathways (Figure. 4) [Hong et al. 2007]. 
Figure 4. IL-6-JAK-STAT signaling pathway [Guo et al. 2012] 
Past studies showed the anti-apoptotic effects of IL-6 by up-regulating Bcl-2 
family proteins, XIAP, c-Myc, FAS [Darnell  Jr. 1997] and more recently high 
levels of IL-6 and Bcl-XL have been correlated in myeloma patients with 
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disease progression [Bommert et al. 2006]. In addition, IL-6-STAT3 signaling 
pathway drives the activation of PI3K/AKT, MEK/ERK, WNT downstream 
transduction signalings demonstrating a role of IL-6 in the control of cell 
growth and proliferation of tumor cells [Ara et al. 2010]. IL-6 has a pivotal role 
in controlling inflammation-related disease such as colitis, inflammatory bowel 
disease, associated to colon cancer (CAC) and hepatitis-associated liver cancer, 
the hepatocellular carcinoma (HCC) [Ara et al. 2010]. During CAC 
development, IL-6 is produced from dendritic cells and macrophages placed in 
lamina propria. In this specific mouse model used in this study seems that the 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) 
activation in intestinal epithelial cells (IECs) sustained the survival of 
premalignant cells through the induction of anti-apoptotic genes. On the other 
hand, in macrophages the NF-kB activation induced the release of IL-6 with 
effects on pre-malignant IECs thus regulating tumor formation and growth. 
Subsequently, the activation of canonical STAT-3 dependent signaling pathway 
that synergizes with NF-kB induce the up-modulation of survival genes, thus 
demonstrating that the NF-kB-IL-6-STAT3 axis is an important regulator of the 
proliferation and survival of tumor initiating IEC [Neurath et al. 2011]. In a 
HCC model, upon inflammatory stimuli (e.g. toxins, viral infections, iron 
overload, fat, and alcohol) a chronic inflammation is induced. Subsequently, the 
Kupffer cells produce IL-6 through NF-kB transcriptional activation regulating 
the cellular inflammatory response. This response can itself cause more damage 
to the remaining hepatocytes, inducing a circle of inflammation and injury. The 
IL-6 produced by hepatocytes through STAT3 autocrine pathway causes 
hepatocyte compensatory proliferation that could induce cellular proliferation 
such as malignant transformation [Liu et al. 2011]. Moreover, IL-6 has also 
been involved in drug resistance in many types of tumors, infact, multi-drug 
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resistant breast cancer cells but not sensitive tumors release high levels of IL-6 
[Conze et al. 2001]. Many studies highlighted the role of IL-6 as a growth-
promoting factor for many type  of tumors, like prostate cancer in which IL-6 
makes the tumor cells resistant to cisplatin cytotoxic effects [Pu et al. 2004]. In 
summary, IL-6-STAT3 signaling is involved in regulating many signaling 
pathways involved in growth and progression of tumors including, prostate and 
breast cancer [Salgado et al. 2003], as well as in some B or T cell lymphomas 
with a role of stimulating cytokine [Hong et al. 2007]. 
5.2 IL-6 and EOC 
EOC is one of the tumors in which there is a strong evidence for a very 
complex cytokine network. Indeed, many papers have been demonstrated the 
autocrine or paracrine cytokine loops involved in the progression of EOC [Nash
et al. 1999]. Many studies have associated EOC progression to IL-6 expression 
[Hong et al. 2007;Lane et al. 2011]. The role of ascites in EOCs has been 
mentioned above (see Chapter 4). Other cytokines are present in the EOC 
microenvironment, but IL-6 is one of the first cytokines released in ascites fluid 
of women with advanced EOC. High levels of IL-6 have been found in ascites 
and serum of advanced EOC thus correlating with poor clinical outcome 
[Scambia et al. 1994] and resistance to chemotherapy [Cohen et al. 2013]. 
Specifically, patients with high levels of IL-6 in ascites have a shorter survival 
than patients with normal levels of IL-6. One of the mechanisms that induced 
the production  of IL-6, is mediated by LPA in EOC tumor microenvironment 
[Fang et al. 2004]. Further in vitro studies have elucidated that LPA is able to 
induce the IL-6 release through NF-kB transcriptional activation by a Gi/PI3K–
Akt/NF-kB mediated signaling pathway [Chou et al. 2005]. Preclinical studies 
showed that IL6 enhances tumor cell survival and resistance to chemotherapy 
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via JAK/STAT signaling in tumor cells [Wang et al. 2010] and recent in vitro 
studies showed as chemokinetic network produced by stromal cells, including 
IL-6, could regulate the EMT process in cancer cells [Yadav et al. 2011]. On 
this regard, it has been recently demonstrated that siltuximab (CNTO328), a 
chimeric murine anti-human IL-6 monoclonal antibody, is able to block IL-6 
trans-signaling in many type of cancer [Voorhees et al. 2009]. In EOC, in vitro 
treatment with siltuximab reduced the expression of apoptosis related genes 
increasing the cytotoxic effects of paclitaxel on paclitaxel-resistant EOC cell 
lines [Guo et al. 2010]. Moreover, siltuximab treatment in IL-6-producing 
intraperitoneal ovarian cancer xenografts reduced constitutive cyto/chemokine 
production and inhibited IL-6 signaling, tumor growth, the tumor-associated 
macrophage infiltrate, and angiogenesis, [Guo et al. 2010]. IL-6 has also pro-
angiogenic properties [Wang et al. 2010], regulating immune cell infiltration, 
and the tumor-promoting actions of IL-17–producing T cells (Th17) through 
STAT3 signaling pathway [Wang et al. 2009b]. Although Th17 have been 
found in increased numbers of tumors [Middleton et al. 2012], at the moment is 
not clear whether IL-17 promotes or inhibits cancer progression. On this regard, 
recently has been suggested a crosstalk between IL-17 and IL-6 in cancer, 
indeed IL-17 induced IL-6 release which activates Stat3 in both tumor and 
stromal cells, IL-6-STAT3 signaling pathway in tumor cells increased the 
activation of anti-apoptotic and pro-angiogenic genes [Tzeng et al. 2013], but at 
the same time IL-6-Stat3 signaling in T cells promoted Th17 cell differentiation 
[Harris et al. 2007]. Since that Th17 cell differentiation could be also induced 
by TGF-, a cytokine highly expressed in tumors, IL-17–induced IL-6 
production can induce an autocrine loop for Th17 cells in the tumor 
microenvironment. However, further knowledge on IL-6-expressing EOCs is 
needed to select patients that could be responsive to IL-6 dependent therapies. 
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Furthermore, selective targeting of the IL-6 trans-signaling pathway reduces 
malignant ascites formation [Vaughan et al. 2011]. These findings have now 
led to the clinical evaluation of siltuximab and toclizumab (anti-IL-6 receptor 
antibody) in EOC. However, despite the progress made, malignant ascites 
remain a major challenge in the clinical management of ovarian cancer thus 
further research are necessary to develop novel therapeutic approaches. 
6. Epidermal Growth Factor Receptor 
The Epidermal Growth Factor Receptor (EGFR), whose gene is on 
chromosome 7p12, is a transmembrane glycoprotein receptor that belongs to 
ErbB family. ErbB family comprises four members named: 
erbB1/EGFR/HER1, ErbB2/HER2/Neu, ErbB3/HER3 and ErbB4/HER4. They 
share a common structure that consists in three domains: 1) an extracellular N-
terminal ligand binding domain with a dimerization arm; 2) a trans-membrane 
domain; 3) a C-terminal domain with a tyrosine kinase activity. ErbB receptors 
binds different ligands: EGF (epidermal growth factor), betacellulin (BTC), 
heparin binding EGF-like growth factor (HB-EGF), transforming growth 
factor- (TGF-), amphiregulin (AR), epiregulin (EPR), epigen (EPG) and 
neuregulins (NRG) [Citri et al. 2006]. EGFR could bind different of these 
ligands: EGF, TGF-, AR, BTC and EPR. Once EGFR have bound one of its 
ligands, the receptor dimerizes, and the tyrosine kinase domain of one receptor 
is able to induce the phosphorylation of specific tyrosine residues placed on the 
other receptor (Figure 5). These events are necessary to create a scaffold 
platform to recruit different effector proteins [Siwak et al. 2010]. These 
proteins, containing Src homology-2 (SH2) and phosphotyrosine binding 
domanins (PTB) could be recruited to the phosphotyrosine of the receptor 
directly or through docking proteins. The platform constituited by  effector and 
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docking proteins associated to the activated receptor is able to recruits 
downstream signaling molecules thus causing the activation of different 
signaling cascade, i.e. MAPK (mitogen-activated protein kinases), 
phosphoinositide 3-kinase (PI3K), STAT3, and phospholipase C gamma 
(PLCG) signaling pathways, associated to cell proliferation, migration, survival, 
adhesion and angiogenesis [Lemmon et al. 2010]. EGF ligands can induce the 
homodimerization of EGFR with HER1 [Seshacharyulu et al. 2012] and the 
heterodimerization with other member of the family: HER2, HER3 and HER4. 
Figure 5. The structure of EGFR [Seshacharyulu et al. 2012]
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6.1 EGFR and EOC
EGFR is expressed on the surface of different kind of mammalian cells such as 
epithelial cells, fibroblast and keratinocytes. Many studies have demonstrated 
that EGFR is necessary for embryonic and post-natal development [Sibilia et al.
1995]. Indeed EGFR knock-out mice don’t alive due to many anomalies in 
lung, brain, heart and in various epithelia. In physiological conditions, EGFR 
has a pivotal role in the development, growth and differentiation of gonads and 
follicles [Auersperg et al. 2001]. In EOC, EGFR expression and activation 
could contribute to aggressiveness of EOC cells through the promotion of the 
cell proliferation, the invasion, the angiogenesis and resistance to cell apoptosis 
[Lafky et al. 2008]. EGFR was found amplified in about 4-22 % of ovarian 
cancer patients [Vermeij et al. 2008] and in about 4% of EOC cases activating 
mutations in the catalytic domain of EGFR were found [Lassus et al. 2006]. 
The most common of EGFR rearrangement EGFRvIII activating mutation, is 
not involved in the pathogenesis of ovarian cancer [Steffensen et al. 2008]. 
EGFR was found over-expressed in a variable percentual of EOC (from 3 to 
70%) and was associated with advanced-stage disease, poor prognosis, aberrant 
p53 expression and high cell proliferation index. However, the use of EGFR 
targeted-therapies, like monoclonal antibodies and tyrosine kinase inhibitors, 
for advanced or recurrent EOC patients gave poor clinical response Due to this 
discrepancy, one of the problems for the identification of patients that could 
respond to EGFR targeted-therapies is the selection just on the basis of EGFR 
staining by immunohistochemistry (IHC) [Shia et al. 2005]. As already pointed 
out, the range of EGFR expression is highly variable since it depends by 
different assessment methods and/or study cohorts [de et al. 2009]. At the 
moment, many studies have focused their attention to the status of EGFR 
activation instead of EGFR total expression in EOC samples. Since EGFR 
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activation induces the stimulation of many intracellular signaling pathways that 
drive tumor growth, development and invasion, the inhibition of EGFR 
activation together with that of the downstream pathways seems a more 
promising strategy for EOC treatment. Therefore, the identification of new 
molecular markers can allow to discriminating better EGFR-responder and 
EGFR-non responder patients towards anti-EGFR therapies. 
6.2 Endocytosis and recycling of EGFR 
The discovery of EGFR and its ligands was followed by study of the pathways 
and mechanisms of EGFR endocytosis. The major and well known pathway of 
EGFR degradation is mediated by clathrin coated vesicles, but it occurs also 
through a clatrin-independent mechanism (Figure 6) [Goh et al. 2010;Scita et 
al. 2010]. The clathrin-coated endocytic vesicles are fused with early 
endosomes, and when the receptor is placed in early endosomes could return to 
the cell surface by recycling, or to intraluminal vesicles (ILVs), thus directing 
the receptor to lysosomes for the degradation. It is well known that the receptor 
ubiquitination is an essential process that control endocytosis and degradation 
receptor processes. The major part of RTK after its dimerization and activation 
undergoes to a rapid ubiquitination process. The family of E3 ubiquitin ligases 
involved in ubiquitination of RTKs belongs to CBL family [Joazeiro et al.
1999]. CBL E3 ligases are recruited to Tyrosine 1045 residue in the 
cytoplasmatic region through the TKB domain or indirectly through the adaptor 
protein growth factor receptor-bound protein2 (GRB2) thus promoting EGFR 
ubiquitination at the plasma membrane [De Melker et al. 2004;Dikic et al. 
2007]. Further studies showed that the ligand concentration and ubiquitination 
process can affect the receptor internalization [Sigismund et al. 2005]. Indeed, 
at low doses of EGF, the EGFR is not ubiquitinated and is directed to clathrin-
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mediated endocytosis. On the contrary, the presence of high EGF dose, induces 
the receptor ubiquitination thus promoting its lipid raft-dependent endocytosis 
[Sigismund et al. 2005]. These two endocytic mechanisms affect the EGFR 
levels on the membrane as well as the duration of EGFR-downstream signaling 
pathways activation [Sigismund et al. 2008]. Indeed, clathrin-mediated receptor 
endocytosis induces the receptor internalization and its rapid recycling on the 
cell surface, on the contrary the clathrin-independent endocytosis mechanism 
directs the receptor to lysosomial compartment to its degradation [Sigismund et 
al. 2008]. Although, the ubiquitination process seems a pivotal signal to induce 
receptor degradation, some studies showed that ubiquitination process can 
occur also at low EGF doses thus promoting receptor endocytosis in clathrin-
coated vesicles [Madshus et al. 2009a]. Further investigations to elucidate the 
involvement of ubiquitination process in receptor trafficking will be necessary. 
Figure 6. Ubiquitination in receptor endocytosis, recycling and degradation processes [Haglund 
et al. 2012]
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6.3 EGFR activation in EOC 
Recently, research attention moved to the phosphorylated EGFR form (pEGFR) 
rather than total EGFR. In vitro and in vivo studies showed that EGFR 
activation is present in the EOCs and many different signaling pathways 
involved in tumor proliferation and metastasis are induced. Recently EGFR has 
been linked to the lack of response to the conventional chemotherapy treatment 
(cisplatin and taxol) in EOC patients [Sheng et al. 2011]. Indeed, several events 
have been involved in the development of the resistance to cisplatin, including 
genetic mutation [Gadducci et al. 2002], downregulation of multidrug 
resistance proteins [Samimi et al. 2004] and upregulation components of 
autophagic pathway [Yu et al. 2011]. However, the molecular mechanisms 
associated to the resistant phenotype remains poorly defined. An in vitro study 
conducted in resistant cisplatin EOC cell lines demonstrated that EGFR 
receptor and STAT3 hyperactivations upregulate the expression of 
mesenchymal markers, usually associated to a more aggressive phenotype, and 
are correlated with an altered response to chemotherapy. All these data 
demonstrate that the combined inhibition of EGFR and STAT3 could be useful 
to sensitize resistant EOC to cisplatin treatment [Yue et al. 2012]. EGF 
stimulation can also increase the growth of OSE cells in culture [Siemens et al
1988] and, moreover, the gene expression analysis of normal rat ovarian surface 
epithelial EGF-simulated cells showed the up-modulation of genes involved in 
cell cycle and proliferation, apoptosis, and protein turnover [Abdollahi et al.
2003]. On the other hand, in EOC cells autocrine and paracrine stimulation of 
the EGFR promotes tumor cell growth [Choi et al. 2009]. In addition, EGFR 
activation is associated with induction of metastasis. As already mentioned, 
EGFR activation can induce EMT-associated events in EOC thus promoting the 
production of matrix degrading proteinases. Indeed it was already demonstrated 
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that EGFR activation could induce the release of metalloproteases such as 
MMP-9 promoting migration and invasion of EOC cells. In particular, EGFR 
activation induces the disruption of adherent junctions by decreasing E-cadherin 
expression. Interestingly, the induced-MMP-9 mediates E-cadherin ectodomain 
shedding and EOC peritoneal dissemination [Cowden Dahl et al. 2008]. Among 
the bioactive components present in EOC ascites, there are also three activators 
of EGFR: HB-EGF, endothelin-1 (ET-1) ad LPA. HB-EGF, one of the EGFR 
ligands is present at high levels in ascitic fluids [Miyamoto et al. 2004]. Indeed, 
HB-EGF could activate EGFR through an indirect way; infact, the G protein 
coupled receptors GPCRs upon the activation by ligands like ET-1 or LPA 
induce the activation of cell surface ADAM family metalloproteases. Pro-
HBEGF, the membrane-anchored form of HB-EGF, could be cleaved from 
ADAMs family metalloproteases followed by the production of the active and 
soluble forms of HB-EGF that subsequently activate the EGFR [Higashiyama et 
al. 2011]. Among the soluble factors present in EOC tumor microenvironment, 
the bioactive lipid LPA synthesized by platelets and activated mesothelial cells 
[Wang et al. 2007] can contribute to tumor development, progression, and 
metastasis formation [Bese et al. 2010]. Upon binding to GPCRs protein, LPA 
activates many signaling pathways, involved in cell proliferation, motility and 
invasiveness [Do et al. 2007]. As already mentioned, EGFR trans-activation 
could be induced from GPCR proteins, and on this regard, it was also 
demonstrated that LPA induces the intracellular activation of src kinase, 
followed by EGFR trans-activation and cyclooxygenase-2 (Cox-2) production 
with increased inflammation [Jeong et al. 2008]. Further studies have 
demonstrated that EGFR phosphorylation is induced by LPA through a 
mechanism mediated by the Ras/Rho/ROCK signaling cascade and NF-kB 
transcriptional activity with the production of MMP2 and urokinase 
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plasminogen activator (UPA) [Jeong et al. 2013]. Among the mechanisms in 
which EGFR is commonly involved, other studies link EGFR activation with 
the induction of a pro-inflammatory microenvironment. For example, the EGFR 
over-expression is associated with the induction of the vascular endothelial 
growth factor (VEGF), IL-6 and interleukin-8 (IL-8) in mouse models of lung 
adenocarcinomas and colon cancer [Gao et al. 2007;Sasaki et al. 2008]. Taken 
together these studies indicate a new role for EGFR as a possible link between 
the induction of inflammation related-pathways and the changes in tumor 
microenvironment thus favoring tumor growth and progression. In vitro, EGFR 
activation can induces STAT3 activation and IL-6 release thus promoting EMT 
activation in EOC cell lines [Colomiere et al. 2009]. 
7. EGFR targeted therapies 
The therapeutic approaches that are used to targeting EGFR in different types of 
human cancers involve monoclonal antibodies and small molecules tyrosine 
kinase inhibitors. 
Figure 7. The mode of action of Cetuximab and TK inhibitors (modified from [Graham et al.
2004]) 
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7.1 Anti-EGFR monoclonal antibodies 
The monoclonal antibodies directed to the extracellular domain of EGFR are 
able to bind to the ligand binding domain thus preventing ligand-dependent 
receptor dimerization, its phosphorilation and the activation of the downstream 
signaling pathways [Burgess et al. 2003]. Cetuximab (Erbitux®), a chimeric 
monoclonal antibody of IgG1 isotype, binds the extracellular L2 domain of 
EGFR (Figure.7) promoting the receptor internalization, degradation and 
inhibiting the activation of downstream signaling pathways. Cetuximab is able 
to inhibit the growth of different types of cancer cells in vitro like breast, lung, 
prostate, head and neck [Mendelsohn 1997]. Pre-clinical in vitro and in vivo 
studies have demonstrated that Cetuximab is able to reduce the chemotherapy-
derived resistance in different type of human cancer cell lines and in xenograft 
models including EOC models [Bull Phelps et al. 2008]. Cetuximab was the 
first agent approved as therapeutic drug for treatment of patients with metastatic 
colorectal cancer failed with irinotecan- and oxaliplatin-based chemotherapy in 
USA and Europe [Jonker et al. 2007]. Phase II trials for treatment of EOC 
patients used Cetuximab alone [Schilder et al. 2009] or in combination with 
carboplatin with or without taxol [Konner et al. 2008;Secord et al. 2009], 
however the effects observed were limited. In these clinical studies the patients 
were included on the basis of EGFR positivity tested by IHC, and 4% of 
patients partially responded to Cetuximab treatment as single agent [Schilder et 
al. 2009], while in the combinated trial (Cetuximab+carboplatin) the response 
was complete in 12% and partial in 23% of EOC patients [Schilder et al. 2009]. 
No response was observed in the clinical trial in which Cetuximab was used in 
combination with carboplatin and taxol, where the progression free-survival at 
18 months was 39%, evaluated not significant by the authors. The main 
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conclusion of these clinical trials was that no correlations between the EGFR 
positivity and the response to Cetuximab treatment were observed. 
7.2 Tyrosine kinase inibitors 
Tyrosine kinase inhibitors (TKI) are low molecular weight compounds which 
inhibit the intracellular receptor phosphorylation at the activation domain. They 
are analogues of adenosine triphosphate (ATP), able to compete for ATP 
binding site on the intracellular catalytic domain of RTKs, inhibiting the 
receptor auto-phosphorylation and the activation of downstream signaling 
pathways. No correlations between EGFR expression on tumor cells and 
response to TK inhibitor were observed in EOC. The most studied TKI 
inhibitors specific for EGFR are Gefitinib (Iressa®) and Erlotinib (Tarceva®) 
(Figure.7). 
7.2.1 Gefitinib 
Gefitinib (Iressa®) is an anilinoquinazoline and it was the first TKI 
characterized in 1996 [Barker et al. 2001]. Gefitinib is a low molecular weight 
inhibitor with a specific inhibitory activity towards tyrosine phosphorylation 
with a 200-fold greater affinity for EGFR than other ErbB family receptors 
[Thomas et al. 2004]. In vitro studies have demonstrated that Gefitinib inhibits 
cell growth of many human cancer cell lines [Ciardiello et al. 2001], and in 
xenograft models of ovarian, lung, colon, breast and prostate cancer Gefitinb 
treatment improved the effects of standard chemotherapy [Sirotnak et al. 2000]. 
At present, the mechanism of action of Gefitinib as anti-proliferative agent is 
not completely clarified. Gefitinib might up-regulate Cycline-dependent kinase 
(CDK) inhibitor p27 downregulating the transcription factor c-fos and inducing 
the G1 phase cell cycle arrest [Busse et al. 2000]. Gefitinib was initially 
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approved for treatment of NSCLC (non-small-cell lung carcinoma), failed after 
both platinum and docetaxel based chemotherapy. In vitro studies have 
demonstrated that the combined treatment of Gefitinib with other chemotherapy 
agents increased the cytotoxic activity of platinum sensitive ovarian cancer cell 
lines [Smith et al. 2008]. When Gefitinib was used in a clinical trial involving 
platinum resistant EOC patients, only a patient among eleven (9%) was 
responding. Indeed, the tumor of this patient was highly expressing EGFR 
[Schilder et al. 2005]. In another clinical trial in which Gefitinib was used in 
combination with Tamoxifen in a cohort of patients refractary to platinum-
taxane based therapy, no therapeutic effect was observed [Wagner et al. 2007]. 
In another phase II study the patients received 6-8 cycles of Gefitinib, paclitaxel 
and carboplatin every 3 weeks followed by Gefitinib tratment alone. The 
overall response rates and disease control rates were respectively, 62% and 81% 
for sensitive patients, and 19% and 63% respectively, for refractary patients 
[Schilder, et al 2005]. This is the clinical trial in which the EGFR-TKI 
treatment gave the better response in platinum resistant EOC patients. 
7.2.2 Erlotinib 
Erlotinib (Tarceva®) hydrocloride is a potent and reversible EGFR TK 
inhibitor of both wild type EGFR and constitutive active mutant form 
EGFRvIII in vitro. Erlotinib does not decrease the levels of EGFR protein and 
inhibits cell proliferation with effects on apoptosis and cell cycle. Studies in 
vitro have been shown that Erlotinib exerts its effects inhibiting EGF-dependent 
cell growth at very low concentrations blocking cell cycle in G1 phase [Ranson 
2004]. At present, Erlotinib is approved for treatment of relapsed NSCLC 
patients positive for EGFR that does not show disease progression after four 
cycles of platinum based-chemotherapy [Rocha-Lima et al. 2009]. In vitro 
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studies showed few effects on EOC cell proliferation respect to lung cancer 
cells [Bull Phelps et al. 2008]. Erlotinib was used as single agent in EOC phase 
II trial, where the patients were platinum resistant and EGFR positive, and a 
partial response and a stable disease were observed for 6% and 44% of patients 
respectively [Gordon et al. 2005]. The other clinical trial in which Erlotinib was 
used in combination with standard based chemotherapy such as or carboplatin-
docetaxel, [Blank et al. 2010] no clinical benefits were observed.  
To summarize, the response rate of patients pre-treated with platinum is very 
low (0-0,6%), slightly better in patients positive for EGFR (6-9%). When 
Gefitinib or Erlotinib are used in combination, the response rate is 7-19% in 
platinum resistant patients and 57-62% in platinum sensitive patients [Stordal et 
al. 2007].Therefore, other studies are necessary to better define the cohort of 
patients that could really benefit from EGFR-targeted therapies. There is no 
correlation between EGFR expression and response to EGFR-targeted 
therapies. For this reason it is necessary to indentify new predictive biomarkers 
for response or resistance to anti-EGFR drugs, by deeply analyzing the different 
signaling cascades elicited upon EGFR activation. 
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Aim of the Project 
EGFR is considered an important key therapeutic target in many types of 
cancer, including EOCs. Unfortunately, treatment of EOC patients with anti-
EGFR drugs resulted in a very poor clinical response and with no correlation 
with EGFR positivity in the tumor cells. For these reasons it is necessary to 
better investigate EGFR downstream signaling cascade and the relationship 
between EGFR activation and the tumor microenvironment. This study is 
mainly committed to investigate: 
a) The functional role of EGFR-driven pro-inflammatory program in the 
biology of EOC, knowing that EGFR expression and activation 
increased during EOC progression. Therefore, the goal of this section 
will be to identify pro-inflammatory pathways and to investigate the role 
of EGFR activation in the induction of those pathways in EOCs.
b) The dissection of the signaling pathways activated by EGFR leading to 
the expression of pro-inflammatory/invasive molecules. 
c) The biological role of the identified inflammatory molecules by in vitro 
experiments on EOC cell lines. 
The results of this study will contribute to elucidate the complex signaling 
network that modulates the growth and the dissemination of EGFR-expressing 
EOC cells and to identify new players that could be exploited to develop novel 
therapeutic approaches or prognostic assays. 
Chiara Alberti
31 
SECTION 1 - The role of EGFR in the progression of EOCs. 
Results and Discussion 
1.1 IGROV1 and OAW42 EOC cell lines express the highest levels of 
EGFR with the major release of IL-6 
In order to study the role of the axis EGF/EGFR in the expression of 
inflammation-related molecules, normal and several EOC cell lines were 
analyzed for EGFR expression and for IL-6 release. The EOC cells analyzed 
were: OVCAR3, IGROV1, OAW42, SKOV3 and OVCA432, serous 
adenocarcinoma; A2780, mucinous carcinoma. All these cell lines were tested 
for EGFR expression by flow cytometry and we found that all cell lines derived 
from patients with serous adenocarcinomas expressed variable levels of 
membrane EGFR (Figure 1A): IGROV1, OAW42 and SKOV3 cell lines 
expressing the highest levels and OVCAR3, OVCA432 and A2780 cell lines 
expressing medium and low levels of membrane EGFR respectively. The same 
cell lines were analyzed for IL-6 release by ELISA assay. The analysis of the 
media conditioned for 24 hr revealed that IGROV1 and OAW42 released the 
highest amounts of IL-6 in vitro (422 pg/ml and 140 pg/ml respectively) (Figure 
1B). SKOV3 and OVCA432 cell lines released very low amount of IL-6 (6 
pg/ml and 10.5 pg/ml, respectively). Moreover, analyzing conditioned media 
from OVCAR3 and A2780 cell lines no IL-6 released levels were detected. On 
the basis of these preliminary analyses, two cell lines, IGROV1 and OAW42, 
expressing the highest levels of EGFR with the major release of IL-6 were 
selected. Based on the evidence that, in the human EOC microenvironment, are 
present the natural EGFR ligands EGF, TGF- and HB-EGF that cause EGFR 
trans-phosphorylation [Hudson et al. 2009], we then analyzed EGFR 
phosphorylation together with the main EGFR-activated downstream pathways, 
the PI3K/AKT and MEK/ERK. Indeed, both the selected EOC cell lines were 
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stimulated with EGF up to 60 min (Figure 1C). In IGROV1 cell line EGF 
stimulation induced an early EGFR activation in 5 min, followed by a rapid 
EGFR degradation and membrane recycling as demonstrated from EGFR levels 
upon ligand-stimulation. Moreover in IGROV1 cell line seemed that EGFR 
activation was ligand-dependent and in starved cells P-EGFR levels were not 
detectable. On the other hand, in OAW42 cells, EGFR levels remained stable 
upon EGF stimulation and P-EGFR levels were comparable in starved cells and 
upon serum stimulation indicating that in these cells EGFR activation is ligand-
independent or that these cells produce the ligand. The downstream pathways 
MEK/ERK and PI3K/AKT have been evaluated by Western blotting as 
phosphorylated ERK1,2, and AKT respectively. We found that in both cell lines 
EGF stimulation induced mainly the activation of MEK/ERK signaling 
pathway. On the other hand, in both cell lines PI3K/AKT signaling pathway 
was constitutively activated. As already mentioned, it is known that when EGF 
interacts with EGFR, the complex is internalized and eventually degraded in 
lysosomes [Madshus et al. 2009b]. Indeed, immunofluorescence (IF) performed 
on fixed IGROV1 and OAW42 cells with anti-EGFR Ab showed that in starved 
cells EGFR was mostly localized on the cell membrane (Figure 1D). After 20 
min EGF stimulation EGFR expression was only detectable in an intracellular 
small punctuate vesicles in IGROV1 cells, compatible with endocytic 
mechanism of receptor degradation. On the other hand, in OAW42 EGF-
stimulated cells EGFR expression was mainly localized in endocytic vesicles 
even if part of the receptor remains on the membrane. This result is in 
accordance with those obtained by Western blot analysis of EGFR levels upon 
EGF stimulation (see Figure 1C). These results demonstrated that ligand-
induced EGFR activation elicited the internalization and intracellular sorting of 
the complex. The results obtained up to now revealed that in both cell lines 
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EGF stimulation induce the EGFR activation, evaluated as phospho-EGFR Tyr 
1173, and mainly the concomitant activation of MER/ERK downstream 
signaling pathway. Moreover, in the selected EOC cell lines the membrane 
EGFR stability seems differently regulated. 
1.2 EGFR phosphorylation is not a predictor of sensitivity to anti-EGFR 
compounds  
To analyze whether PI3K/AKT and MEK/ERK signaling were indeed EGFR- 
activated downstream pathways, anti-EGFR drugs were used. IGROV1 and 
OAW42 cell lines were stimulated with EGF for 20 min alone or together with 
two different concentrations of the EGFR tyrosine kinase inhibitor (AG1478). 
The downstream pathways MEK/ERK and PI3K/AKT have been evaluated by 
Western blotting as phosphorylated ERK1,2 and AKT respectively together 
with that of EGFR (Figure 2A). In both IGROV1 and OAW42 cell lines EGFR 
phosphorylation increased upon 20 min EGF treatment, followed by a strong 
phosphorylation of MAPK but not of PAKT. EGFR and ERK1,2  
phosphorylations were completely inhibited by AG1478 by the lowest 
concentration. These data indicate that in both cell lines EGFR activation is 
followed by ERK phosphorylation. Subsequently, the effect on cell 
proliferation of anti-EGFR drugs was evaluated. The IGROV1 and OAW42 cell 
growth capability was evaluated in the presence of anti-EGFR monoclonal 
antibody Cetuximab or the EGFR inhibitors Erlotinib and Gefitinib. Although 
EGFR in both cell lines was activated by the ligand, only the proliferation of 
IGROV1 cells (50% inhibition using the lowest drug concentration) but not that 
of OAW42 cells was affected by Cetuximab treatment (15% inhibition using 
the higher drug concentration) (Figure 2B). In OAW42 cells the response to 
Cetuximab treatment is in accordance with previous results. Indeed, in OAW42 
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cells EGFR activation is not totally dependent from ligand stimulation, arguing 
that other mechanisms of receptor activation might occur. Accordingly, 
IGROV1 cells were about eight-fold more sensitive to Erlotinib and Gefitinib 
than OAW42 cells (Figure 2C), arguing that the presence of activated EGFR is 
not a predictor of sensitivity to EGFR compounds. These data also indicate that 
other factor/s, such as the specific signalings induced by EGFR, may be related 
to drug sensitivity. 
1.3 EGFR activation induces IL-6 releasing in EOC cell lines 
In order to analyze if IL-6 release was dependent from EGFR activation, IL-6 
levels were evaluated in both cell lines upon 4, 8 and 24 hr EGF treatment in 
the presence or absence of AG1478. In both cell lines, IL-6 levels increased 
after 4 hr EGF treatment and its release was time-dependent. After 24 hr IL-6 
release was nearly completely inhibited by AG1478 treatment in IGROV1 cells 
(96%), while in OAW42 cells the inhibition was just partial (30%) (Figure 3A). 
As already mentioned, in EGF-stimulated OAW42 cells IL-6 release was seven-
fold higher than in the presence of serum (Figure 1B) and the IL-6 production 
was not inhibited by AG1478 treatment (Figure 3A). All these observations 
support the notion that in OAW42 cells IL-6 production could be independent 
from EGFR activation. On the contrary, in IGROV1 cells IL-6 production 
seems dependent from EGFR activation as demonstrated by the inhibition of 
IL-6 production using AG1478. Interestingly, when both cell lines were 
transfected with a luciferase reporter construct containing four STAT3 binding 
sites [Besser et al. 1999], we found that in EGF-stimulated IGROV1 cells 
STAT3 transcriptional activation increased slightly and was not inhibited by 
JAK inhibitor AG490 treatment. On the contrary In EGF-stimulated OAW42 
cells, STAT3-related promoter activity increased of about 2.5 fold and STAT3 
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promoter activity was inhibited of about 40% using AG490 (Figure 3B). These 
results demonstrated that in both cell lines the activation of the signaling loop 
of IL-6 with its bivalent receptor could induce STAT3 transcriptional 
activation; moreover in OAW42 but not in IGROV1 cells, STAT3 
transcriptional activity seemed dependent from EGFR activation. Subsequently 
IL-6 transcripts levels were evaluate by real time RT-PCR in presence of 
AG1478, the PI3K inhibitor LY294002 and MEK inhibitor UO126. In 
agreement with the previous results, IL-6 transcript levels increase after 24 hr of 
stimulation with EGF in IGROV1 cells and decrease to levels comparable with 
starved cells using AG1478 as well as LY294002 and UO126 inhibitors (Figure 
3C). On the contrary, In OAW42 cells IL-6 transcript levels increased of about 
3-fold after EGF stimulation and were not inhibited by AG1478, as well as with 
UO126 where an increase of IL-6 transcripts levels of about 16-fold was 
observed, arguing for that IL-6 release in OAW42 cells is independent from 
EGFR activation. These data demonstrated that in EOCs, at least in vitro, the 
ligand-dependent EGFR activation could induce the IL-6 release through the 
MEK/ERK or PI3K/AKT downstream pathways. Indeed, in other EOC in vitro 
models, it has been shown that EGF stimulation induced IL-6 release and EMT 
although the molecular mechanism responsible of these observations was not 
investigated [Colomiere et al. 2009]. 
1.4 Ligand dependent EGFR activation induce NF-kB transcriptional 
activation 
We have then asked whether EGF stimulation could induce NF-kB 
transcriptional activation. NF-kB is a transcription factor activated in many 
types of cancer, including EOC and it is known to activate the transcription of 
inflammation-related proteins thus regulating and controlling inflammatory and 
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immunologic mechanisms, such IL-6 production [Karin 2009]; indeed it is 
considerate the link between inflammation and cancer. The NF-kB family of 
transcription factors is composed by five distinct subunits: RelA (p65), c-Rel, 
RelB, p50 (NF-kB1) and p52 (NF-kB2). In un-stimulated cells, NF-kB is 
present in the cytoplasm in an inactive form due to its binding to the IkB family 
of proteins [Tergaonkar et al. 2005]. Generally, the NF-kB/IkB complex is 
activated by phosphorylation in response to stimulation thus inducing the 
immediate poly-ubiquitination of IkB proteins thus promoting its degradation 
[Karin 2006]. Activated NF-kB p65 subunit could translocate to the nucleus 
thus binding to specific DNA sequences in target genes, named kB elements, 
and regulating transcription of over 400 genes involved in inflammation, 
immunoregulation, tumor cell proliferation, invasion, metastasis, angiogenesis, 
chemoresistance and radioresistance [Balkwill et al. 2012]. First of all, we 
performed an IF to evaluate nuclear translocation of NF-kB p65 subunit in 3 hr 
EGF stimulated IGROV1 and OAW42 cells. In EGF-stimulated IGROV1 cells 
NF-kB p65 staining was more brilliant than in starved cells and mainly 
localized at nuclear level while in OAW42 cells the effect of EGF stimulation 
on NF-kB nuclear translocation is less evident (Figure 4A). In particular, in 
OAW42 cells, although a more brilliant p65 staining upon EGF stimulation was 
observed, it seemed localized at nuclear level as well as in the cytoplasm, as 
seen from merged picture of DAPI, and p65 staining. These preliminary data 
indicated that in both cell lines EGF stimulation increased the NF-kB 
expression; however p65 nuclear translocation upon EGF stimulation was more 
evident in IGROV1 than in OAW42 cells. These data were confirmed analyzing 
NF-kB transcriptional activity upon EGF stimulation. Both cell lines were 
transfected with a luciferase reporter construct containing two NF-kB binding 
sites; in IGROV1 cells, NF-kB-related promoter activity increased soon after 1 
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hr reaching the maximum after 3 hr EGF stimulation and remained stable until 
24 hr (Figure 4B); in OAW42 cells, NF-kB-related promoter activity was 
observed only after 20 hr EGF stimulation. Subsequently, to investigate if NF-
kB transcriptional activity was dependent from EGFR activation, NF-kB 
promoter activity was measured in both cell lines in presence of AG1478, 
LY294002 and UO126 inhibitors. We found that in IGROV1 cells NF-kB 
promoter activity was almost completely inhibited using AG1478, and UO126, 
and of about 60% using LY294002 (Figure 4C). In OAW42 cells, the NF-kB 
promoter activity was inhibited of about 40%, 80% and 65% using AG1478, 
LY294002 and UO126 respectively. All these data demonstrated that in 
IGROV1 cells but not in OAW42 cells, the activation of EGFR/MEK/ERK or 
EGFR/PI3K/AKT signaling pathways could induce the NF-kB transcriptional 
activity with the expression of IL-6. In line with these data, in HER-2 amplified 
breast cancer cells IL-6 secretion was induced by HER2 over-expression 
through STAT3 transcriptional activity. The authors proposed HER2-IL6-
STAT3 as a new signaling axis useful for treatment or diagnosis of HER2-
amplified breast cancers, thus demonstrating a possible link between erbB 
activation to inflammatory mechanism in cancer [Hartman et al. 2011]. 
Moreover, it was demonstrated that in estrogen-receptors negative breast 
cancer, NF-kB could be induced by EGF stimulation through an unknown 
mechanism that involved a new scaffold protein named Carma3 [Van Laere et 
al. 2007], that recently, by others, has been demonstrated to be a possible link 
between EGFR, Ikk kinase and NF-kB activation [Jiang et al. 2011]. Overall, 
these data highlight that iper-activation of HER-RTK could induce 
inflammation molecules such as IL-6. 
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1.5 Ligand-dependent EGFR activation induces the release of specific 
inflammatory molecules through NF-kB activation 
In order to evaluate if EGF stimulation could induce the release of specific 
inflammatory cyto-/chemokines beside IL-6, we performed a multiplex dosage 
of 51 inflammatory molecules in conditioned media from IGROV1 cells 
stimulated with EGF for 4, 8 and 24 hr and/or in presence of AG1478. The 
media collected from IGROV1 cells were analyzed by bioplex technology and, 
many soluble molecules were found up-regulated upon EGF stimulation and 
inhibited by AG1478 treatment. In the Table 1 the levels of release of 
inflammatory molecules were reported. Among these, the factors up-regulated 
upon EGF stimulation and inhibited by the simultaneous AG1478 treatment, 
beside IL-6, were PAI-1 (plasminogen activator inhibitor 1), transforming 
growth factor alfa (TGF), MCSF (macrophage colony stimulating factor), IL-
8. Levels of PAI-1, IL-8 (Figure 5A) and IL-6 (Figure 3A left panel) found in 
the conditioned media upon EGF stimulation and in the absence or in the 
presence of AG1478 were reported. Among the 51 inflammatory molecules 
measured, these are the proteins that displayed a 2-fold increase after 24 hr of 
EGF stimulation and whose release was inhibited by AG1478 treatment. PAI-1, 
is a member of the serine proteinase inhibitor (SERPIN) family and is the main 
physiological inhibitor of both tissue-type plasminogen activator (tPA) and of 
pericellular plasmin- generating UPA/UPAR system [Kwaan et al. 2009]. Both 
urokinase plasminogen activator (UPA) and urokinase plasminogen activator 
receptor (UPAR) expressions are correlated with progression of EOCs [Wang et 
al. 2009a]. It has been demonstrated that PAI-1 expression is mediated by 
TGF1/SMAD signaling pathway, thus correlating to invasive cancer, possibly 
as regulator of UPA/UPAR function [Dass et al. 2008]. PAI-1 expression has 
been associated to progression and angiogenesis in many human malignancies 
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[Stefansson et al. 2001] but its role in the invasion of tumor cells is not well 
clarified. It has been proposed that PAI-1 promotes cancer cell detachment from 
ECM causing the internalization of the PAI-1/UPA/UPAR/integrin complex 
and thus favoring the dissemination of cells from primary tumor [Czekay et al.
2003]. 
The bioplex results were validated by real-time RT-PCR on total RNA from 
IGROV1 cells stimulated with EGF alone or in presence of AG1478. Indeed, 
we observed an increase of PAI-1 and IL-8 transcripts upon 24 hr EGF 
stimulation, and such increase was inhibited using AG1478 (Figure 5B), as 
observed for IL-6 transcript levels (Figure 3C left panel). In order to investigate 
if NF-kB transcriptional activity could be involved in the production of 
identified inflammatory molecules, the releasing of IL-6, PAI-1 and IL-8 was 
measured in presence of an NF-kB inhibitor named DHMEQ 
(Dehydroxymethylepoxyquinomicin). DHMEQ is an NF-kB inhibitor that 
inhibits the binding of NF-kB to DNA [Umezawa 2006;Yamamoto et al. 2008]. 
The levels of IL-6, PAI-1 and IL-8 were measured by bioplex technology on 
IGROV1 conditioned media 24 hr EGF-stimulated alone or together with 
DHMEQ, (Figure 5C). We found that upon DHMEQ treatment and EGF 
stimulation the levels of IL-6, PAI-1 and IL-8 decrease of 32%, 35% and 45% 
respectively. In starved IGROV-1 cells the treatment with DHMEQ decrease 
the levels of the IL-6 (from 250 pg/ml to 217 pg/ml), PAI-1 (from 366.51 pg/ml 
to 254.81 pg/ml) and IL-8 (26.6 pg/ml to 15.5 pg/ml) suggesting an autocrine 
activity. The data obtained using DHMEQ showed that in EGF-stimulated 
IGROV1 cells the production of IL-6, PAI-1 and IL-8 is partially dependent 
from NF-kB transcriptional activity. Other signaling pathways could induce the 
release of these inflammatory molecules. The data obtained up to now 
demonstrated that in EOC in vitro model the ligand-dependent EGFR activation 
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could induce the activation of PI3K/AKT and MEK/ERK downstream signaling 
pathways that at nuclear level induce NF-kB transcriptional activity and the 
production of inflammatory molecules such as IL-6, PAI-1 and IL-8. 
1.6 EGFR silencing inhibits the expression of IL-6 and PAI-1 
The previous results were validated in EGFR-silenced IGROV1 cells. EGFR 
knockdown was obtained with anti EGFR small interfering RNA (siRNA). 
EGFR silencing was monitored in IGROV1 cells up to 96 hr (Figure 6A). 
EGFR expression was evaluated by western blotting together with ERK and 
AKT phosphorylations. We chose to treat IGROV1 cells for 48 hr with EGFR 
siRNA, since at that time the highest levels of EGFR silencing was observed, 
together with a strong decrease of MAPK and PAKT (Figure 6A). IGROV1 
cells were silenced for 48 hr and a 60% decrease in EGFR expression was 
concomitant to 90% and 50% decrease of ERK and AKT phosphorylation 
respectively (Figure 6B). Subsequently, EGFR-silenced IGROV1 cells were 
transfected with the luciferase reporter construct as above. The analysis of NF-
kB transcriptional activation revealed that in EGFR-silenced cells for 48 hr NF-
kb transcriptional activity decrease 70% respect to control cells (Figure 6C). 
The transcripts levels of EGFR, IL-6, PAI-1 and IL-8 were evaluated by Real 
time RT-PCR on total RNA from EGFR 48 hr silenced IGROV1 cells, and we 
found that a 15-fold decrease of EGFR transcripts were associated to both IL-6 
and PAI-1 transcripts decrease and only of 25% decrease in IL-8 transcripts 
(Figure 6D). Interestingly, the decrease of IL-6 levels in EGFR silenced cells 
were comparable to those observed in IGROV1 cells stimulated with EGF and 
inhibited with AG1478 demonstrating once more that IL-6 release is dependent 
from EGFR activation. Thus, these in vitro data demonstrated that the releasing 
of IL-6 and PAI-1 is mediated by ligand-dependent EGFR activation mainly 
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through induction of MEK/ERK activation and consequent nuclear 
translocation of NF-kB transcription factor.  
1.7 The expression of IL-6 and PAI-1 in EOC samples
The in vitro results were validated through IHC analysis. Thus the expression of 
EGFR, IL-6 and PA-1 was evaluated on 23 formalin-fixed embedded primary 
tumors of EOC and four arbitrary scores were given: (negative (-), faint (+), 
moderate (++) and strong (+++)), for EGFR membrane and/or cytoplasmic 
protein localization. The majority of samples (74%), expressed heterogeneously 
EGFR on the membrane of tumor cells (Table 2). Samples that showed high 
reactivity for membrane EGFR, expressed the protein also in the cytoplasm. Six 
cases expressed EGFR only in the cytoplasm. Seventy percent of tumor samples 
expressed IL-6 and interestingly, among the samples with the highest EGFR 
expression, 4 of these also showed the strongest expression for IL-6. An 
example of this type of correlated expression between EGFR and IL-6 is 
reported in Figure 7A. On the contrary, in some sections with strong EGFR 
expression, not all tumor cells express IL-6. Some samples showed 
homogeneous staining with anti-PAI-1 (samples 7 and 23) but in other samples 
it seemed heterogeneous. Of note, the samples with the highest reactivity for 
PAI-1 were the same that expressed the highest levels of both EGFR and IL-6 
(Figure 7A). The levels of IL-6, PAI-1 and IL-8 were evaluated by ELISA 
assay in the ascites of corresponding tumor samples. We found that among the 
23 ascites tested, 12 expressed medium-high levels of both IL-6 and PAI-1 
(Figure 7B), they showed a positive and statistically significant correlation with 
r 0.68 and P value 0.002 (Figure 7C). Interestingly, the corresponding tumor 
cells of these 12 ascites, co-expressed EGFR, IL-6 and PAI-1 (Table 2). IL-8 
levels seemed not to be correlated with IL-6 and PAI-1 release; some samples 
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expressed variable levels of three molecules. Moreover, we collected all 
cytological informations associated with the tested EOC ascites (Table 3), and 
we found that most of samples with medium/high release of IL-6 and PAI-1 
contained tumor cells only or traces of immune cells, indicating that both 
inflammatory molecules could be indeed produced by tumor cells (Figure 8A). 
As already said, IL-6 is one of the main inflammatory cytokine produced by 
immune cells such as macrophages or dendritic cells. Thus, IL-6 production is 
also due to immune cells. On the other hand, there are no evidences that PAI-1 
can be produced by immune cells yet. Of note, 25% of EOC samples contained 
medium and high levels of PAI-1, indeed we can argue that it is produced only 
by tumor cells. However, whether immune system could contribute to PAI-1 
production in EOC microenvironment needs further investigation. 
1.8 The analysis of IL-6 and PAI-1 in EOC publicly available datasets 
To deeply investigate the relationship between EGFR, IL-6, PAI-1 and IL-8 we 
examined four available datasets of gene expression profile of EOC patients. 
The four publicly available datasets were generated using Affimetrix platform 
and downloaded from web. These datasets were named I [Tothill et al. 2008], II 
[Anglesio et al. 2008] III [Bild et al. 2006] and IV [Berchuck et al. 2009]. The 
characteristics of EOC gene expression datasets used are summarized in Table 
4. On dataset I, containing the highest number of EOC patients, we decided to 
first evaluate EGFR, IL-6, PAI-1 and IL-8 gene expression intensities. As 
shown in Figure 9A the EGFR transcript levels (red line) seemed very 
homogeneous while variable levels of IL-6, PAI-1 and IL-8 transcript levels 
were expressed. Indeed, the analysis of all possible correlations between EGFR, 
IL-6, PAI-1 and IL-8 were carried out, and the highest correlation score was 
only found between IL-6 and PAI-1 (r=0.58, P>0.00001); the correlations 
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between the other molecules were not significant (Figure 9B). As well, the 
correlation between IL-6 and PAI-1 was statistically significant also in the other 
datasets (II, III, IV) (Figure 9C). Subsequently, to investigate if IL-6 and PAI-1 
expression was possibly correlated with clinical parameters like stage, survival 
and chemotherapy resistance, we decided to analyze data set I, reporting 
detailed clinical annotations. The patients of dataset I were filtered for high and 
low IL-6 and PAI-1 co-expressions (by selecting patients expressing both genes 
above the respective 3rd quartile or below the 1st quartile), and we found that 
high IL-6 and PAI-1 co-expression was associated with advanced-stage EOCs 
disease (Figure 10A). The patients of dataset I were also analyzed for 
progression free survival (PFS), the time from chemotherapy treatment to 
disease relapse. The analysis of PFS showed that the patients with high IL-6 
and PAI-1 co-expression relapsed earlier than patients with low IL-6 and PAI-1 
co-expression as seen from Kaplan-Meier curves (Figure 10B). Interestingly, 
IL-6 and PAI-1 expressions individually did not discriminate between the two 
groups (Figure 10C). 
The in silico analyses demonstrated that IL-6 and PAI-1 co-expression could 
identify a subgroup of EOC patients resistant to conventional chemotherapy. 
These patients in which the ligand-dependent EGFR activation induces the co-
expression and release of IL-6 and PAI-1 through NF-kB activation, could 
identifying the EOC patients that could benefit from anti EGFR drugs. 
Conclusions and Future Prospects 
The results collected so far in EOCs demonstrated that 1) ligand-dependent 
EGFR activation leads to a signaling cascade that through MEK/ERK pathway 
and subsequent NF-kB transcriptional activation induces the co-release of IL-6 
and PAI-1. The in vivo results, demonstrated that 57% of advanced-stage EOC 
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patients co-express EGFR, IL-6 and PAI-1. 2) The analysis on ascites from the 
corresponding patients revealed the presence of both IL-6 and PAI-1. 3) The in 
silico analyses on four publicly available datasets of EOC gene expression 
profile revealed that the high co-expression of IL-6 and PAI-1 is associated 
with advanced-stage EOCs and with patients that relapsed earlier after 
chemotherapy. 
These results suggest that the signaling cascade EGFR/MEK-ERK/NF-kB/IL-6-
PAI-1 could identify the EOC patients: 1) less sensitive to conventional 
chemotherapy (cisplatin+paclitaxel); 2) but that could be sensitive to anti-
EGFR therapy. Overall these results gave evidence that only considering EGFR 
expression is not sufficient to define a role of EGFR activation and sensitivity 
to anti-EGFR therapeutic approach. These data are supported by other scientific 
works, showing similar pathways in glioblastoma cell lines where EGFR 
activation drives PAI-1 production through PKC/SPHK1/AP1 cell signaling 
activation [Paugh et al. 2008]. In agreement with our results of IL-6 and PAI-1 
co-expression, a meta analysis performed on publicly available datasets of gene 
expression profile of breast carcinomas revealed a positive correlation between 
these two molecules [Sternlicht et al. 2006]. We suggest that evaluation of IL-6 
and PAI-1 co-expression could give informations about EOC progression. PAI-
1, together with UPA, is already used as prognostic marker in breast cancer. 
Indeed, for breast cancer patients UPA/PAI-1 expression levels give 
information about risk relapse and response to endocrine and chemotherapeutic 
treatment [Leissner et al. 2006]. PAI-1 is usually quantified through protein-
based assay, but unfortunately in breast cancer this technique is not applicable 
due to exiguity of available biopsy tissues [Look et al. 2002]. On the contrary, 
in EOC, PAI-1 levels could be measured in ascites in a very easy way using a 
small quantity of the biologic fluid. Therefore, we will extend the analysis of 
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IL-6 and PAI-1 co-expression on a large number of EOC patients to validate the 
present data. 
SECTION 2 - Characterization of IL-6 and EGFR expressing EOCs 
Results and Discussion 
2.1 IL-6 correlated genes 
To deeply investigate the role of IL-6 in EOCs, we decided to apply a 
bioinformatic analysis examining seven publicly available datasets of gene 
expression profile of EOCs. These datasets were named I [Tothill, et al. 2008], 
II, [Anglesio, et al. 2008] III, [Bild, et al. 2006] IV [Cancer Genome Atlas 
Research Network 2011],V [Berchuck, et al. 2009], VI [Dressman et al. 2007] 
and VII [Yoshihara et al. 2010]. In Table 5 the characteristics of seven datasets 
are summarized: six of them are arrayed on Affimetrix platform and one on 
Agilent platform, containing the gene expression profile of advanced-stage 
disease and low malignant potential (LMP) EOC patients. The raw data from 
each datasets were downloaded from the web, normalized and the Pearson’s 
correlation analysis of IL-6 vs all genes was performed. This kind of analyses 
allowed to identify the genes that are positively correlate to IL-6 in all seven 
datasets with a P value 0.05 and a Pearson’s correlation coefficient (r) 
exceeding 0.4. In Figure 11 are reported the IL-6 correlated genes in at least 
four datasets. The forty IL-6 correlated genes founded in all seven datasets 
included CXCL2, HBEGF, SERPINE1, DUSP1, ZFP36 and IER3. As shown in 
Table 6 the majority of genes are associated to proliferation; some of them are 
involved in inflammation pathways and few of them in metabolism, cell cycle 
and apoptosis. Of note, is that SERPINE1, gene encoding for PAI-1 protein, is 
one of the six genes found common to all datasets, and with HBEGF, an EGFR 
ligand. Therefore, in accordance with our previous results, IL-6 and PAI-1 co-
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expression may be driven by EGFR activation in advanced EOC patients. 
Thanks to this analysis, we found that the majority of genes correlated to IL-6 
are mainly associated to proliferation pathways, indicating that IL-6 expression 
might affect EOC cells proliferation. 
2.2 Identification of an IL-6 correlated gene signature specific for 
advanced-stage EOCs 
In order to investigate if the identified gene signature associated to IL-6 was 
specific for advanced EOCs or LMP EOCs, the correlation analysis on I, II and 
IV datasets, containing also LMP EOC patients, was carried out. We found that 
33 out of the 40 IL-6 correlated genes are highly correlated in both LMP and 
advanced-stage EOCs. Seven of these genes (C5AR1, FPR1, GOS2, IL-8, 
KLF2, MMP19 and THBD) were significantly correlated only in advanced-
stage EOCs (Table 7). By this analysis, among the 40 positively IL-6 correlated 
genes, we have identified two different signatures: one associated to 
proliferative pathways common to advanced-stage EOCs and LMP EOCs, and 
the second specific for advanced-stage EOCs associated with signaling 
pathways involved in thrombosis and cardiovascular disease. These data 
suggested that only in advanced-stage EOCs the pathways associated to 
thrombosis and cardiovascular disease are important for growth and/or spread 
of this type of tumor, since that genes like THBD, FPR1 and KLF2 have been 
found correlated to IL-6 only in advanced-stage EOCs. 
2.3 IL-6-correlated gene signature is associated to growth factor response 
in EOC. 
To deeply understand the role of IL-6 correlated genes in the biology of EOC, 
we decided to apply the GSEA analysis (gene set enrichment assay) 
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[Subramanian et al. 2005] on all datasets listed in Table 5. Upon GSEA 
analysis we have identified the gene sets related to IL-6 (Table 8). Then, we 
have focused our attention on 5 gene sets: 
AMIT_EGF_RESPONSE_60_HELA, AMIT_EGF_RESPONSE_120_HELA 
[Amit et al. 2007] and NAGASHIMA_NRG1_SIGNALING_UP [Nagashima
et al. 2007] that are all correlated with early growth factor response. These gene 
sets comprise some genes like ZFP36, IER3, FOSB that upon growth factor 
stimulation are up-modulated as negative feedback of growth factor related cell 
signaling. The other gene set identified is KIM_WT1_TARGET_UP that 
comprises the WT1 targets AREG, EREG and HBEGF genes [Kim et al. 2007] 
that are EGFR ligand, and SERPINE1 gene that we are already correlated to 
EGFR activation in our EOC in vitro model [Alberti et al. 2012]. The gene set 
BILD_KRAS_ONCOGENIC_SIGNATURE [Bild et al. 2006] that included 
genes related to H-RAS oncogene, is our positive control since that derived 
from dataset III that has been used in this work. These results are strongly in 
line with those reported in the previous section where ligand-dependent EGFR 
activation characterized IL-6 expressing EOCs. 
2.4 Validation in vitro of some of the 40 IL-6-correlated genes. 
Seen these results, we decide to validate the expression of the some of the 
identified IL-6-correlated genes in vitro, in cells stimulated with EGF. We 
performed Real time RT-PCR on total RNA from IGROV1, OAW42, SKOV3 
serous EOC cell lines together with IOSE-HTERT64, the non-transformed 
ovary cell line. In all EOC cell lines EGF induced the IL-6 release in a EGF-
dependent manner. In particular, CXCL2, HBEGF, SERPINE1 and DUSP1, 
common to 7 datasets, were up-modulated in all three EOC cell lines, as well, 
NR41, common to 6 datasets. Among the 7 genes that characterized a gene 
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signature associated to advance-EOCs stage, THBD and KLF2 genes were 
concomitantly up-modulated only in EGF-stimulated SKOV3 cells (Figure 12). 
On the contrary, in EGF-stimulated IGROV1 and OAW42 cells were up-
modulated only THBD and KLF2 respectively. To summarize, 75%, 58% and 
75% of the IL-6-correlated genes were up-modulated in IGROV1, OAW42 and 
SKOV3 cells, respectively. Instead, in IOSE-HTERT64 only 25% of the 
transcripts were up-modulated upon EGF stimulation, furthermore, only a small 
increase of IL-6 was observed. All these data argue for the hypothesis that in 
EOCs this gene set is dependent from EGFR activation, leading to a specific 
gene signature named ”growth factor response’’, indicating that the ligand-
dependent EGFR activation in serous EOC cells induce IL-6 release and genes 
associated to growth factor stimulation. 
2.5 The biological role of IL-6 in EOC 
In order to assess the biologic role of IL-6, in vitro experiments were 
performed. IL-6 knockdown was performed with anti-IL-6 siRNA. First of all, 
the IL-6 silencing conditions were assessed. In IGROV1 cells IL-6 was silenced 
24 hr, 48 hr and 72 hr using two different siRNA concentrations (20 pm/ml and 
40 pm/ml) and the expression of IL-6 transcript was evaluated by Real time 
RT-PCR on total RNA. IGROV1 cells IL-6 silenced for 24 hr with the highest 
siRNA concentration were used for further experiments (Figure 13A). Indeed 
IGROV1 cells were silenced for IL-6 and the effect on cell proliferation was 
evaluated. IGROV1 cells IL-6 silenced for 24 hr showed about 30% less of 
growth capability respect to treated control-cells (Figure 13B), in accordance 
with other works, which showed a link between IL-6 and EOC tumor growth 
and with the results showed above about the gene signature of IL-6 correlated 
genes in serous EOCs associated mainly to proliferation pathways. IL-6, is an 
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important inflammatory cytokine present at high levels in the ascites of EOC 
patients, where its presence could be related with tumor aggressiveness [Wang
et al. 2012]. We previously reported (Section I) a clear correlation between 
EGFR activation and IL-6 release. For these reasons we decided to test in 
IGROV1 cells the effects of IL-6 silencing on Gefitinib sensitivity of EOC 
cells. IL-6 silenced IGROV1 cells were treated with Gefitinib and cell 
proliferation was followed up to 96 hr. We found an increase of sensitivity to 
Gefitinib treatment associated with IL-6 silencing of about 3-fold respect to 
control-treated cells (Figure 13C). These data suggest that IL-6 not only have a 
role in the proliferation, as already stated [Wang et al. 2012] but it is also 
involved in the efficacy of anti-EGFR drugs of EOC cells. To further 
investigate on the signaling cascade induced by IL-6 release in EOCs, we 
silenced IL-6 in IGROV1 cells from 24 hr and up to 72 hr, and the IL-6 
downstream effectors of IL-6 signaling pathways were evaluated by western 
blot analysis (Figure 14A). In IL-6 silenced cells for 72 hr we observed a strong 
decrease of P-EGFR Tyr1068, a STAT3 binding site. Indeed, upon IL-6 binding 
to its membrane receptors the activation of STAT3 dependent signaling 
pathway is induced. Since IL-6 receptors has no intrinsic kinase domain, the 
JAK1, JAK2 are found to be associated constitutively with gp130 and are 
activated in response to IL-6 and other IL-6 family members [Stahl et al. 1994]. 
The activation of these kinases, induce the phosphorylation of Stat3 at Tyr705. 
STAT3 Tyr705 as dimer, could translocates from the cytoplasm to the nucleus, 
where its transcriptional activation could be regulate upon serine 727 
phosphorylation through MAPK or mTOR pathways [Sansone et al. 2012]. 
STAT3 phosphorylations Tyr705 and Ser727 by Western blot analysis were 
evaluated. We observed a decrease of both STAT3Tyr705 and STAT3Ser727 
phosphorylation levels, meaning that the IL-6 loss in EOC impaired STAT3 
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nuclear translocation as well as transcriptional activation. Moreover, exploring 
EGFR activation status, we found that in IL-6-silenced IGROV1 cells the auto-
phosphorylation site Tyr1173 on EGFR levels were lower than in control cells, 
with the concomitant decrease of MAPK phosphorylation. Finally, in IL-6 
silenced cells P-Tyr416Src levels were reduced, in parallel with diminished P-
Tyr845 EGFR levels, a known Src phosphorylation site on EGFR [Tice et al.
1999]. These data showed that in the same cell line where is activated the 
EGFR/MEK/NF-kB pathway, IL-6 release appears to activate an autocrine loop 
of ligand/EGFR activation through STAT3/src signaling that induces a 
hyperactivation of EGFR (Figure 14B).
Conclusions and Future Prospects 
The results collected in this section are aimed to elucidate the biologic role of 
IL-6 in the progression of EOCs expressing EGFR using different experimental 
approaches: i) identifying co-regulated genes and gene networks by 
bioinformatic approaches, ii) studying the IL-6 downstream signaling pathways 
and its relevance in EOC biology. We have applied the bioinformatic 
approaches analyzing seven publicly available datasets of gene expression 
profile of EOCs. Thanks to this analysis we could study the gene expression 
profile of more of 1200 EOC samples, and found that IL-6 co-regulated genes 
encoding for proteins mainly involved in proliferation-associated pathways. 
Next, we were also able to identify two IL-6 correlated gene signatures: one (33 
genes) common to LMP serous and advanced-stage EOCs, and the second (7 
genes) specific for advanced-stage EOCs. Of note, the 7-gene signature 
comprised genes like THBD, KLF2 and FPR1 that are involved in thrombosis, 
coagulation pathways and cardiovascular disease, suggesting that these 
pathways could contribute to progression and spread of EOCs. The results 
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obtained by GSEA analysis showed that both LMP and advanced-stage EOCs 
express IL-6 and IL-6-co-regulated genes associated with “early growth factor 
response”. Indeed, from GSEA analysis, one of the selected gene set was those 
identified from Amit I. et al named “delayed early genes” (DEG) cluster, 
encoding for proteins with a role in controlling growth factor effects. Indeed, 
the in vitro validation, demonstrated that the hypothesis formulated upon the in 
silico analysis was successful, showing that negative feedback regulator genes 
like ZFP36 and KLF2 were up-modulated upon growth factor stimulation of 
EOC cells. While negative feedback regulator proteins are a physiological 
cellular mechanism to turn off the intracellular signaling pathways, its role in 
cancer is deregulated as observed in BRAF mutant melanomas [Pratilas et al.
2009]. Of note, the feedback negative mechanisms have been correlated with 
the cell sensitivity to growth factor receptor targeted-therapy [Chandarlapaty 
2012], and accordingly our results suggested that EOC cells presenting 
activated EGFR/MEK/NFKB/IL-6 signaling pathway are more sensitive to anti-
EGFR drugs, maybe due to up-regulation of negative feedback mechanisms. 
Moreover, the bioinformatic analyses showed a new 7-gene signature 
specifically associated to advanced-stage EOCs, that included genes involved in 
angiogenesis, cardiovascular disease, thrombosis and coagulation pathways. 
These pathways could open new frontiers in the knowledge on the progression 
and spread of advanced-stage EOCs. Recently, it has been demonstrated that the 
use of aspirin as anti-thrombotic agent or selective COX-2 inhibitors could 
reduce risk of EOCs by reducing inflammation and thrombosis-associated 
pathways [Lo-Ciganic et al. 2012]. Indeed, the concomitant inhibition of these 
pathways could represent a new approach to reduce the progression and 
peritoneal dissemination of advanced-stage EOCs. On the other hand, the in 
vitro experiments on IGROV1 cells demonstrated that IL-6 silencing inhibited 
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cell growth and that IL-6, produced by EGFR/MEK/NF-kB pathway, triggers 
an autocrine and secondary loop of ligand/EGFR activation through STAT3/src 
signalling. The lattest data may indicate that EGFR-mediated IL-6 release could 
induce a secondary signaling loop thus inducing the hyper-activation of EGFR. 
Experiments are ongoing to study how the IL-6 co-regulated signature could 
identify the EOC patients more responsive to anti EGFR compounds. 
Moreover, further in vitro experiments will be necessary to better clarify IL-6 
downstream signalling pathways associated to drug resistance and induction of 
EMT.
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SECTION 3 
Results and discussion 
3.1 The biological role of PAI-1 in EOC 
In the section 1, we have showed that EGFR/MEK/NF-kB pathway activation 
induces the co-expression of IL-6 and PAI-1. In the present section the role of 
PAI-1 will be analyzed. PAI-1, the physiological inhibitor of uPA/UPAR 
complex has been associated to progression and angiogenesis in many human 
malignancies [Stefansson et al. 2001]. PAI-1 expression, often induced by 
TGF-ß1, has been associated to invasive cancer, possibly as regulator of 
uPA/UPAR function [Dass et al. 2008]. Both UPA and UPAR expressions are 
correlated with progression of EOCs [Wang et al. 2009a]. Seen the 
heterogeneity tipical of tumors, we also observed that the modulation of PAI-1 
expression in EOC cell lines could be differently regulated. In the EOC cell line 
OAW42, representative of less aggressive EOC cells, PAI-1 expression was not 
up-modulated upon EGF stimulation, evaluated as PAI-1 transcript (Figure 
15A). Accordingly, PAI-1 in the OAW42 conditioned media, although present, 
was not EGFR-dependent (Figure 15B). Among the EOC cell lines, SKOV3 
cells, representative of a more aggressive EOC cells, PAI-1 expression could be 
induced by TGF-ß/SMAD signaling pathway and regulates their invasiveness 
[Wakahara et al. 2004]. When the expression of PAI-1 and TGF-ß1 transcript 
levels were evaluated on RNA from SKOV3 cell line we found, as expected, 
that these cells expressed TGF-ß1 together with PAI-1 at high levels, while in 
OAW42 cells, TGF-ß1 and PAI-1 transcripts were 76- and 10-fold less 
expressed, respectively (Figure 15C). These data confirmed that in SKOV3 but 
not in OAW42 cells, PAI-1 release may be mediated by TGF-ß1. In order to 
assess the biologic role of PAI-1, experiments on PAI-1 silenced OAW42 and 
SKOV3 cells were performed. PAI-1 knockdown was performing with anti- 
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PAI-1 siRNA. OAW42 and SKOV3 cells were silenced for PAI-1 for 48 hr 
using two different siRNA (siRNA1 and siRNA2) at two different 
concentrations (20 pm/ml and 40 pm/ml). The expression of PAI-1 transcripts 
levels were evaluated by Real time RT-PCR on total RNA from OAW42 and 
SKOV3 cells. EOC cells silenced with a PAI-1 specific siRNA for 48 hr, using 
40 pm/ml resulted to knockdown the majority of PAI-1 transcripts (Figure 
15D); therefore these conditions were used for further experiments. OAW42 
and SKOV3 cells were silenced for PAI-1 and the effect on cell proliferation 
was evaluated (Figure 16A). We found no differences on cell growth between 
PAI-1 silenced EOC cells and control cells, arguing that PAI-1 expression had 
no effects on cell proliferation. PAI-1 expression has been correlated to 
invasive cancer, possibly as regulator of UPA/UPAR function [Dass et al. 
2008]. Both UPA and UPAR expressions are correlated with progression of 
EOCs [Wang et al. 2009a]. Indeed, PAI-1 should inhibit UPA function, but its 
role in the invasion of tumor cells is not well clarified. PAI-1 could also affect 
cell migration through the recruitment of low-density lipoprotein receptor-
related protein-1 (LRP1) and its receptor [Czekay et al. 2011]. Furthermore, the 
three different PAI-1 conformations (active, latent and cleaved) interact with 
LRP1 inducing cell migration activating JAK/STAT signalling pathway 
[Kamikubo et al. 2009]. Indeed, active PAI-1 is recycled to cell membrane in a 
complex with UPA/UPAR/LRP1, while the latent and cleaved forms of PAI-1 
remain in the ECM, as reservoir, to mantain cell movement.  In this way, PAI-1 
promotes cancer cell detachment by causing the internalization of the PAI-
1/UPA/UPAR/integrin complex [Czekay et al. 2003]. Moreover, PAI-1 may 
also have a role in the control of cell adhesion through the interaction between 
LRP1 and Vitronectin (VN), thus promoting cell detachment from different 
substrates such as VN, fibronectin (FN) and collagen matrices thus activating 
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cell migration [Czekay et al. 2009]. In order to evaluate whether PAI-1 
contributes to EOC cell attachment to different substrates, adhesion assays of 
PAI-1-silenced cells were performed. The capability of PAI-1 silenced OAW42 
and SKOV3 cells to adhere to FN and VN matrices was tested. Silenced cells 
were allowed to adhere to FN and VN for 1 hr and we found that PAI-1-
silenced OAW42 cells adhere 32% and 40% less than control cells on FN and 
VN respectively. PAI-1-silenced SKOV3 cells adhere 28% less on FN substrate 
than control cells, although this effect was less evident on VN substrate, where 
they adhere 20% less than control cells (Figure 16B). These results indicate that 
PAI-1 could regulate EOC cell attachment to different substrates; this effect 
was more evident in OAW42 cells. These results are in agreement with the 
studies on the interactions between PAI-1 and VN in regulating cell adhesion 
and migration. In particular, PAI-1 expression was able to protect VN from 
proteolysis through the inhibition of UPA/UPAR system and stabilization of the 
cell adhesion to VN [Kamikubo et al. 2009].  In human myogenic cells PA-1 
increased adhesion and spreading with a mechanism that involved 5ß3 integrin 
[Planus et al. 1997]. More robust and abundant are the studies about the 
involvement of PAI-1 in the regulation of the cell motility. In fibrosarcoma and 
melanoma cells treatment with anti-PAI-1 antibodies impaired their migratory 
and invasive capability [Brooks et al. 2000]. Moreover, PAI-1 down-regulation 
in a cutaneous healing model inhibited the wound closure by 85% thus further 
demonstrating the involvement of PAI-1 in the motility of keratinocytes 
[Providence et al. 2008]. Therefore, we decide to test the migratory capacity of 
PAI-1 silenced OAW42 and SKOV3 cells. Twenty-four hours PAI-1 silenced 
cells clearly showed significant impairment in wound closure when compared 
with the control cells. PAI-1-silenced OAW42 cells repaired the wound by 
2.3% and 15%, following incubation of physically wounded cells at 8 hr and 24 
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hr respectively. While OAW42 control cells repaired the wound by 15% and 
42% following incubation of physically wounded cells at 8 hr and 24 hr 
respectively. At 4 hr no differences were observed between OAW42 PAI-1 
silenced cells and control cells (Figure 16C left panel). Similar results were 
obtained with SKOV3 cells: PAI-1 silenced cells showed significant 
impairment in wound closure when compared with the control cells. PAI-1-
silenced SKOV3 cells repaired the wound by 3%, 12% and 24% following 4 hr, 
8 hr and 24 hr respectively (Figure 16C right panel). PAI-1 has been observed 
at the invasive front of the tumor and its expression was significantly up-
regulated in both cancer cells and stromal cells [Illemann et al. 2009]. Studies 
performed in a transgenic mouse ocular tumor model, showed that PAI-1 
deficiency affected the induction of brain metastasis [Maillard et al. 2008]. On 
the basis of these indications, the effect of PAI-1 expression on cell invasion 
was tested in OAW42 and SKOV3 cells. PAI-1 silenced OAW42 and SKOV3 
cells were assessed for the capacity to invade through an 8µM pore 
polycarbonate membrane with a Matrigel matrix. As expected, 58% and 15% of 
PAI-1 silenced OAW42 and SKOV3 cells were able to invade the matrigel 
matrix as compared to control cells, respectively (Figure 17A). All these data 
indicated that PAI-1 expression could have also a role in the control of EOC 
cells motility. As already mentioned, PAI-1 expression can be induced by TGF-
1 , which in turn is  also a strong inducer of EMT [Heldin et al. 2012]. 
Furthermore, EMT occurring during tumor progression has been linked to a 
more migratory and invasive behaviour [Gao et al. 2012]. To evaluate whether 
PAI-1 could be an EMT inducer, IF was performed on control and PAI-1 
silenced OAW42 and SKOV3 cells. IF analysis showed that in PAI-1 silenced 
SKOV3 cells E-cadherin expression, epithelial marker, was higher than in 
control cells and in some cells is particularly localized at cell-cell junctions. In 
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contrast, in SKOV3 silenced cells N-cadherin expression seemed decreased 
respect to control cells arguing for the notion that PAI-1 silencing could induce 
a more epithelial phenotype (Figure 17B). Accordingly, to this evidence, in 
PAI-1 silenced SKOV3 cells the expression of the epithelial proteins 
cytokeratin8/18 was higher respect to control cells while the mesenchymal 
protein vimentin was less expressed. In addition, F-actin fibers stained with 
phalloidin, had a cortical localization demonstrating epithelial phenotype once 
more. In PAI-1 silenced OAW42 cells similar results were obtained (Figure 
17B). To deeply investigate the role of PAI-1 in EOCs, we performed a 
correlation analysis on dataset I (Section 1) as reported previously [Alberti et al. 
2012]. This kind of analyses allowed to identify the genes that are positively 
correlated to PAI-1 with a P value 0.05 and a Pearson correlation coefficient 
(r) exceeding 0.55. This analysis yielded 119 PAI-1-correlated genes. In 
agreement with in vitro results we found that 65 genes among the 119 PAI-1-
correlated genes have functions related to ECM remodeling, cell-adhesion, or 
encode for ECM components (Figure 18) arguing for the notion that PAI-1 in 
EOC may have a role in controlling and regulating these pathways. 
Conclusions and Future Prospects 
The results collected in this section are aimed to elucidate the biologic role of 
PAI-1 in the progression of EOCs. To this aim we preformed in vitro 
experiments on two different EOC cell lines: SKOV3 and OAW42 representing 
two different EOC cell models. The main role of PAI-1 is the physiological 
inhibition of UPA/UPAR system thus regulating ECM remodelling [Gramling 
et al. 2010]. The binding of UPA to its cognate receptor UPAR induces the 
conversion of plasminogen to plasmin thus activating many metalloproteases 
including gelatinase, collagenases and MMP1, involved in matrix degradation. 
A pro-inflammatory program driven by EGFR activation in the epithelial ovarian cancer
58 
PAI-1 is able to form a complex with UPA thus inhibiting these proteolytic 
processes. Therefore, the observation that PAI-1 levels were found up-regulated 
in many type of cancer including EOCs and were correlated with worst 
prognosis could be considered a paradox. PAI-1 has been also implicated in 
regulating adhesion and de-adhesion cell processes. For these functions, PAI-1 
inhibits cell adhesion, by a mechanism not well understood yet. On the other 
hand, it has been suggested that PAI-1could induce the de-adhesion from many 
substrates inactivating integrin cluster and signaling [Czekay et al. 2003], or, 
alternatively, through the binding with UPA thus inducing the dissociation of 
UPA/UPAR complex to VN [Madsen et al. 2007]. On the basis of these 
evidences, we performed in vitro experiments on PAI-1 silenced SKOV3 and 
OAW42 cells. We found that the loss of PAI-1 in our in vitro models affected 
the cell adhesion to FN and VN, as well as inhibited cell migration and invasion 
likely as regulator of EMT. Indeed, our results showed that in both cell lines 
PAI-1 silencing induced up-modulation of the epithelial markers E-cadherin 
and cytokeratin8/18 as well as the partial loss of mesenchymal proteins such as 
N-cadherin and vimentin. Of note, this transition to an epithelial phenotype is 
an event more evident in SKOV3 cells, maybe due to the fact that this cell line 
has a more mesenchymal phenotype than OAW42 cells. Moreover, preliminary 
bioinformatic analyses showed the correlation between PAI-1 with genes 
involved in cell-matrix, cell-cell interactions and ECM-remodelling. The 
specific objectives of my future research will focus on deeply investigating the 
biological role of PAI-1 developing a mouse model of EOC xenografts in which 
PAI-1 will be stably knockdown. Subsequently, the computational analyses on 
publicly available datasets of gene expression profile from EOC patients will be 
carried out. 
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Figure 1. A.  EGFR membrane staining was determined by flow cytometry on EOC cell lines. 
The gray peaks represent the fluorescence of the cells incubated with an isotype control 
antibody. The purple peaks represent the fluorescence of cells incubated with anti-EGFR 
antibody. The numbers above the histograms represent the percentage of mean fluorescence 
intensity. B. IL-6 release was assayed by ELISA in media from EOC cells grown for 24 hr in 
medium supplemented with 10% FCS. C. Western blot analysis was performed on total cell 
lysates from IGROV1 and OAW42 cells. After 24 hr of serum starvation, cells were left 
untreated or treated with 20 ng/ml EGF alone from 5 min to 60 min. The antibodies used are 
indicated. -actin is shown as a control for protein loading. A representative experiment of 3 is 
shown. D. IF analysis with anti-EGFR Ab on serum-starved IGROV1 and OAW42 cells left 
untreated or treated with 20 ng/ml EGF for 20 min.The samples were analyzed using a Nikon 
inverted light microscope with a 20X PanFluor objective
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Figure 2. A. Western blot analysis was performed on total lysates from starved IGROV1 and 
OAW42 cells left untreated or treated for 20 min with EGF alone or together with AG1478. The 
antibodies used are indicated. -actin is shown as a control for protein loading. A representative 
experiment is shown; all experiments were performed in triplicate. B. IGROV1 and OAW42 
cells were exposed to different concentrations of Cetuximab for 96 hr in medium with FCS and 
cell growth was assayed using the CellTiter-Glo® Luminescent Cell Viability Assay Kit. Result 
represented as mean of five independent replicates ± standard deviation. RLU, Relative 
Luminescence Unites C. Dose response curves of IGROV1 and OAW42 cells treated with 
Erlotinib or Gefitinib for 72 hr. B and C: Representative growth curves of three independent 
experiments are shown; each point represents the mean of five independent replicates ± SD. 
Asterisks indicate a significant difference by two-way ANOVA. 
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AG1478 (20 µM). Representative growth curves of one of three independent experiments are 
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promoter gene assay of starved EOC cells transiently transfected with reporter plasmids 
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efficiency in a representative experiment. C. Real-time RT-PCR for IL-6 from total RNA of 
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Table1.  Levels of cyto/chemokines measured by Bioplex technology. Asterisks indicate value 
interpolated beyond standard range 
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Figure 5. A. Fold change in PAI-1 and IL-8 levels compared to un-stimulated cells released in 
media from starved IGROV1 cells stimulated for 4, 8, and 24 hr with EGF alone (20ng/ml), 
EGF plus AG1478 (20 µM), or AG1478 alone (20 µM) evaluated by the Procarta cytokine 
assay. B. Real-time RT- PCR for PAI-1 and IL-8 from total RNA of IGROV1 treated as above. 
Results are presented as relative expression normalized for GAPDH mRNA levels. C. IL-6, 
PAI-1, and IL-8 levels measured by the Procarta cytokine assay on conditioned media from 
starved EOC cell lines left untreated, treated for 24 hr with EGF alone, or together with 
DHMEQ (5 µg/ml). Asterisks indicate a significant difference by one-way ANOVA (B) and t-
test (C). 
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Figure 6. A. Western blot analysis of total lysates from IGROV1 cells treated with control or 
EGFR-specific siRNA from 24 hr up to 96hr. The antibodies used are indicated. -actin is 
shown as a control for protein loading. A representative experiment is shown. B. Western blot 
analysis of total lysates from IGROV1 cells treated with control or EGFR-specific siRNA for 
48 hr. The antibodies used are indicated. -actin is shown as a control for protein loading. A 
representative experiment is shown. C. Luciferase promoter gene assay of EGFR-silenced 
IGROV1 cells transiently transfected with reporter plasmids containing NF-kB binding sites. 
Data are mean values (±SD) normalized for transfection efficiency in three independent 
experiments performed in triplicate. RLU, Relative Luminescence Unites. D. Real-time RT-
PCR analysis for EGFR, PAI-1, IL-6, and IL-8 on total RNA from EGFR-silenced IGROV1. 
Results are represented as relative mRNA expression normalized for GAPDH mRNA levels. C
and D: Asterisks indicate a significant difference by t-test. 
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 EGFR                 IL-6                 PAI-1
A
B C
EOC Sample
a
EGFR 
  Mb                Cc  
IL-6 
C 
PAI-1 
C 
1                   +/++d - + 
2 ++ + + 
3 + + + 
4 ++ + ++ 
5 +                  ++ + ++ 
6 ++                ++ + + 
7 +++            +++                    +++ +++ 
8 ++ ++ + 
9                      +     - - 
10 +                   + + + 
11                     ++ ++ ++ 
12 ++  + ++ 
13                     ++ - + 
14 ++                ++ - - 
15 ++                 + + + 
16                   +/++ - + 
17 +++ - - 
18                    +++                                         + ++
19 +++ - ++ 
20 +++            +++ + ++ 
21 ++              +++ + ++ 
22 +++           +++                    ++ +++ 
23 +                  + + + 
Table 2. Expression and localization of EGFR, IL-6, and PAI-1 in formalin-fixed, paraffin 
embedded EOC samples evaluated by IHC.The numbers in bold italics indicate patients whose 
ascites co-expressed detectable levels of IL-6 and PAI-1 
b Membrane staining. 
c Cytoplasmic staining 
dArbitrary scores were given by two independent observers: negative (-), faint (+), moderate  
(++), and strong (+++) staining 
Figure 7. A. IHC for EGFR, IL-6, and PAI-1 in a primary formalin-fixed, paraffin embedded 
EOC sample. Representative images from sample #22 are shown. B. IL-6, PAI-1, and IL-8 
quantification by ELISA in 23 ascites samples from the same EOC patients. C. Correlation 
between IL-6 and PAI-1 levels measured in ascites. The linear regression line, Spearman 
correlations, and P values are shown. 
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Sample 
ID
Histotype Grading FIGOa
Stage 
Presence of:
Tumor 
cellsb
Immune 
cellsb
Mesothelial 
cellsb
1 Serous G3 IV Abundant Absent Present 
2 Serous G3 IIIC Abundant Present Present 
3 Serous G3 IIIC Abundant Rare Present 
4 Serous G3 III Rare Abundant Present
5 Serous G3 IIIC Abundant Abundant Abundant 
6 Serous G3 IIIC Present Present Present 
7 Serous G3 IIIC Rare Present Abundant 
8 
Serous and 
endometroid 
G3 IV Abundant Present Present 
9 Serous G3 IIIC Abundant Present Rare 
10 
Mullerian 
mixed 
NA IIIC Present Rare Abundant 
11 Serous G3 IIIC Rare Present Present 
12 Serous G2 IIIC Abundant Absent Present 
13 Serous G2 IIIC Abundant Present NA 
14 Serous G3 IIIC Rare Abundant Abundant 
15 Endometroid G3 IV Rare Absent Abundant 
16 Serous G3 IIIC/IV Present Abundant Abundant 
17 Serous G3 IV Abundant Present Rare
18 Serous G3 IIIC Abundant Absent Absent 
19 Endometroid NA IIIC Present Absent Abundant 
20 Serous NA IIIC Abundant Abundant Rare 
21 Serous G3 IIIC Present Absent Present 
22 Serous G2/G3 IIIC Abundant Absent Rare 
23 Serous G3 IIIC Abundant Present Present 
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Table 3. EOC patients characteristics evaluated in this study.
a     Federation of  Gynecologists and Obstetricians.  
b   The amount of cells present in ascites of EOC patients as defined by the cytopathologist at 
diagnosis 
Figure 8. A. Distribution of IL-6 and PAI-1 levels in the EOC ascites containing tumor cells 
alone (open circle), together with immune cells (filled circle) or containing only immune cells 
(filled square). 
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Dataset Totala Ib IIb IIIb IVb NAc
I 204 9 9 168 17 0
II 60 2 2 47 9 0
III 132 3 4 103 20 2
IV 41 0 0 31 10 0
4 6 8 10
4
6
8
10
12
r= -0.02957
p= 0.6746
EGFR
IL
6
4 6 8 10
4
6
8
10
12
r= -0.03351
p= 0.6342
EGFR
P
A
I-
1
4 6 8 10
4
6
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r= -0.008615
p= 0.9027
EGFR
IL
8
4 6 8 10
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r= 0.5817
p< 0.0001
IL6
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IL6
IL
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PAI-1
IL
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Dataset                            I                                                                                      I
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p=0.0006
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Table 4.  Characteristics of EOC gene expression datasets used.
a Number of patients 
b FIGO stage   
c Not available
Figure 9. A. Gene expression intensities of EGFR, IL-6, PAI-1, and IL-8 on dataset I for each 
of the 204 cases; EGFR expression is reported on the right Y axis, and the others on the left Y 
axis. B. Correlation among EGFR, IL-6, PAI-1, and IL-8 were determined and the values are 
plotted on a log2 scale. Pearson correlations (r), linear regression and P values are reported. C. 
Correlation between IL-6 and PAI-1 was analyzed in EOC datasets II, III, and IV. The values 
are plotted as log2 scale. Pearson correlations (r), linear regression and P values are reported. 
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Figure 10. A. Association between IL-6/PAI-1 expression intensities and tumor stage was 
analyzed on samples filtered for expression higher or lower than the respective median. Asterisk 
indicates a significant difference by Fisher’s exact test. B and C. Kaplan-Meier curves reporting 
the progression-free survival analysis on patient subgroups selected for IL-6/PAI-1 expression 
higher than the 3rd quartile and lower than the 1st quartile (log-rank test). 
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Table 5 
a Whole human genome oligonucleotide microarray. 
Dataset Platform Array
N. of 
probes
N. of serous EOC 
patients
Serous        LMP 
I  Affymetrix HG-U133 Plus 2 54675 204 18 
II  Affymetrix HG-U133 Plus 2 54675 59 30 
III  Affymetrix HG-U133A 22283 132 0 
IV  Affymetrix HG-U133A 22283 40 19 
V  Affymetrix HG-U133A 22283 118 0 
VI Affymetrix HT_HG-U133Aa 22277 598 0 
VII Agilent G4112A 41000 110 0 
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Figure 11. The heatmap of Pearson’s correlation coefficient (r) of the genes with IL6 was 
drawn by using R programming language. The r scores are represented in grayscale as reported 
in the color key. IL-6 self-correlation was artificially set to the maximum score. Correlation 
score below 0.4 were considered not significant (NS). Genes not spotted on the array were 
defined NA (not available). The number of data sets in which the gene resulted significantly 
correlated with IL-6 is reported on the right. 
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Gene Symbol Name Biological Function
a
IL6 interleukin-6  Inflammation
CXCL2 chemokine (C-X-C motif) ligand 2 Inflammation
HBEGF heparin-binding epidermal growth factor Proliferation
SERPINE1 plasminogen activator inhibitor 1 Motility/Adhesion
DUSP1 dual specificity protein phosphatase 1  Proliferation
ZFP36 tristetraprolin, zinc finger protein ZFP-36 Proliferation
IER3 immediate early response 3 Proliferation
FOSB AP-1 , fosB Proliferation
NR4A1 TR3 orphan receptor, growth factor-inducible nuclear protein N10 Proliferation
SOCS3 suppressor of cytokine signaling 3, cytokine-inducible SH2 protein 3 Inflammation
EGR2 early growth response protein 2  Proliferation
EGR3 early growth response protein 3  Proliferation
SLC2A3 solute carrier family 2 (facilitated glucose transporter), member 3   Metabolism
MMP19 matrix metalloproteinase-19  Motility/Adhesion
KLF4 Krueppel-like factor 4 Proliferation
ATF3 cyclic AMP-dependent transcription factor ATF-3 Proliferation
RGS2 cell growth-inhibiting protein 31 , regulator of G-protein signaling 2  Proliferation
EGR1 early growth response protein 1 Proliferation
SOD2 manganese-containing superoxide dismutase, mitocondrial  Metabolism
CYR61 cysteine-rich, angiogenic inducer, 61 ,  IGF-binding protein 10  Metabolism
IL8 interleukin 8 Inflammation
DUSP5 dual specificity protein phosphatase 5 Proliferation
GADD45B growth arrest and DNA damage-inducible protein GADD45 beta 
Cell cycle 
control/Apoptosis
TNFAIP3 tumor necrosis factor, alpha-induced protein 3 Inflammation
FPR1 formyl peptide receptor 1, N-formylpeptide chemoattractant receptor Inflammation
CCL3 chemokine (C-C motif) ligand 3 Inflammation
GFPT2 hexosephosphate aminotransferase 2  Metabolism
NAMPT nicotinamide phosphoribosyltransferase, pre-B-cell colony-enhancing factor 1 Metabolism
NR4A3 Mitogen-induced nuclear orphan receptor,  Nuclear hormone receptor NOR-1  Proliferation
GEM RAS-like protein KIR, GTP-binding mitogen-induced T-cell protein Proliferation
FOS AP-1, c-fos  Proliferation
PPP1R15A growth arrest and DNA-damage-inducible 34 
Cell cycle 
control/Apoptosis
CEBPD CCAAT/enhancer-binding protein delta,  Nuclear factor NF-IL6-beta Inflammation
THBD thrombomodulin Motility/Adhesion
KLF6 Krueppel-like factor 6 Proliferation
RHOB rho-related GTP-binding protein RhoB  Proliferation
KLF2 Krueppel-like factor 2  Proliferation
IL1B interleukin 1, beta Inflammation
G0S2 G0/G1 switch regulatory protein 2  
Cell cycle 
control/Apoptosis
C5AR1 complement component 5 receptor 1  Motility/Adhesion
MCL1 bcl-2-like protein 3 
Cell cycle 
control/Apoptosis
Table 6. Biological functions of the IL6-correlated genes. 
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r p value r p value
IL6 7 1 0 1 0
CXCL2 7 0,644456742 0 0,697061814 0,001304437
HBEGF 7 0,633236241 0 0,746049768 0,000377708
SERPINE1 7 0,617885675 0 0,727385502 0,000624219
DUSP1 7 0,616057037 0 0,675458685 0,002095758
ZFP36 7 0,602872198 0 0,804934823 5,60E-05
IER3 7 0,457370363 6,11E-12 0,615046491 0,006595854
FOSB 6 0,612878984 0 0,694288987 0,001389343
NR4A1 6 0,608438009 0 0,78682387 0,000107134
SOCS3 6 0,602119838 0 0,694178984 0,001392803
EGR2 6 0,589618707 0 0,800376807 6,63E-05
EGR3 6 0,545444523 0 0,733305623 0,000534605
SLC2A3 6 0,532251177 2,22E-16 0,696150061 0,001331866
MMP19
 a
6 0,486497665 1,62E-13 0,286460466 0,249135082
KLF4 6 0,460453533 4,23E-12 0,760981555 0,000244923
ATF3 5 0,59109885 0 0,705256847 0,001078276
RGS2 5 0,523498505 8,88E-16 0,496895958 0,035920545
EGR1 5 0,500293907 2,55E-14 0,624864798 0,005561011
SOD2 5 0,491615639 8,24E-14 0,627796331 0,005279035
CYR61 5 0,483189771 2,49E-13 0,682254573 0,001812845
IL8 5 0,478566297 4,50E-13 0,342656402 0,163931736
DUSP5 5 0,470635954 1,22E-12 0,740398416 0,000441677
GADD45B 5 0,450745623 1,33E-11 0,826460171 2,36E-05
TNFAIP3 5 0,426642256 1,98E-10 0,414811504 0,086958934
FPR1 5 0,419782692 4,11E-10 0,011874577 0,962701286
CCL3 5 0,410205953 1,11E-09 0,6581332 0,00298543
GFPT2
 b
5 0,388844059 9,06E-09 0,194385482 0,439570915
NAMPT 4 0,635895421 0 0,793260281 8,57E-05
NR4A3 4 0,578948177 0 0,67169717 0,002267398
GEM 4 0,523546652 8,88E-16 0,65882084 0,00294502
FOS 4 0,51419416 3,55E-15 0,627368969 0,005319402
PPP1R15A 4 0,500620422 2,44E-14 0,717907297 0,000793704
CEBPD 4 0,500141632 2,60E-14 0,870239801 2,67E-06
THBD 4 0,485757602 1,78E-13 0,161729988 0,521428838
KLF6 4 0,464399685 2,62E-12 0,751280185 0,000325625
RHOB 4 0,45930097 4,86E-12 0,72703803 0,000629847
KLF2 4 0,4672555 1,85E-12 0,359700306 0,142615452
IL1B 4 0,451260825 1,26E-11 0,509916869 0,030629039
G0S2 4 0,436132869 7,01E-11 -0,24941141 0,318237531
C5AR1 4 0,411525245 9,67E-10 0,323428665 0,19046521
MCL1 4 0,347545245 0,000000352 0,599949083 0,008486538
Gene Symbol Common to:
Serous EOC
Advanced Stage LMP
Table 7. Comparison of IL6-correlated genes in serous and LMP EOCs in data set I. 
 aGenes specifically correlated in advanced stage EOCs are in bold. 
 bGFPT2 gene correlated to IL-6 in data sets III-VII.
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GENESETS
I II III IV V VI VII
NES
FDR 
q-val
NES
FDR 
q-val
NES
FDR 
q-val
NES
FDR 
q-val
NES
FDR 
q-val
NES
FDR q-
val
NES
FDR 
q-val
AMIT_EGF_RESPONSE_120_HELA 2.31 0.00 1.99 0.02 2.06 0.00 1.92 0.04 2.06 0.00 2.26 0.00 1.78 0.04
AMIT_EGF_RESPONSE_60_HELA 2.35 0.00 1.96 0.02 2.08 0.00 2.15 0.01 2.21 0.00 2.31 0.00 1.89 0.03
BILD_HRAS_ONCOGENIC_SIGNATURE 2.53 0.00 2.04 0.01 2.25 0.00 1.92 0.04 2.36 0.00 2.51 0.00 2.17 0.02
DAUER_STAT3_TARGETS_UP 2.28 0.00 2.06 0.01 2.18 0.00 2.10 0.02 2.18 0.00 2.36 0.00 2.02 0.01
DAZARD_RESPONSE_TO_UV_NHEK_UP 2.34 0.00 2.06 0.01 2.22 0.00 1.95 0.03 2.50 0.00 2.40 0.00 1.92 0.02
DIRMEIER_LMP1_RESPONSE_EARLY 2.39 0.00 2.29 0.00 2.36 0.00 1.97 0.03 2.24 0.00 2.30 0.00 2.12 0.02
GERY_CEBP_TARGETS 2.38 0.00 1.92 0.03 2.35 0.00 1.88 0.04 2.41 0.00 2.56 0.00 2.08 0.01
GRAHAM_CML_QUIESCENT_VS_NORMAL_DIVIDING_UP 2.43 0.00 2.05 0.01 2.21 0.00 1.98 0.03 2.24 0.00 2.47 0.00 2.03 0.01
HALMOS_CEBPA_TARGETS_UP 2.35 0.00 1.91 0.03 2.14 0.00 1.89 0.04 2.05 0.00 2.34 0.00 1.92 0.02
KIM_WT1_TARGETS_UP 2.38 0.00 1.93 0.03 2.26 0.00 1.93 0.04 2.40 0.00 2.51 0.00 2.04 0.01
MARZEC_IL2_SIGNALING_UP 2.34 0.00 2.16 0.01 2.03 0.01 1.60 0.15 1.88 0.02 2.28 0.00 2.03 0.01
NAGASHIMA_NRG1_SIGNALING_UP 2.47 0.00 2.04 0.01 2.54 0.00 2.21 0.01 2.54 0.00 2.54 0.00 2.15 0.02
OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN
_GEL_DN
2.65 0.00 2.20 0.00 2.55 0.00 2.10 0.02 2.52 0.00 2.77 0.00 2.32 0.00
OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN
_GEL_UP
2.65 0.00 2.20 0.00 2.55 0.00 2.10 0.02 2.52 0.00 2.77 0.00 2.32 0.01
PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_DN 2.47 0.00 1.94 0.03 2.12 0.00 1.95 0.03 2.28 0.00 2.25 0.00 2.00 0.02
SENESE_HDAC1_AND_HDAC2_TARGETS_UP 2.41 0.00 1.88 0.04 2.04 0.01 2.00 0.03 2.07 0.00 2.62 0.00 2.16 0.02
SMIRNOV_CIRCULATING_ENDOTHELIOCYTES_IN_CANC
ER_UP
2.30 0.00 2.03 0.01 2.45 0.00 2.13 0.02 2.26 0.00 2.43 0.00 1.96 0.02
THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_UP 2.45 0.00 2.02 0.01 2.24 0.00 1.96 0.03 2.16 0.00 2.26 0.00 1.91 0.02
VART_KSHV_INFECTION_ANGIOGENIC_MARKERS_UP 2.36 0.00 1.93 0.03 2.20 0.00 1.78 0.07 2.19 0.00 2.63 0.00 1.99 0.02
ZHANG_RESPONSE_TO_IKK_INHIBITOR_AND_TNF_UP 2.27 0.00 2.13 0.01 2.22 0.00 1.87 0.04 2.21 0.00 2.37 0.00 1.96 0.02
Table 8. Significant IL-6 correlated gene sets identified by GSEA analysis 
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Figure 12. Real time RT-PCR on selected IL-6-correlated genes was performed using total 
RNA of starved EOC cell lines untreated (white bars) or treated (grey bars) for 4 hr (IGROV1, 
OAW42 and IOSE 64 hTERT) or 8 hr (SKOV3) with EGF (20 ng/ml). The number of data sets 
in which the gene resulted significantly correlated with IL6 is reported on the bottom. Data are 
mean values (± SD) presented as relative expression normalized for GAPDH mRNA levels. 
Asterisks indicate significant positive variations (Student’s t test). 
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Figure 13. A. Real-time RT-PCR analysis for IL-6 on total RNA from IL-6-silenced 
IGROV1cells from 24 hr , 48 hr and 72 hr using two different siRNA concentrations 20 pm/ml 
and 40 pm/ml, gray and black bars respectively. Results are represented as relative mRNA 
expression normalized for GAPDH mRNA levels. B. IGROV1 cells were transfected with 
siRNA IL-6 and negative control siRNACo. Cell growth was assayed at 24 hr and using the 
CellTiter-Glo® Luminescent Cell Viability Assay Kit. Each point represents the mean of five 
independent replicates ± SD. RLU, Relative Luminescence Unites. C. Dose response curves of 
IGROV1 cells transfected with IL-6 or control siRNA treated with Gefitinib for 72 hr. Each 
point represents the mean of five independent replicates ± SD  
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A
Figure 14. A. Western blot analysis of total lysates from IGROV1 cells treated with FCS (nt), 
IL-6-specific or control siRNA from 24 hr up to 72 hr. The antibodies used are indicated. -
actin is shown as a control for protein loading. 
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Figure 14. B. Model for IL-6 signaling pathway in EOC cells 
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Figure 15. A. Real-time RT-PCR for PAI-1 from total RNA of OAW42 treated as above. 
Results are presented as relative expression normalized for GAPDH mRNA levels. B. Fold 
change in PAI-1 levels compared to un-stimulated cells released in media from starved OAW42 
cells stimulated for 4, 8, and 24 hr with EGF alone (20ng/ml), EGF plus AG1478 (20 µM), or 
AG1478 alone (20 µM) evaluated by the Procarta cytokine assay. C. Real-time RT-PCR for 
PAI-1 and TGF- from total RNA of OAW42 and SKOV3 cells. Results are presented as 
relative expression normalized for GAPDH mRNA levels. D. Real-time RT- PCR analysis for 
PAI-1 on total RNA from PAI-1-silenced OAW42 and SKOV3 cells for 48 hr using two 
different siRNA (siRNA 1 and siRNA 2) at two different concentrations 20 pm/ml and 40 
pm/ml, gray and black bars respectively. 
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Figure 16. A. OAW42 and SKOV3 cells were transfected with siRNA PAI-1 and negative 
control siRNA Co. Cell growth was followed from 24 hr intervals for up to 96 hr and assayed 
using the CellTiter-Glo® Luminescent Cell Viability Assay Kit. Each point represents the mean 
of five independent replicates ± SD. RLU, Relative Luminescence Unites. B. OAW42 and 
SKOV3 cells transfected with siRNA 1 PAI-1 and negative control siRNA Co for 48hr were 
plated into dishes coated with FN and VN substrates and incubated for 1 hr at 37°C. Crystal 
violet, which stained cells attached to dishes, was eluted with 10% acetic acid and was 
measured by spectrophotometer at 590 nm. The absorbance values were reported in the bar 
graphs. C. Cell migration capability was determined with a wound healing assay. A confluent 
monolayer OAW42 and SKOV3 cells at 24 hr after exposure to PAI-1 siRNA 1 (black bars) or 
negative control siRNA (white bars) was wounded. The data present the mean distance of cell 
migration to the wound area at 4 hr, 8 hr and 24 hr after wounding in four independent wound 
sites per group expressed as percentage respect to mean distance taken to the wound at time 0. 
B and C Asterisks indicate significant positive variations (Student’s t test).
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Figure 17. A. OAW42 and SKOV3 cells treated with control or PAI-1-specific siRNA for 24 hr 
were placed on 8µM pore polycarbonate membrane with a Matrigel matrix and incubated for 24 
hr at 37°C. The cells attached to the membrane were stained with sulforhodamine B colorant. 
The invasion assay was acquired using a Nikon inverted light microscope with a 4X objective, 
and the cells number quantified by the Image-Pro Plus 6.3 software. B. IF analysis of SKOV3 
and OAW42 treated with control or PAI-1-specific siRNA. The samples were analyzed using a 
Nikon inverted light microscope with a 20X PanFluor objective. The antibodies used are 
indicated. 
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Figure 18. Pie chart of the biological functions of the119 PAI-1-correlated genes in dataset I
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The epidermal growth factor receptor (EGFR), a member
of the ErbB family of receptor tyrosine kinases, is
expressed in up to 70% of epithelial ovarian cancers
(EOCs), where it correlates with poor prognosis. The
majority of EOCs are diagnosed at an advanced stage,
and at least 50% present malignant ascites. High levels of
IL-6 have been found in the ascites of EOC patients and
correlate with shorter survival. Herein, we investigated the
signaling cascade led by EGFR activation in EOC and
assessed whether EGFR activation could induce an EOC
microenvironment characterized by pro-inflammatory
molecules. In vitro analysis of EOC cell lines revealed
that ligand-stimulated EGFR activated NFkB-dependent
transcription and induced secretion of IL-6 and plasmino-
gen activator inhibitor (PAI-1). IL-6/PAI-1 expression
and secretion were strongly inhibited by the tyrosine
kinase inhibitor AG1478 and EGFR silencing. A sig-
nificant reduction of EGF-stimulated IL-6/PAI-1 secre-
tion was also obtained with the NFkB inhibitor
dehydroxymethylepoxyquinomicin. Of 23 primary EOC
tumors from advanced-stage patients with malignant
ascites at surgery, 12 co-expressed membrane EGFR,
IL-6 and PAI-1 by immunohistochemistry; both IL-6 and
PAI-1 were present in 83% of the corresponding ascites.
Analysis of a publicly available gene-expression data set
from 204 EOCs confirmed a significant correlation
between IL-6 and PAI-1 expression, and patients with
the highest IL-6 and PAI-1 co-expression showed a
significantly shorter progression-free survival time
(P¼ 0.028). This suggests that EGFR/NFkB/IL-6-PAI-
1 may have a significant impact on the therapy of a
particular subset of EOC, and that IL-6/PAI-1
co-expression may be a novel prognostic marker.
Oncogene (2012) 31, 4139–4149; doi:10.1038/onc.2011.572;
published online 12 December 2011
Keywords: epithelial ovarian cancer; EGFR; IL-6; PAI-1;
NFkB
Introduction
Epithelial ovarian cancer (EOC) is one of the most lethal
gynecological cancers. Metastatic dissemination of EOC
is confined to the intraperitoneal cavity and involves
malignant ascites (Bast et al., 2009). Its specific
metastatic pattern of spread suggests the presence of
specific microenvironmental factors that guide the
formation of permissive niches that are very important
for the growth and development of secondary lesions.
EOCs, as other solid tumors, are strictly associated
with inflammation and a complex cytokine/chemokine
network. By computational search of co-expression of
ligand/receptor pairs in EOC gene-expression data sets,
our group has highlighted the possible signaling
activated by specific chemokines (Castellano et al.,
2006), whereas others have reported that the receptor/
ligand pair CXCR4/CXCL12 and the cytokines IL-1b,
IL-6 and IL-8 contribute to proliferation of EOC
(Hagemann et al., 2006). EOC cells in vitro have also
been demonstrated to modulate the macrophage phe-
notype by inducing the expression of inflammatory
mediators (Hagemann et al., 2005). Among the cyto/
chemokines found in EOC ascites, IL-6 has been shown
to be a growth-promoting and anti-apoptotic factor
(Kryczek et al., 2000). Moreover, patients with high
levels of IL-6 expression have shorter survival than
patients with lower levels (Penson et al., 2000).
Metastatic and drug resistant recurrent EOC have
significantly higher IL-6 production compared with that
in primary tumors. Indeed, treatment of EOC cell lines
with a chimeric anti-IL-6 monoclonal antibody
increased paclitaxel cytotoxicity (Guo et al., 2010).
The connection between inflammation and cancer
consists of extrinsic and intrinsic pathways, driven by
inflammatory conditions and genetic alterations (for
example, mutations in genes encoding RAS, MYC and
RET), respectively. The epidermal growth factor recep-
tor (EGFR), a member of ErbB family of receptor
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tyrosine kinases, activates multiple signaling cascades
that cause growth and invasion of tumor cells. In most
cancers, its expression has been associated with disease
progression and poor outcome (Lemmon and Schles-
singer, 2010). Although EGF-stimulated EOC cells that
undergo epithelial–mesenchymal transition may upre-
gulate production of IL-6 (Colomiere et al., 2009), the
EGFR signaling cascade has not yet been directly
associated with induction of an inflammatory network.
In a homeostatic state, EGFR has a key role in normal
ovarian follicle development and cell-growth regulation
of the ovarian surface epithelium (Conti et al., 2006),
whose cells might give rise to EOC. In EOC tumor
samples, EGFR is expressed in an estimated 10–70% of
EOCs, and its altered expression is associated with
advanced-stage disease and poor prognosis (Hudson
et al., 2009). Very recently, EGFR overexpression has
been also associated with a lack of response to
chemotherapy in patients with EOC (Sheng and Liu,
2011). EGFR is considered to be a key therapeutic
target in many types of cancer. However, for reasons
that are still unclear, treatment of EOC patients with
anti-EGFR results in a very poor response and is not
correlated to EGFR expression (Siwak et al., 2010).
Therefore, there is an urgent need to further understand
the relationships between the tumor microenvironment,
EGFR activation and disease outcome in ovarian
cancer.
Herein, we further investigate the signaling cascade
led by EGFR activation in EOC, and assess whether
EGFR activation may induce a microenvironment that
favors survival of EOC by stimulating the expression of
IL-6 and other pro-inflammatory molecules. In vitro, it
was found that ligand-dependent EGFR activation
triggered co-expression of the pro-inflammatory mole-
cules IL-6 and plasminogen activator inhibitor-1 (PAI-1)
via transcriptional activation of NFkB. High levels of IL-6
and PAI-1 co-expression were also found to characterize a
subset of advanced EOC that express membrane EGFR.
Results
Ligand-dependent EGFR activation is not a predictor of
sensitivity to anti-EGFR compounds
EOC cell lines were analyzed for EGFR expression by
flow cytometry; all those derived from patients with
serous adenocarcinomas expressed variable levels of
membrane EGFR (Supplementary Figure 1A). In the
same cell lines, IL-6 release was determined, in media
conditioned for 24 h, by ELISA. IGROV1 and OAW42
cell lines released the highest amounts of IL-6 (422 pg/ml
and 140 pg/ml, respectively) (Supplementary Figure 1B)
and were selected for further characterization.
IGROV1 and OAW42 cells stimulated with EGF up
to 60min were analyzed by western blotting for the
EGFR signaling cascade. In both the cell lines,
phospho-EGFR was detected after 5min of EGF
stimulation reaching a maximum after 60min. However,
EGFR appeared to be degraded within a few minutes in
IGROV1 cells (Supplementary Figure 1C), whereas it
remained stable in OAW42, suggesting that the receptor
is immediately degraded upon stimulation only in the
former. EGFR phosphorylation was assessed in cells
stimulated for 20min with EGF alone or together with
the tyrosine kinase inhibitor AG1478. In both cell lines,
AG1478 completely inhibited EGFR phosphorylation
together with that of the downstream effector ERK and
most AKT phosphorylation (Figure 1a).
The effects on cell growth of the anti-EGFR
monoclonal antibody cetuximab, which affects the
ligand binding to the receptor, and the EGFR inhibitors
gefitinib and erlotinib, which interfere with ATP for
binding to EGFR, were then evaluated. Although
EGFR in both cell lines is activated by the ligand, only
the proliferation of IGROV1 cells (50% inhibition with
5 mg/ml), but not that of OAW42 cells (15% inhibition
with 100 mg/ml), was affected by cetuximab treatment
(Figure 1b). Accordingly, IGROV1 cells were about
eight-fold more sensitive to gefitinib and erlotinib than
OAW42 cells (Figure 1c).
Ligand-dependent EGFR signaling triggered IL-6
production and NFkB activation
IL-6 release, quantified in conditioned media after EGF
stimulation alone or together with AG1478, was time
dependent for both cell lines; after 24 h it was almost
completely inhibited by AG1478 treatment in IGROV1
cells, but only partially inhibited in OAW42 cells (96%
and 30%, respectively) (Figure 2a). In starved IGROV1
cells, EGFR appeared to be directly involved in IL-6
release, as its release was inhibited by AG1478,
suggesting autocrine EGFR activation. In starved
OAW42 cells, IL-6 production was not inhibited by
AG1478 treatment, and EGF stimulation led to IL-6
levels that were seven-fold higher compared with fetal
calf serum-maintained cells (see Supplementary Figure
1B), arguing for a mechanism of IL-6 production that is
independent of EGFR activation.
In agreement with this possibility, IL-6 transcript
levels evaluated by real-time RT–PCR increased about
20-fold after 24 h of stimulation with EGF in IGROV1
cells, and were inhibited to levels comparable to those in
starved cells after treatment with AG1478, as well as
with the PI3K inhibitor LY294002 and the MEK
inhibitor UO126; in OAW42 cells, IL-6 transcript levels
increased only about three-fold and were not inhibited
by AG1478. LY294002 treatment inhibited the expres-
sion of IL-6 transcripts, whereas UO126 led to a 16-fold
increase in IL-6 transcript levels (Figure 2b).
NFkB activity, which is known to activate the
transcription of inflammation-related proteins such as
IL-6 (Karin, 2006), was then assayed upon EGF
stimulation by transient transfection with a luciferase
reporter construct containing two NFkB-binding sites.
In IGROV1 cells, NFkB-associated promoter activity
increased within 1 h, reaching a maximum after 3 h EGF
stimulation and remained stable up to 24 h. In contrast,
in OAW42 cells NFkB-containing promoter activity was
measurable only after 20 h of EGF stimulation
(Figure 2c). In order to evaluate whether NFkB-
containing promoter activity was dependent on the
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EGFR signaling cascade, it was measured in the
presence of AG1478, LY294002 or UO126. EGF-
stimulated NFkB-containing promoter activity was
almost completely inhibited by AG1478 and UO126
treatment, strongly reduced (60%) by LY294002
treatment in IGROV1 cells (Figure 2d), and inhibited
about 40%, 80% and 65% with AG1478, LY294002
and UO126 treatment, respectively, in OAW42 cells.
These results demonstrate that, in IGROV1 cells, but
not in OAW42, ligand-dependent EGFR/MEK/ERK or
EGFR/PI3K/AKT activation leads to transcriptional
activation of NFkB and IL-6 production.
Ligand-dependent EGFR activation and expression
induced production of specific cyto/chemokines
To evaluate whether EGF stimulation of EOC cells
could induce the expression and release of other
inflammatory cyto/chemokines in addition to IL-6, we
performed a 51 cyto/chemokine multiplex analysis using
Bioplex technology on IGROV1 conditioned media
collected after EGF stimulation alone or together with
AG1478. In media collected after 24 h of EGF stimula-
tion, several soluble factors were found to be upregu-
lated and inhibited by concomitant treatment with
AG1478, namely IL-6, vascular endothelial growth
factor, PAI-1, TGF (transforming growth factor) a,
macrophage colony stimulating factor and interleukin-8
(IL-8) (Supplementary Table 2). Figure 3a shows the
time course of levels of the soluble factors, PAI-1, IL-8
and IL-6 (Figure 2a), which all exhibited a two-fold
increase after 24 h of EGF stimulation, and whose
release was inhibited by AG1478 treatment.
As observed for IL-6 transcripts (Figure 2b), PAI-1
and IL-8 transcript levels were upregulated after 24 h of
EGF stimulation and inhibited by treatment with
AG1478 (Figure 3b).
To evaluate the involvement of NFkB transcriptional
activity in the production of IL-6, PAI-1 and IL-8,
the Bioplex quantification was also applied to condi-
tioned media after EGF stimulation alone or together
with Dehydroxymethylepoxyquinomicin (DHMEQ).
DHMEQ decreased the levels of the IL-6 (from 250 to
217 pg/ml), PAI-1 (from 366.51 to 254.8 pg/ml) and IL-8
(from 26.6 to 15.5 pg/ml) secreted by starved cells,
suggesting an autocrine activity. A further and signifi-
cant decrease of IL-6 (from 500.4 to 341.8 pg/ml, 32%),
PAI-1 (from 1225.76 to 807.29 pg/ml, 35%) and IL-8
(from 54.94 to 30.29 pg/ml, 45%) releases was observed
upon DHMEQ treatment of EGF-stimulated cells.
These data argued for the notion that in EGF-
stimulated IGROV1 cells IL-6, PAI-1 and IL-8 produc-
tions are partially dependent on NFkB transcriptional
activation.
IL-6 and PAI-1 expressions are inhibited by EGFR
knockdown
To validate these results, EGFR knockdown was
performed with anti-EGFR small-interfering RNA
(siRNA). Forty-eight hours after transfection, total cell
lysates from silenced IGROV1 cells were analyzed by
western blotting to evaluate EGFR expression and
phosphorylation of the downstream effectors AKT and
ERK. A 60% reduction in EGFR expression corre-
sponded to 90% and 50% reduction of ERK and AKT
Figure 1 Ligand-dependent EGFR activation is not a predictor of
sensitivity to anti-EGFR compounds. (a) Western-blot analysis
was performed on total lysates from starved IGROV1 and OAW42
cells left untreated or treated for 20min with EGF alone or
together with AG1478. The antibodies used are indicated. b-actin is
shown as a control for protein loading. A representative experi-
ment is shown; all experiments were performed in triplicate.
(b) IGROV1 and OAW42 cells were exposed to different
concentrations of cetuximab for 96 h in medium with fetal calf
serum. (c) Dose-response curves of IGROV1 and OAW42 cells
treated with Erlotinib or Gefitinib for 72h. (b, c): Representative
growth curves of three independent experiments are shown; each point
represents the mean of five independent replicates±s.d. Asterisks
indicate a significant difference by two-way analysis of variance.
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phosphorylation, respectively (Figure 4a). NFkB tran-
scriptional activity of EGFR-silenced cells was 70%
lower compared with cells transfected with a control
siRNA (Figure 4b). Real-time RT–PCR on total RNA
from EGFR-silenced cells revealed that a 15-fold
decrease of EGFR transcript was accompanied by a
dramatic decrease of PAI-1 and IL-6 transcripts, and to
only a 25% decrease in IL-8 transcripts (Figure 4c). The
decrease in IL-6 transcript levels was similar to that
obtained in IGROV1 cells stimulated with EGF and
Figure 2 Ligand-dependent/EGFR signaling triggers IL-6 production via NFkB activation. (a) IL-6 levels measured by ELISA on
conditioned media from starved EOC cell lines left untreated, or treated for the indicated times with EGF (20 ng/ml) alone or together
with AG1478 (20mM). Representative growth curves of one of three independent experiments are shown. Each point represents the
mean of five independent replicates± s.d. (b) Real-time PCR for IL-6 from total RNA of starved EOC cell lines left untreated, treated
for 24 h with EGF (20 ng/ml) alone or together with AG1478 (20 mM), LY294002 (50mM) or with UO126 (40mM). Results are presented
as relative expression normalized to GAPDH mRNA levels. (c) Luciferase promoter gene assay of starved EOC cells transiently
transfected with reporter plasmids containing the NFkB binding sites and stimulated for 24 h with EGF (20 ng/ml). (d) Inhibition of
NFkB transcriptional activity of starved EOC cells transiently transfected as above and stimulated for 24 h with EGF alone or together
with AG1478 (black), LY294002 (gray) and UO126 (white). (c, d) Data are mean values (±s.d.) normalized for transfection efficiency
in a representative experiment.
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treated with AG1478 (Figure 2b), demonstrating a
direct correlation between EGFR expression/activation
and IL-6/PAI-1 transcription and production.
IL-6 and PAI-1 are highly co-expressed in EOC samples
To validate the in vitro results, we used immunohisto-
chemistry to evaluate the expression of EGFR, IL-6 and
PAI-1 in 23 formalin-fixed, paraffin-embedded primary
ovarian cancers (Table 1). The characteristics of patients
and cytological information associated with the ascites
are summarized in Supplementary Table 1. The majority
of EOC samples (74%) heterogeneously expressed
EGFR on the membrane of tumor cells; samples with
the strongest reactivity with the anti-EGFR antibody
also showed EGFR expression in the cytoplasm. Six
samples stained with anti-EGFR only in the cytoplasm.
Tumor cells of 16 of 23 EOC samples (70%) also
showed staining with the anti-IL-6 antibody. Of the 23
samples with the highest EGFR expression, 4 also
showed the strongest staining with anti-IL-6 (for
example, sample no. 22, Figure 5a). In some sections
with high reactivity for anti-EGFR, not all tumor cells
stained with anti-IL-6. Some samples showed homo-
genous staining with anti PAI-1 (samples no. 7 and no.
23), whereas in other samples PAI-1 expression
appeared heterogeneous. Interestingly, the samples that
stained strongly with anti PAI-1 were also strongly
reactive with both anti-EGFR and -IL-6 antibodies
(Figure 5a).
IL-6 and PAI-1 levels were measured in the corre-
sponding ascites. Medium/high levels of both IL-6 and
PAI-1 were seen in 12 of 23 ascites (Figure 5b), and
their expression showed a positive correlation (r¼ 0.68;
P¼ 0.002) (Figure 5c). These 12 EOC ascites samples
Figure 3 Ligand-dependent EGFR activation induced the production of specific cyto-/chemokines. (a) Fold change in PAI-1 and IL-8
levels compared with unstimulated cells released in media from starved IGROV1 cells stimulated for 4, 8 and 24 h with EGF alone
(filled square), EGF plus AG1478 (open square), or AG1478 alone (open circle) evaluated by the Procarta cytokine assay. (b) Real-time
RT–PCR for PAI-1 and IL-8 from total RNA of IGROV1 treated as above. Results are presented as relative expression normalized for
GAPDH mRNA levels. (c) IL-6, PAI-1 and IL-8 levels measured by the Procarta cytokine assay on conditioned media from starved
EOC cell lines left untreated, treated for 24 h with EGF alone, or together with DHMEQ (5mg/ml). Asterisks indicate a significant
difference by one-way analysis of variance (b) and t-test (c).
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were derived from patients whose primary tumors
co-expressed membrane EGFR, IL-6 and PAI-1. In
contrast, the presence of IL-8 in ascites was not
associated with release of IL-6 or PAI-1, although some
samples contained detectable levels of the three mole-
cules. Furthermore, in ascites the majority of samples
with medium/high IL-6 and PAI-1 expression contained
tumor cells alone or together with immune cells
(Supplementary Table 1 and Supplementary Figure 3),
excluding that the two molecules could be released only
by immune cells.
Expression of EGFR-associated molecules in publicly
available EOC data sets
To investigate the relationship between EGFR, IL-6,
PAI-1 and IL-8 expression, we analyzed four publicly
available data sets containing the gene-expression profile
of EOC patients. From data set I (Supplementary Table 3),
the profiles of 204 serous EOC were selected and the
expression intensity of the EGFR, IL-6, PAI-1 and IL-8
genes were plotted together to evaluate trends in
expression. EGFR transcript levels appeared to be
highly homogeneous, and no significant correlations
were found (Supplementary Figure 2A). The highest
correlation score (r¼ 0.58, Po0.0001) was found
between IL-6 and PAI-1; all the other combinations
showed lower correlation scores ranging from r¼ 0.44
(for IL-8 and IL-6) to r¼ 0.30 (for IL-8 and PAI-1)
(Figure 6a). A significant correlation between IL-6 and
PAI-1 was also obtained after analysis of the other three
data sets (Supplementary Figure 2B).
Upon filtration of data set I for high or low expression
of both IL-6 and PAI-1, it was found that high
co-expression of IL-6 and PAI-1 was significantly
associated with the advanced-stage EOC (Fisher’s exact
test, P¼ 0.0006) (Figure 6b). In the same data set,
progression-free survival was analyzed in the subset of
patients exhibiting expression levels of both IL-6
and PAI-1 below the first and above the third quartile.
High IL-6 and PAI-1 was significantly associated with
shorter progression-free survival (log-rank test,
P¼ 0.028; HR¼ 2.13, confidence interval¼ 1.08–4.20)
(Figure 6c). Of note, the expression of either IL-6 or
Figure 4 IL-6 and PAI-1 expressions are inhibited by EGFR
knockdown. (a) Western-blot analysis of total lysates from
IGROV1 cells treated with control or EGFR-specific siRNA.
The antibodies used are indicated. b-actin is shown as a control
for protein loading. A representative experiment is shown.
(b) Luciferase promoter gene assay of EGFR-silenced IGROV1
cells transiently transfected with reporter plasmids containing
NFkB binding sites. Data are mean values (±s.d.) normalized for
transfection efficiency in three independent experiments performed
in triplicate. (c) Real-time RT–PCR analysis for EGFR, PAI-1,
IL-6 and IL-8 on total RNA from EGFR-silenced IGROV1.
Results are represented as relative mRNA expression normalized
for GAPDH mRNA levels. (b, c): Asterisks indicate a significant
difference by t-test.
Table 1 Expression and localization of EGFR, IL-6, and PAI-1 in
formalin-fixed, paraffin embedded EOC samples evaluated by IHC
EOC samplea EGFR IL-6 PAI-1
M C C C
1 þ /þ þ b ÿ þ
2 þ þ þ þ
3 þ þ þ
4 þ þ þ þ þ
5 þ þ þ þ þ þ
6 þ þ þ þ þ þ
7 þ þ þ þ þ þ þ þ þ þ þ þ
8 þ þ þ þ þ
9 þ ÿ ÿ
10 þ þ þ þ
11 þ þ þ þ þ þ
12 þ þ þ þ þ
13 þ þ ÿ þ
14 þ þ þ þ ÿ ÿ
15 þ þ þ þ þ
16 þ /þ þ ÿ þ
17 þ þ þ ÿ ÿ
18 þ þ þ þ þ þ
19 þ þ þ ÿ þ þ
20 þ þ þ þ þ þ þ þ þ
21 þ þ þ þ þ þ þ þ
22 þ þ þ þ þ þ þ þ þ þ þ þ
23 þ þ þ þ
Abbreviations: C, cytoplasmic staining; EGFR, epidermal growth
factor receptor; EOC, epithelial ovarian cancer; IHC, immunohisto-
chemistry; M, membrane staining, PAI, plasminogen activator
inhibitor.
aThe characteristics of EOC patients are reported in Supplementary
Table 1. The numbers in bold italics highlight patients whose ascites
co-expressed detectable levels of IL-6 and PAI-1 (see Figure 6b).
bArbitrary scores were given by two independent observers: negative
(ÿ), faint (þ ), moderate (þ þ ), and strong (þ þ þ ) staining.
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PAI-1 when considered individually did not discriminate
between the two groups.
Discussion
This study showed that IL-6 and PAI-1 co-expression is
a potential marker for the ligand-dependent EGFR/
NFkB signaling cascade. In vitro we demonstrated that
the ligand-dependent EGFR/NFkB signaling cascade
leads to co-expression of IL-6 and PAI-1. Ex vivo, using
23 EOC from advanced-stage patients with malignant
ascites at surgery, we observed co-expression of EGFR,
IL-6 and PAI-1 in 57% of primary tumors, and
concomitant expression of both IL-6 and PAI-1 in the
corresponding ascites. Finally, in-silico analysis on four
publicly available data sets of EOC gene expression
showed a correlation between the expression of the IL-6
and PAI-1 genes in advanced EOC patients, which in
one case was associated with shorter progression-free
survival.
Despite the evidence for EGFR expression in the
majority of EOCs, to date a uniform picture of the
biological and clinical consequences of EGFR expres-
sion and activation has not emerged. In advanced
EOCs, the expression of EGFR and PAI-1(Carey et al.,
2010), or IL-6 (Guo et al., 2010) are associated with
chemoresistance, thus supporting the hypothesis of a
functional connection between these three molecules in
the progression and chemoresistance of advanced EOCs.
In the present study, we provide several lines of
evidence suggesting that simply considering EGFR
expression levels alone is not sufficient to define a role
of receptor activation. We propose here that co-
expression as well as the concomitant presence of IL-6
and PAI-1 in EOC ascites could characterize a subset of
EGFR-expressing EOCs with shorter progression-free
survival after chemotherapy. As we have also shown
in vitro that the EOC cell line resembling this subset of
EOC is more sensitive to anti-EGFR compounds, it can
be argued that the association of anti-EGFR agents with
taxol and cisplatin could be more appropriate for
treating this subset of EOCs.
In EOC cells, the mitogenic effects of EGFR
activation has been already documented and leads to
upregulation of genes involved in cell cycle and
proliferation, apoptosis and protein turnover (Siwak
et al., 2010). The present in vitro data demonstrate that a
Figure 5 IL-6 and PAI-1 are highly co-expressed in EOC samples. (a) Immunohistochemistry for EGFR, IL-6 and PAI-1 in a primary
formalin-fixed, paraffin-embedded EOC sample (characteristics reported in Supplementary Table 1). Representative images from
sample no. 22 are shown. (b) IL-6, PAI-1 and IL-8 quantification by ELISA in 23 ascites samples from the same EOC patients.
(c) Correlation between IL-6 and PAI-1 levels measured in ascites. The linear regression line, Spearman correlations and P-values are
shown.
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signaling cascade from ligand-stimulated EGFR/MEK/
ERK or EGFR/PI3K/AKT activates the transcriptional
activity of NFkB with expression of IL-6 together with
PAI-1. A similar signaling pathway has been experi-
mentally demonstrated in glioblastoma cell lines (Paugh
et al., 2008), and a positive correlation between PAI-1
and IL-6 gene expression has been observed in a meta-
analysis carried out on publicly available data sets of
gene expression of breast carcinoma (Sternlicht et al.,
2006). Interestingly, very recently ErbB2 expression,
another member of the ErbB family, was found to
upregulate IL-6 production through the transcriptional
activity of NFkB (Hartman et al., 2011).
In vitro, we found that the EGFR/NFkB signaling
cascade is ligand dependent in an in vitro EOC model,
which is in agreement with previous reports on EGFR
activation by ligands, such as EGF, TGFa and the
heparin-binding-EGF (Hudson et al., 2009) present in
the EOC microenvironment. EGFR ligands can be
found in the EOC microenvironment due to the
activation of A disintegrin and metalloprotease by
endothelin-1- or lysophosphatidic acid-stimulated G-
protein-coupled receptors (Braun and Coffey, 2005).
Several growth factors including EGF may also induce
activation of NFkB. NFkB is a family of transcription
factors that modulate immunological and inflammatory
responses by directly controlling the transcription of
pro-inflammatory cytokines. NFkB is activated in many
malignancies including ovarian cancer (Karin, 2006).
Production of IL-6 has been shown to be increased in
the EOC cell lines SKOV3 and OVCA433 after
stimulation with EGF, as observed here, although the
Figure 6 Expression of EGFR-associated molecules in EOC data set I. (a) Correlation among IL-6, PAI-1 and IL-8 were determined
and the values are plotted on a log2 scale. Pearson correlations (r), linear regression and P-values are reported. (b) Association between
IL-6/PAI-1 expression intensities and tumor stage was analyzed on samples filtered for expression higher or lower than the respective
median. Asterisk indicates a significant difference by Fisher’s exact test. (c) Kaplan–Meier curves reporting the progression-free
survival analysis on patient subgroups selected for IL-6/PAI-1 expression higher than the 3rd quartiles and lower than the 1st quartile
(log-rank test).
IL-6 and PAI-1 co-expression in epithelial ovarian cancer
C Alberti et al
4146
Oncogene
molecular mechanism responsible for the increase is still
unclear (Colomiere et al., 2009). In ER-negative breast
carcinoma, stimulation with EGF activates NFkB
through an unknown mechanism that may involve the
scaffold protein Carma3 (Van Laere et al., 2007).
Indeed, Carma3 has been recently demonstrated to be
a link between EGFR, Ikk kinase and NFkB activation
(Jiang et al., 2011). Further experiments are needed to
confirm or exclude that this mechanism is linked with
EGFR activation of NFkB transcriptional activity.
Our demonstration that the levels of IL-6 and PAI-1
transcripts and proteins correlate with one another may
be advantageous not only in studying the mechanisms
associated with progression of EOC, but also for their
exploitation as potential prognostic markers. PAI-1, one
of three plasminogen-activator inhibitors, is a major
regulator of the pericellular plasmin-generating uPA/
uPAR cascade. To date, both uPA and uPAR are
associated with invasiveness and metastasis of a variety
of cancers, including EOC (Dass et al., 2008). In breast
carcinoma, uPA/PAI-1 expression levels have provided
clinically relevant information on the risk of relapse and
may have relevance when choosing endocrine therapies
and chemotherapy (Leissner et al., 2006); PAI-1 has
been associated with shorter recurrence-free and overall
survival, although its expression is rarely used as
prognostic/predictive factor, as protein-based assays
are difficult to routinely adopt to the limited amount
of biopsy tissue that is generally available (Look et al.,
2002). In contrast, in EOC PAI-1 expression in ascites
could be more easily tested compared with other tumors.
Furthermore, in silico analysis, performed on a very
informative data set of EOC gene expression that
reports detailed clinical annotations and used by other
investigators to validate high-throughput results
(Cancer Genome Atlas Research Network, 2011), gives
a clear indication that also the use of concomitant IL-6
and PAI-1 gene expression may be a useful tool to
identify EOC patients whose tumors are potentially
resistant to conventional chemotherapy. A study on a
large number of EOC patients is therefore warranted to
further validate these data.
Although further study of EGFR-mediated inflam-
mation in EOC is needed, taken together these findings
highlight novel and interesting tools that may provide
useful therapeutic information for a particular subset of
EGFR-expressing EOC and the use of IL-6 and PAI-1
co-expression as a potential prognostic marker.
Materials and methods
Tumor samples
The Institutional Review Board approved the use of archived
material and ascites, as well as clinical data. All clinical
specimens were accompanied by informed consent from all
patients to use excess biological material for investigative
purposes. Histological selection of patients was based on
advanced stage at diagnosis and the presence of ascites at
surgery. EOC samples were selected and collected by a
pathologist (BV). Twenty-three pairs of formalin-fixed,
paraffin-embedded primary tumors and ascites were used.
Antibodies and reagents
The following antibodies were used in blotting experiments: anti-
EGFR, anti-MAP kinase activated (pERK1/2), anti-AKT, anti-
phosphoAKT (Ser473) (clone D9E) from Cell Signaling Tech-
nology (New England BioLabs, Beverly, MA, USA); anti-
phospho-EGFR (Tyr1173) from Nano Tools (Teningen, Ger-
many); anti-MAP kinase (ERK1/2) from Santa Cruz Biotecnol-
ogy (Santa Cruz, CA, USA) and anti-Actin from Sigma-Aldrich
(St Louis, MO, USA). The anti-EGFR monoclonal antibody
MINT-5 was used for flow cytometry (Tosi et al., 1995).
Fluorochrome-conjugated Alexa Fluor 488 secondary Ab was
from Molecular Probes (Invitrogen, San Francisco, CA, USA).
AG1478 was from Sigma-Aldrich. Gefitinib and erlotinib were
from Axon MedChem (Groningen, the Netherlands); the MEK
inhibitor UO126 was from Promega (Promega, Madison, WI,
USA) and the PI3K inhibitor LY294002 was from Sigma
Aldrich. DHMEQ, an NFkB inhibitor that blocks the binding of
NFkB to DNA (Umezawa, 2006; Yamamoto et al., 2008), was
synthesized by one of the authors (KU). Recombinant human
EGF was from Peprotech (Peprotech Inc, Rocky Hill, NJ, USA).
Erbitux (Merck-Serono, Geneva, Switzerland) was used for
cetuximab. Taqman Gene Expression Assays were from Applied
Biosystems (Foster City, CA, USA). ELISA for IL-6, PAI-1 and
IL-8 dosage was from R&D Systems (Minneapolis, MN, USA).
Immunohistochemistry
Detailed immunohistochemistry studies are reported in the
Supplementary Materials and Methods.
Ovarian cancer cell culture
OVCAR3, OVCA432, SKOV3, IGROV1 (serous histotype)
and A2780 (mucinous histotype) cell lines were maintained in
RPMI 1640 (Sigma Aldrich) with 10% fetal calf serum
(Hyclone, Logan, UT, USA) and 2mmol/l glutamine in a
5% CO2 humidified atmosphere at 37 1C. OAW42 (serous
histotype, kindly provided by Dr A. Ullrich, Max Planck
Institute of Biochemistry, Martinsried, Germany) cells were
cultured in MEM (Sigma Aldrich) and supplemented as above.
ELISA
Cell lines were grown until confluence, fresh medium was
added and samples for IL-6 dosage were collected after 24 h.
Western blotting
Preparation of total cell lysates and Western blotting analysis
was performed as previously described (De Santis et al., 2009).
Blots were viewed and analyzed using ChemiDoc XRS and
Quantity One software (Biorad, Hercules, CA, USA).
Cell proliferation
IGROV1 and OAW42 cells were plated into 96-well plates at a
density of 5 103 cells/well or 2.5 103 cells/well, respectively.
At 0, 24, 48, 72 and 96 h, mitochondrial activity was measured
using a CellTiter-Glo luminescent cell viability assay per-
formed according to the manufacturer’s instructions (Promega).
Analysis of promoter activity
Analysis of promoter activity was performed as described
(Tomassetti et al., 2008). Cells were transfected with a plasmid
containing the NFkB promoter–reporter gene construct
(Promega) using Lipofectamine 2000 (Invitrogen). At 24 h
after transfection, cells were inhibited with AG1478,
LY294002, UO126 and/or stimulated with EGF 20 ng/ml
(Peprotech). The dual-luciferase assay was performed as
suggested by the manufacturer (Promega).
IL-6 and PAI-1 co-expression in epithelial ovarian cancer
C Alberti et al
4147
Oncogene
Cyto/chemokines quantification in cell culture media
Conditioned media from IGROV1 cells was collected after 4, 8
and 24 h of EGF stimulation alone or together with AG1478
(20mM) or with the NFkB inhibitor DHMEQ (5 mg/ml). The
samples and an aliquot of the medium were analyzed in
duplicate. The assay was performed using the Procarta
cytokine kits on the Luminex platform (Affimetrix, Santa
Clara, CA, USA) as described in the Supplementary Materials
and Methods.
RNA extraction and real-time RT–PCR analysis
Total RNA from cell lines was extracted using a commercial
kit (Amersham Bioscience-GE Healthcare, Piscataway, NJ,
USA). RT–PCR analysis was performed as described
(Degl’Innocenti et al., 2010).
siRNA treatment
Cells were transfected with 40 pmol/ml siRNA duplex against
EGFR mRNA (Smart Pool, Thermo Scientific, Dharmacon
Inc, Chicago, IL, USA) or control siRNA (Quiagen-Xeragon,
Germantown, MD, USA). Transfection was performed
using Lipofectamine 2000, according to the manufacturer’s
protocol. Total RNA and lysates were prepared at 48 h after
transfection.
Bioinformatic and statistical analyses
Four publicly available data sets of gene expression generated
using the Affymetrix platform were downloaded from the web
(see Supplementary Table 3) (Bild et al., 2006; Anglesio et al.,
2008; Tothill et al., 2008; Berchuck et al., 2009) and their
characteristics are reported in the Supplementary Materials
and Methods. Before analysis, samples of data set I (GSE9899)
were filtered for ‘malignant’, primary site ‘ovary’ and
histological type ‘serous’, and the remaining 204 samples
were used. Data were normalized by the RMA algorithm.
Cross-hybridizing probes were filtered out and data were
collapsed on Gene Symbol using the median of probes. EGFR,
IL-6, SERPINE1 (the gene encoding for PAI-1, as named
herein) and IL-8 gene-expression intensities were extracted and
analyzed further. The Pearson correlation scores with the
related P-value (two-tailed) were computed for each gene pair.
Patients in data set I were categorized as expressing both IL-
6 and PAI-1 higher (n¼ 77) or lower (n¼ 78) than the
respective median and divided in ‘early’ (I and II, n¼ 15)
and ‘advanced’ (III and IV, n¼ 140) stages.
The survival analysis was performed in data set I by
considering only patients with both IL-6 and PAI-1 expression
intensities below the first (n¼ 22) and above the third (n¼ 28)
quartile. Progression-free survival (defined as the time
interval between the date of diagnosis and the first confirmed
sign of disease recurrence) was used as the primary end point.
Curves were generated with the Kaplan Meyer method, and
hazard ratios and 95% confidence intervals were also
computed.
GraphPad Prism 5 software (GraphPad Software, San
Diego, CA, USA), R statistical language version 2.10.0
(URL http://www.R-project.org) and Bioconductor (URL
http://www.bioconductor.org) were used for statistical tests.
The P-values of all statistical tests were two-sided; a Pp0.05
was considered significant. Significance of differences was
determined: for in vitro assays, by one- and two-way analysis
of variance and Student’s t-test when appropriate; for
association between categorical variables by Fisher’s exact
test; for survival analysis with a non-parametric (log-rank)
test.
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SUPPLEMENTARY DATA   
MATERIALS AND METHODS 
Cyto/chemokines quantification in cell culture media 
The plates were assayed for a total of human 51 targets: EGF, FGF basic, GCSF, GM-CSF, GRO 
alpha, HGF, IFN alpha, IFN beta, IFN gamma, IL-1 alpha, IL-1 beta, IL-1 ra, IL-2, IL-4, IL-5, IL-6, 
IL-7, IL-8, IL-10, IL-12 (p40), IL-12, (p70), IL-13, IL-15, IL-17A, IL-17F, ITAC, leptin, MCP-1, 
MCP-3, MCSF, MIG, MIP-1alpha, MIP-1 beta, MIP-3 alpha, PAI-1, PDGFBB, RANTES, SAA, 
sCD40 ligand, TGF beta, TGF alpha, TNF alpha, TNF beta, VEGF, MIF, SDF-1, sE-selectin, 
MMP-2, MMP-3, MMP-7, and MMP-9. Beads were washed and re-suspended with 50 µl of sample 
or standard. Standards and samples were incubated for 60 min with beads, which were then read in 
a Luminex instrument (Bio-Rad) that was calibrated prior to use using Bio-Rad calibration beads 
and Bioplex 5.0 software. The detection antibody mix was optimized for human cell culture 
samples. Limit of detection (LOD) was measured using the following method: the standard 
deviation of the blank was multiplied by 2, and that value was added to the mean fluorescence 
intensity (MFI) of the blank value. The resulting value was then compared to the MFI values of the 
standards using the last 3 points. Based on the curve of the 3 standard points, the LOD is calculated 
using the MFI value plus two standard deviations.  
IHC 
IHC on formalin-fixed, paraffin embedded sections was performed as follows after 
deparaffinization as described (Tomassetti et al., 2009). To block endogenous peroxidase, sections 
were incubated with 3% hydrogen peroxide solution for 10 min at room temperature. For EGFR 
staining, antigen retrieval was carried out in 1 mM EDTA buffer (pH 8) for 10 min at 95°C in a 
pressure-cooker and then left at room temperature for 30 min. Samples were incubated in blocking 
solution (5% BSA/TBS) for 40 min at room temperature. The primary rabbit polyclonal anti-human 
EGFR antibody was diluted 1:150. For IL-6 staining, antigen retrieval was carried out in 10 mM 
citrate buffer (pH 6) for 10 min at 95°C in a pressure-cooker, and then left at room temperature for 
30 min. Blocking solution was 10% BSA/TBS, 0.025% Tiron X-100 for 1 hr at RT. The primary 
rabbit polyclonal anti-human IL-6 antibody was diluted 1:400. For PAI-1 staining, antigen retrieval 
was carried out in 10 mM citrate buffer (pH 6) for 3 min at 120°C in a pressure-cooker, and then 
left at room temperature for 30 min. Blocking was carried out in 10% BSA/TBS, 0.1% Triton X-
100 for 30 min at room temperature. The primary rabbit polyclonal anti-human PAI-1 antibody was 
diluted to 3 µg/ml. Incubation with each of the primary antibodies was performed overnight at 4ºC, 
slides were then incubated for 30 min at room temperature with the secondary biotinylated 
antibodies diluted 1:200. Slides were washed with PBS and peroxidase activity was revealed by 
incubating sections in DAB (3-3diaminobenzidine) (DAKO, Denmark) for 5 min. After washing 
with water, sections were counterstained with Gill’s hematoxylin solution for 5 sec. 
In silico analysis of EOC datasets
Before analysis, samples of dataset I (GSE9899) were filtered for "malignant", primary site "ovary" 
and histological type "serous", and the remaining 204 samples were used. Samples of dataset II 
(GSE12172) (Anglesio et al., 2008), already normalized by RMA, were filtered for type 
“malignant”. The filtered dataset was composed of 60 samples. Dataset III (GSE3149) (Bild et al., 
2006) was normalized using the RMA algorithm. Outlier and anomalous samples were filtered out, 
and the remaining 132 samples were used for analyses. For dataset IV, the raw data were 
downloaded from http://data.genome.duke.edu/earlystageovc (Berchuck et al., 2009), borderline 
and anomalous samples were filtered out and the remaining 78 samples were used. The data from 
datasets I and II were produced using the Affymetrix HG-U133 Plus 2 arrays, and those from 
datasets III and IV with the Affymetrix HG-U133A arrays. 
LEGENDS TO SUPPLEMENTARY FIGURES 

Fig. 1. EGFR membrane staining was determined by flow cytometry on EOC cell lines. The gray 
and black peaks represent the fluorescence of the cells alone or incubated with an isotype matched 
unrelated antibody. The bold peaks represent the fluorescence of cells incubated with anti-EGFR 
antibodies. The numbers above the histograms represent the percentage of mean fluorescence 
intensity. B. IL-6 release was assayed by ELISA in media for 24 hr from EOC cells grown for 24 hr 
in medium supplemented with 10% FCS. C. Western blot analysis was performed on total cell 
lysates from IGROV1 and OAW42 cells. After 24 hr of serum starvation, cells were left untreated 
or treated with 20 ng/ml EGF alone from 5 min to 60 min. The antibodies used are indicated. -
actin is shown as a control for protein loading. A representative experiment of 3 is shown.
Fig. 2. A. Gene expression intensities of EGFR, IL-6, PAI-1, and IL-8 on dataset I for each of the 
204 cases; EGFR expression is reported on the right Y axis, and the others on the left Y axis. B. 
Correlation between IL-6 and PAI- was analyzed in EOC datasets II, III, and IV. The values are 
plotted as log2 scale. Pearson correlations (r), linear regression and P values are reported. 
Fig. 3. A. Distribution of IL-6 and PAI-1 levels in the EOC ascites containing tumor cells alone (open 
circle), together with immune cells (filled circle) or containing only immune cells (filled square).
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Supplementary Table 1. Characteristics of the EOC patients evaluated in the present study. 
Sample 
ID
Histotype Grading FIGO
a
Stage 
Presence of:
Tumor 
cells
b
Immune 
cells
b
Mesothelial 
cells
b
1 Serous G3 IV Abundant Absent Present 
2 Serous G3 IIIC Abundant Present Present 
3 Serous G3 IIIC Abundant Rare Present 
4 Serous G3 III Rare Abundant Present 
5 Serous G3 IIIC Abundant Abundant Abundant 
6 Serous G3 IIIC Present Present Present 
7 Serous G3 IIIC Rare Present Abundant 
8 
Serous and 
endometroid 
G3 IV Abundant Present Present 
9 Serous G3 IIIC Abundant Present Rare 
10 
Mullerian 
mixed 
NA IIIC Present Rare Abundant 
11 Serous G3 IIIC Rare Present Present 
12 Serous G2 IIIC Abundant Absent Present 
13 Serous G2 IIIC Abundant Present NA 
14 Serous G3 IIIC Rare Abundant Abundant 
15 Endometroid G3 IV Rare Absent Abundant 
16 Serous G3 IIIC/IV Present Abundant Abundant 
17 Serous G3 IV Abundant Present Rare 
18 Serous G3 IIIC Abundant Absent Absent 
19 Endometroid NA IIIC Present Absent Abundant 
20 Serous NA IIIC Abundant Abundant Rare 
21 Serous G3 IIIC Present Absent Present 
22 Serous G2/G3 IIIC Abundant Absent Rare 
23 Serous G3 IIIC Abundant Present Present 
  
a     Federation of Gynecologists and Obstetricians.  
b   The amount of cells present in ascites of EOC patients as defined by the cytopathologist at 
diagnosis.
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Supplementary Table 3. Characteristics of EOC gene expression datasets used  
Dataset Total
a
 I
b
 II
b
 III
b
 IV
b
 NA
c
I 204 9 9 168 17 0 
II 44 2 2 37 3 0 
III 132 3 4 103 20 2 
IV 41 0 0 31 10 0 
a   Number of patients 
b FIGO stage   
c  Not available
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Abstract 
Background: Epithelial ovarian cancer (EOC) is one of the most lethal gynecological cancers; the 
majority of EOC is the serous histotype and diagnosed at advanced stage. IL6 is the cytokine that 
has been found most frequently associated with carcinogenesis and progression of serous EOCs. 
IL6 is a growth-promoting and anti-apoptotic factor, and high plasma levels of IL6 in advanced 
stage EOCs correlate with poor prognosis. The objective of the present study was to identify IL6 
co-regulated genes and gene network/s in EOCs. 
Results: We applied bioinformatics tools on 7 publicly available data sets containing the gene 
expression profiles of 1262 EOC samples. By Pearson's correlation analysis we identified, in 
EOCs, an IL6-correlated gene signature containing 40 genes mainly associated with proliferation. 
33 of 40 genes were also significantly correlated in low malignant potential (LMP) EOCs, while 7 
genes, named C5AR1, FPR1, G0S2, IL8, KLF2, MMP19, and THBD were IL6-correlated only in 
advanced stage EOCs. Among the 40-gene signature EGFR ligand HBEGF, genes of the EGR 
family members and genes encoding for negative feedback regulators of growth factor signaling 
were included.  The results obtained by Gene Set Enrichment and Ingenuity Pathway Analyses 
enabled the identification, respectively, of gene sets associated with ‘early growth factor response’ 
for the 40-gene signature, and a biological network related to ‘thrombosis and cardiovascular 
disease’ for the 7-gene signature. In agreement with these results, selected genes from the 
identified signatures were validated in vitro by real time RT-PCR in serous EOC cell lines upon 
stimulation with EGF. 
Conclusions: Serous EOCs, independently of their aggressiveness, co-regulate IL6 together with 
genes associated to growth factor signaling, arguing for the hypothesis that common mechanism/s 
driven by EGFR ligands characterize both advanced-stage and LMP EOCs. Only advanced-stage 
EOCs appeared to be characterized by a scenario that involves genes which are so far associated 
with thrombosis and cardiovascular disease, thus suggesting that this pathway is implicated in the 
growth and/or spread of more aggressive tumors. We have discovered novel activated signaling 
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pathways that are possibly involved in the biology of EOC, which in the long term, might be 
successfully targeted with drugs. 
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Background 
Epithelial ovarian cancer (EOC) is the second most common and the most deadly malignancy of 
the female reproductive tract. Serous, endometrioid, clear-cell, and mucinous ovarian cancers are 
the four most common histotypes [1]. The majority of EOCs are diagnosed at stage III and IV 
when the tumor cells are spread in the peritoneum along with the presence of malignant ascites. 
The serous histotype accounts for about 80% of EOCs, and the majority show an inactivating 
mutation of the tumor suppressor gene TP53. Low malignant potential (LMP) serous EOCs are 
thought to arise by the transformation of tumors of borderline malignancy, and activating 
mutations in members of the RAS pathway (KRAS, BRAF, and ErbB2) are found in the majority of 
these tumors [2]. LMP EOCs show a relatively high growth capacity, are usually not invasive but 
resistant to conventional chemotherapy [1]. 
A number of studies suggest that factors related to the inflammation of the ovarian surface 
epithelium (OSE) such as ovulation, endometriosis, and pelvic inflammatory diseases are 
associated with an increased risk for EOC [3]. The most important hypothesis regarding EOC 
carcinogenesis is the ovulation theory, which relates the risk of ovarian cancer to incessant 
ovulation. Recently, it has been hypothesized that high grade serous ovarian cancer and 
endometrioid and clear cell cancers arise from the fallopian tube epithelium and share a common 
pathogenic mechanism, i.e., iron-induced oxidative stress derived from retrograde menstruation 
[4]. Both the incessant ovulation and oxido-reductive fallopian tube epithelial damage hypotheses 
have provided evidence that inflammatory responses induced under physiological conditions may 
foster the development of EOC. In accordance with these hypotheses of ovarian tumorigenesis, a 
number of cyto/chemokines has been found at detectable levels in ascites from EOC patients [5]. 
Among those molecules, IL6 is the cytokine that has been most frequently associated with EOC 
carcinogenesis and progression [6]. Preclinical evidence has shown that IL6 enhances tumor cell 
survival and increases resistance to chemotherapy via JAK/STAT signaling in tumor cells [7] and 
IL6 receptor alpha trans-signaling on tumor endothelial cells [8,9]. In addition, IL6 has pro-
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angiogenic properties [7], regulating immune cell infiltration, a stromal reaction, and the tumor-
promoting actions of Th17 lymphocytes [10]. In patients with advanced disease, high plasma 
levels of IL6 correlate with poor prognosis [11], and elevated levels are also present in malignant 
ascites [12]. Treatment of EOC cells with the anti-IL6 antibody (Ab) siltuximab has been shown to 
reduce constitutive cyto/chemokine production and inhibit IL6 signaling, tumor growth, the 
tumor-associated macrophage infiltrate, and angiogenesis in IL6–producing intraperitoneal 
ovarian cancer xenografts [13]. IL6 stimulates inflammatory cytokine production, tumor 
angiogenesis, and the tumor macrophage infiltrate in ovarian cancer and these actions can also be 
inhibited by a neutralizing anti-IL6 Ab in clinical studies [14]. However, further knowledge on 
IL6-expressing EOCs is needed to select patients who are possibly responsive to IL6-dependent 
therapies. 
We have recently found that IL6 can be co-expressed together with plasminogen activator 
inhibitor (PAI)-1, encoded by SERPINE1, in a subset of advanced stage serous EOCs due to the 
activation of the ligand-dependent EGFR/NFkB signaling cascade [15]. Ex vivo, using 23 EOC 
from advanced-stage patients with malignant ascites at surgery, we observed co-expression of 
EGFR, IL6, and PAI-1 in 57% of primary tumors, and concomitant expression of both IL6 and 
PAI-1 in the corresponding ascites. Computational analysis on four publicly available data sets of 
EOC gene expression showed a correlation between the expression of the IL6 and SERPINE1 
genes in advanced stage EOC patients, which in one case was associated with shorter progression-
free survival [15]. These results further highlight the involvement of IL6 in the progression of 
EOC. 
Herein, we utilized a bioinformatics approach described in the flowchart of Fig. 1 to identify in 
serous EOCs IL6 co-regulated genes and signaling pathway/s in which they are involved. First, we 
identified a list of genes representing a molecular signature for both advanced-stage and LMP 
serous EOC which recapitulate the so-called ‘early growth factor response’. We also identified an 
6 
 
IL6-correlated signature of seven genes involved in vascular thrombosis specific for advanced-
stage serous EOCs. 
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Results 
IL6 expression significantly correlates with a defined gene set in advanced stage serous 
EOCs. Pearson’s correlation analysis of seven data sets containing the expression profiles of 1262 
samples from serous EOCs (Table 1) was performed to identify genes whose expression was 
significantly correlated with IL6 expression in each data set. Correlation scores of each gene pair 
were computed using the R program essentially as described [16] [17] [18]. For genes represented 
by multiple probes in the same array format, the probe with the highest correlation to IL6 in the data set 
with the highest number of patients was chosen and considered for the other data sets when present 
(Additional file 1a). This analysis allowed the identification of genes whose expression positively 
correlated with IL6 along the seven data sets with a p-value ≤0.05 and a Pearson’s correlation 
coefficient (r) exceeding 0.4 (Additional file 1b). A further analysis across the seven data sets 
yielded 40 concordant correlated genes in at least four data sets (Additional file 1b and Fig. 2). Of 
note, 38 of 40 genes were correlated in data set I (204 samples) obtained with an Affymetrix 
platform, and in data set VII (110 samples) obtained with an Agilent platform. Among the 
identified IL6-correlated genes CXCL2, HBEGF, SERPINE1, DUSP1, ZFP36, and IER3 were 
common to all data sets. The correlation between IL6 and HBEGF, an EGFR ligand, and 
SERPINE1, encoding PAI-1, is in agreement with our previously published results on co-
expression of IL6 and PAI-1 in high grade EOCs due to EGFR activation [15]. The majority of 
genes are associated to the biological process ‘proliferation’ (50%) (Table 2). Among the genes 
associated with proliferation, there were a number of growth factor early response genes (EGR1, 
EGR3, NR4A1, FOSB, IER3). The IL6-correlated signature also included genes associated with 
‘inflammation’ (20%), and the remaining genes were associated with ‘cell cycle and apoptosis’, 
‘metabolism’ and ‘migration and invasion’. 
Thus, we identified a gene signature of IL6 correlated genes in serous EOC containing mainly 
proliferation-associated genes. 
Advanced stage EOC-specific IL6-correlated gene signature functionally associated with 
control of cell morphology and cardiovascular disease. Next, to determine whether the 
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identified gene signature was specific for advanced stage EOC or could also be associated with 
LMP EOC, Pearson’s correlation analysis to IL6 was applied to gene expression data of LMP 
EOCs reported in data sets I, II, and IV (see Table I). The density plot of IL6 intensities showed a 
similar trend of expression in advanced stage and LMP EOCs (Additional file 2). The data 
obtained comparing advanced stage EOCs and LMP EOCs were similar in the three data sets, and 
were more reliable (number of cases, genes identified, significance level) in data set I. Among the 
above identified advanced-stage EOCs IL6-correlated genes, 33 were also significantly correlated 
in LMP EOCs, while 7 genes (C5AR1, FPR1, G0S2, IL8, KLF2, MMP19, and THBD) were 
specific for advanced-stages only (Additional file 3). Among these genes, IL8 has already been 
associated with aggressiveness and progression of malignant EOC [19], while the others have not 
previously been associated with EOC biology and clinical outcome.  
To provide insight into the possible biological significance of the 40-gene signature, functional 
analysis of positively correlated genes (41, including IL6) was carried out by Ingenuity Pathway 
Analysis software (IPA) [20]. The top two functions (N1 and N2), associated with the highest 
score network, were ‘Cell death, cellular function and maintenance, hematological system 
development and function’ and ‘Cell death, cellular development, cellular growth and 
proliferation’ (Fig.3 and Additional file 4). When IPA analysis was performed on the seven-gene 
signature specific for advanced stage EOCs, the top function, associated with the highest score 
network, was ‘Cell morphology, cell function, cardiovascular disease’. As shown in Fig. 3 and 
listed in Additional file 4, all seven genes are included in this network (N3) together with genes 
already known to have a role in the progression of EOCs such as VEGF, the receptor tyrosine 
kinases EGFR and HER2, and the PI3K complex [1]. In addition to the input genes, it is 
noteworthy that IL6 is not present in the identified networks (Additional file 4), but when added 
manually to each network establishes a connection with some of the correlated genes (Fig. 3).  
The NFkB complex was included in networks N1 and N3 (Fig. 3), highlighting  its possible 
pivotal role in EOC progression.  
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It thus appears that two signatures are related to IL6 in EOCs: a 33-gene signature common to 
advanced stage and LMP EOCs and associated to control of cell growth and death, while the 7-
gene signature, associated only to advanced-stage EOCs likely presenting NFkB transcriptional 
activation, might be a determinant of tumor aggressiveness, and may be associated with a pathway 
regulating vascular thrombosis.  
An IL6-correlated gene set recapitulates the early growth factor response. To give further 
insight in the biology of EOCs expressing IL6, a GSEA [21] analysis was performed for each data 
set listed in Table 1. By the “use a gene (IL6) as phenotype” analysis, GSEA first ranks the genes 
according to their correlation to IL6. It then determines whether a priori defined set of genes, in 
this instance those belonging to the C2 curated catalogue of functional gene sets are randomly 
distributed throughout the gene list or primarily found at the top or bottom. Common significant 
gene sets obtained from GSEA analysis of the two largest data sets (I and VI) were selected and 
analyzed in the other datasets. This yielded 20 significantly enriched gene sets for all datasets. 
Normalized enrichment scores and FDR values in the different datasets are listed in Table 3. A 
literature search was conducted to identify signaling pathways previously implicated in the 
progression of EOCs and/or in epithelial–derived malignancies. Among the most significant gene 
sets, the BILD_KRAS_ONCOGENIC_SIGNATURE [22] which includes genes whose 
expression is induced by the activation of H-RAS oncogene, was originally derived from the 
herein named data set III and can be considered a positive control. Three additional gene sets, 
AMIT_EGF_RESPONSE_60_HELA, AMIT_EGF_RESPONSE_120_HELA [23] and 
NAGASHIMA_NRG1_SIGNALING_UP [24], were considered possible candidates of signaling 
pathways associated with EOC, and are associated with ‘growth factor response’. These gene sets 
comprise early response genes, i.e. the EGR family members, and the negative feedback 
regulators of the growth factor signaling, i.e. ZFP36 and KLF2. The fifth selected gene set, named 
KIM_WT1_TARGET_UP in some ways also recapitulates the growth factor response, since 
among WT1 target genes the EGF family ligands EREG, AREG, and HBEGF are included [25]. 
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Furthermore, among the WT1 target genes SERPINE1 was also identified in the same study. 
Enrichment plots related to the above described gene-sets in data set I are shown in Fig. 4. It is of 
note that IL6 is not included in the selected gene sets (Additional file 5) as well as other genes that 
are included in network 3 identified by analysis using IPA. Based on the results obtained by the 
above-described computational analysis and on our recent demonstration that IL6 is up-modulated 
in EOC cells upon EGF stimulation in time-dependent manner [15], in vitro validation of 12 genes 
selected from the IL6-correlated gene sets was performed with real time RT-PCR using total RNA 
from EGF-stimulated serous EOC cell lines (Fig. 5). The IL6 was up-modulated in all EOC cells 
analyzed upon EGF stimulation. Concordantly, 75%, 58%, and 75% of the gene transcripts were 
up-modulated in IGROV1, OAW42, and SKOV3 cells, respectively (Fig. 5). Among the 
correlated genes common to 7 data sets (see Fig. 2), CXCL2, HBEGF, SERPINE1, and DUSP1 
were increased in all three EOC cell lines analyzed. Additionally, NR4A1, a correlated gene in 6 
data sets, was up-modulated upon EGF stimulation in all EOC cells. THBD and KLF2 transcripts, 
associated with ’Cardiovascular disease’ by IPA analysis, were up-modulated in 2 of 3 EGF-
stimulated EOC cells. In contrast, the MMP19 transcript, whose relevant protein is associated with 
invasion and tumor progression [26], was not up-modulated in EGF-stimulated EOC cells. 
Interestingly, in non-transformed ovary cells, named IOSE- HTERT64 [27], although IL6 was 
slightly up-modulated by EGF stimulation, only 25% of the transcripts analyzed were up-
modulated. 
These data indicate that ligand-dependent EGFR activation in serous EOC cells induces the 
transcription of genes correlated with IL6 expression.   
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Discussion 
Microarray technology has developed very rapidly, and it has become relatively easy to analyze 
the expression levels of thousands of genes within cancer cells. However, genes do not act in 
isolation, and each acts in complexes and builds networks and activated pathways that ultimately 
give rise to a specific cell phenotype. Thus, the search of co-regulated genes applying 
bioinformatics approaches may spread light on the biology of a tumor and its development. 
Previously, by applying this kind of ‘in silico’ approach on gene expression profiles of ovarian and 
thyroid carcinomas [16] [17] and melanomas [18], we have been able to identify novel signaling 
pathways activated in those tumors. The present study, by applying similar bioinformatics tools, 
highlights possible novel signaling pathways activated in IL6-expressing EOCs. Among those, 
growth factor-dependent signaling was also experimentally validated in vitro in selected cellular 
EOC models. 
First of all, Pearson’s correlation analysis allowed the identification of genes co-regulated with 
IL6 in aggressive EOC providing evidence that co-regulated genes can encode proteins involved 
in common signaling pathways. To identify IL6-coregulated genes we adopted thresholds which 
allowed to obtain a good balance among the statistical significance, the strength of the correlation 
and the biological reproducibility. Furthermore, we performed the analysis on 7 different data sets, 
containing the gene expression profiles of more than 1200 EOC samples, obtained on different 
array platforms, to increase the robustness on the bioinformatics results. We found a gene 
signature common to both advanced stage and LMP serous EOCs, and another 7-gene signature 
specific for advanced stage EOCs. The integration of the results obtained by IPA and GSEA, 
allowed us to determine that all EOCs, independently of their aggressiveness, co-regulate IL6 
together with genes associated with cell growth and early growth factor response, arguing for the 
hypothesis of common mechanism/s of transformation. Only advanced-stage EOCs appeared to be 
characterized by a scenario that involves genes such as FPR1, KLF2 and THBD, to date 
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associated with thrombosis and cardiovascular disease, thus suggesting that this pathway 
contributes to the growth and/or the spread of this type of tumor.  
Although the IL6 gene was not associated with the networks identified by IPA or with the gene 
sets selected by GSEA, these results are in agreement with our previous observations in a subset of 
advanced stage EOC where ligand-dependent EGFR activation induced NFkB-dependent 
transcription of IL6 together with PAI-1, encoded by the SERPINE1 gene [15]. NFkB also 
emerged to be a possible transcriptional regulator of 13 out of 40 genes according to the reported 
informations [28], data which might further indicate that a growth factor-dependent NFkB 
signaling is activated in a subset of EOC. It is noteworthy that IL6 and 19 of the 40 correlated 
gene were found up-modulated upon 2 hr serum stimulation of quiescent keratinocytes [29]. We 
can therefore argue that the activation of growth factor activated signaling can either directly or 
indirectly induces the expression of IL6 and genes which likely play a role in the growth of EOCs. 
Furthermore, this growth factor-induced signaling pathway induces positive regulators of cellular 
function that are in turn regulated by negative feedback regulators such as ZFP36 and KLF2 [23]. 
The HBEGF gene, encoding for an EGFR ligand, was also highly significantly correlated in all 
seven data sets analyzed, indicating the prevalence of ligand-dependent EGFR activation. The 
regulation of growth factor signaling pathways by negative feedback is a universal mechanism for 
limiting the duration and intensity of signaling output. While negative feedback is a key 
component of normal cellular signaling, its role in cancer cells is more complex. Indeed, the loss 
of some negative feedback regulators might contribute to tumor progression, but might also be 
expressed at considerably higher levels in oncogene-mutant tumors as observed in BRAF-mutated 
melanomas [30]. Interestingly, the presence of a feedback negative mechanism has also been 
associated with greater efficacy of growth factor receptor-targeted therapy [31]. The fact that in 
EOC cells, with active EGFR/NFkB/IL6 signaling, EGFR-targeted therapy was more effective 
might be due to the up-regulation of feedback negative regulators of growth factor signaling [15]. 
Taken together, these data suggest that the IL6-associated signature might have a translational 
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impact helping to select EOC patients who are likely responsive to EGFR-targeted therapy. 
Experiments are now ongoing to verify this hypothesis. 
Nuclear expression of the Wilm’s tumor suppressor is found in OSE cells and in the majority of 
serous EOCs [32]. However, the corresponding gene, named WT1, has been never associated with 
IL6 gene expression. WT1 is required for kidney development, and the report in which the 
relevant gene set has been derived particularly emphasized the finding that the genes encoding the 
EGF family ligands EREG, AREG, and HBEGF may be transcriptionally regulated by WT1, 
orchestrating a fine-tuning of the EGF signaling pathway [25]. Altogether these observations 
support that the EGF signaling pathway is pivotal in the biology of EOC.  
The gene signature common to advanced stage serous and LMP EOCs is not unexpected if one 
considers the theory that LMP EOCs derive from serous low grade EOC with a borderline 
morphologic phenotype [33]. However, if this is the case, advanced-stage and LMP tumors might 
share common genetic alterations that induce aberrant growth. In addition, in vitro validation 
experiments performed on gene transcripts of non-transformed surface ovary cells argue for the 
notion that the signature associated with a growth factor response is not expressed and/or EGF-
dependent in normal ovary cells.  
The bioinformatics approach also produced hypothesis-generating results. The association of the 
7-gene signature with advance stage EOCs is novel. At present only angiogenesis-related genes 
and proteins, such as VEGF and its receptor, have a well documented role in EOC biology and are 
already well-exploited targets in the therapy of more aggressive EOCs [32]. Our findings open 
new questions on the role of genes associated with thrombosis and cardiovascular disease in the 
progression of EOCs. It has been recently hypothesized that low-dose aspirin as antithrombotic 
therapy may inhibit progression rather than the induction of EOC [34]. Indeed, aspirin and 
selective COX inhibitors could reduce progression not only by inhibiting prostaglandin 
production, thus reducing inflammation, but also by negatively modulating thrombosis-associated 
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genes. Therefore, the inhibition of both pathways synergistically might be an interesting approach 
to block the growth and dissemination of advanced stage EOCs.  
MMP19, a gene of the 7-gene signature specific for malignant EOCs and encoding the metallo-
protease (MMP) 19 was present in network 3 of IPA analysis, but was not in any of the gene sets 
selected by GSEA analysis. MMPs are key molecules of tumor cell invasion, including EOCs [35] 
and, since the majority of samples were advanced stage EOCs, MMP19 could be a new player in 
the dissemination of these tumors and experiments are now ongoing to test its presence and role in 
advanced stage EOCs.  
Conclusions 
By applying a bioinformatics approach we identified genes associated to IL6 expression in 
clinically-relevant subtypes of EOC, as well as how these genes interact in pathways and 
networks. The identified gene signatures unravel some cellular pathways associated to IL6-
expressing EOCs. One of those, the growth factor–dependent pathway, was also validated in vitro. 
In addition,  these pathways may represent important clues in the biology of EOCs as well as new 
pharmacological targets. 
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Methods 
Computational analysis. Seven EOC data sets, six arrayed on Affymetrix platforms and one on an 
Agilent platform, were analyzed (Table 1). Raw data of data sets I, II, and III [22,36,37] were 
downloaded from the NCBI Gene Expression Omnibus repository {23754} (IDs GSE9891, 
GSE12172 and GSE3149, respectively) and those of data set VI were downloaded from the 
proprietary repository [38]. Data sets IV and V [39,40] were downloaded from the Duke Institute 
website as suggested in the original publications. The raw data from Affymetrix were normalized 
through the RMA method using the Expression Console software developed by Affymetrix. Upon 
quality control, probes were annotated with the current annotation files (version 32) for the proper 
array format. Normalized data of data set VII [41], obtained on Agilent platform, were 
downloaded from GEO (ID GSE17260). 
For each data set, the expression data from serous histotype cases were selected. Since in all but 
one (IV), data sets the percent of cases at early stage (I-II) ranged from 0 to 10%, no stage 
selection was applied; in the case of data set IV, in which stage I and II represented 50% of case 
material, to avoid difficulty in comparison with the others, only advanced stages (III-IV) were 
selected. According to these selection criteria, we considered our overall case material to be 
composed of advanced stage EOC. Each data set was analyzed separately and the gene expression 
intensity of IL6, represented by a single probe in all the analyzed array formats, was correlated to 
the remaining probes across all EOCs samples in the array. The Pearson’s correlation coefficients 
(r) p and FDR values were calculated using cor, cor.test and p.adjust (using the Benjamini & 
Hochberg method) functions, respectively, from the Stats package in R programming language 
(version 2.12.0). For genes represented by multiple probes in the same array format, the probe 
with the highest correlation to IL6 in the data set with the highest number of patients was chosen 
and considered for the other data sets when present. Only genes exhibiting a p value ≤ 0.05 and r ≥ 
0.4 in at least 4 of the 7 data sets were considered significant (Additional file 1). In three studies (I, 
II and IV), serous LMP EOCs were also profiled and their expression data analyzed as described 
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above. Correlation values to IL6 corresponding only to the list of genes significant in advanced 
stage EOC were further considered (Additional file 1). IPA (Ingenuity Systems, 2012 release), a 
software leveraging a manually reviewed repository of biological interactions and functional 
annotations was used to analyze the signalling pathways, cellular location, function, network 
connections of the identified genes [20].  
Gene Set Enrichment Analysis (GSEA) (http://www.broad.mit.edu/GSEA)[21], was used to find 
whether a set of genes defined based on prior biological knowledge (e.g., those in a common 
signaling pathway) shows statistically significant correlations with IL6. Briefly, for each of the 
seven EOCs datasets, through the “use a gene as phenotype” option, GSEA ranks the genes 
according to their correlation with IL6. This ranked lists is then interrogated against gene sets 
contained within the C2 curated gene sets (c2.all.v3.0.symbols.gmt), a collection of 2516 gene sets 
that are part of the Molecular Signatures Database (MSigDB) v3.0 (12, 13). The primary GSEA 
result is the enrichment score (ES), which reflects the degree to which a gene set is 
overrepresented at either the top or bottom of the ranked list of genes. To estimate the statistical 
significance of the ES, a nominal p value is calculated by permuting the genes 1,000 times. The 
ES score is normalized to account for the gene set sizes (NES). Gene sets associated to a false 
positive rate (FDR) of less than 0.25 were considered significant.  
Reagents. Recombinant human EGF was from Peprotech. Taqman® Gene Expression Assays 
were from Applied Biosystems (Foster City, CA, USA) 
Ovarian cancer cell lines. SKOV3, IGROV1 (serous histotype) cell lines were obtained from 
ATCC and maintained in RPMI 1640 medium (Sigma Aldrich) with 10% fetal calf serum (FCS) 
(Hyclone, Logan, UT) and 2 mmol/L glutamine, in a 5% CO2 humidified atmosphere at 37°C. 
OAW42 (serous histotype, kindly provided by Dr. A. Ullrich, Max Planck Institute of 
Biochemistry, Martinsried, Germany) cells were cultured in MEM (Sigma Aldrich) and 
supplemented as above. IOSE-64 hTERT cells were maintained and prepared as described [27]. 
All cell lines used in this study were subjected to short tandem repeat (STR) analysis and the 
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profiles were compared to publically available databases to verify their authenticity. For the in 
vitro validation, a time course (up to 24 hr) with EGF stimulation was performed and IL6 
expression was monitored by real timer RT-PCR in order to assess the shorter time necessary to 
detect IL6 up-modulation. Based on this method IGROV1, OAW42 and IOSE 64 hTERT were 
EGF stimulated for 4 hr and and SKOV3 for 8hr. 
RNA Extraction and real time RT-PCR. Real time RT-PCR on selected IL6-correlated genes was 
performed on total RNA extracted from EOC cell lines stimulated for 4 hr (IGROV1 and OAW42 
cells) and 8 hr (SKOV3 cells) with EGF (20 ng/ml). Total RNA from cell lines was extracted 
using a commercial kit (Amersham Bioscience-GE Healthcare). RT-PCR analysis was performed 
as described [17]. Human GAPD (GAPDH) Endogenous Control (VIC/MGB Probe) (RefSeq 
NM_002046.3) was used as housekeeping gene for normalization among samples. The Taqman 
Assays used for amplification were: Hs00174131_m1 for IL6; Hs00236966_m1 for CXCL2; 
Hs00181813_m1 for HBEGF; Hs01126604_m1 for SERPINE1; Hs00610256_g1 for DUSP1; 
Hs00185658_m1 for ZFP36; Hs00174674_m1 for IER3; Hs00171851_m1 for FOSB; 
Hs00374230_m1 for NR4A1; Hs00166165_m1 for EGR2; Hs00275699_ for MMP19; 
Hs00264920_s1 for THBD; Hs003604396_g1 for KLF2 (Applied Biosystems). Data analysis was 
performed by the Sequence Detection System (SDS) 2.2.2 software (Applied Biosystems).   
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FIGURES 
Figure 1. Flowchart describing the analysis workflow. 
Figure 2. Heatmap of IL6-correlated genes. The heatmap of Pearson’s correlation coefficient (r) of the 
genes with IL6 was drawn by using R programming language. The r scores are represented in grayscale as 
reported in the color key. IL6 self-correlation was artificially set to the maximum score. Correlation score 
below 0.4 were considered not significant (NS). Genes not spotted on the array were defined NA (not 
available). The number of data sets in which the gene resulted significantly correlated with IL6 is reported 
on the right. 
Figure 3. Graphical representation of the top score networks identified by IPA. Molecular interactions 
between IL6-correlated genes in at least four data sets are reported. The top two networks (N1 and N2) 
were identified by loading all IL6-correlated genes in Fig. 1. Network 3 (N3) was identified by loading the 
7 IL6-correlated genes specific for advanced stage EOCs. IL6 (highlighted in blue) was manually added to 
each network. IL6-correlated genes are highlighted in red and the intensity indicates the number of data sets 
where the gene is correlated. The name of the network is reported below the graph. 
Figure 4. GSEA enrichment plots for the five gene sets enriched in EOCs. On the top of each plot, the 
name of the gene set is reported. For each gene set, the enrichment plot was extracted from the GSEA 
output results and each gene set showed significant enrichment in IL6 expressing advanced stage 
EOC (FDR Q value = 0.0; Fig. 3). Genes with higher expression in IL6-positive tumors have 
higher enrichment scores, and are therefore plotted on the left side of the graph, whereas those 
with lower expression in IL6-positive tumors have lower enrichment scores and are plotted on the 
right side of the graph. The bottom portion of the plot shows the value of the ranking metric 
moving down the list of ranked genes. A positive ranking metric indicates that a gene is correlated 
with the IL6 positive phenotype.The results from dataset 1 are reported. 
Figure 5. In vitro validation of selected IL6 correlated genes. Real time RT-PCR on selected IL6-
correlated genes was performed using total RNA of starved EOC cell lines untreated (white bars) or treated 
(grey bars) for 4 hr (IGROV1, OAW42 and IOSE 64 hTERT) or 8 hr (SKOV3) with EGF (20 ng/ml). The 
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number of data sets in which the gene resulted significantly correlated with IL6 is reported on the bottom. 
Data are mean values (± SD) presented as relative expression normalized for GAPDH mRNA levels. 
Asterisks indicate significant positive variations (Student’s t test).  
 
Additional files 
Additional file 1. Table containing: a.Selected probe sets for each platform; b. IL6-correlated 
genes in serous high malignant EOCs. 
Additional file 2. Figure reporting IL6 distribution (density plot) in the three data sets containing 
expression data of both advanced stage (204, 60 and 40 patients in data set I, II and IV, 
respectively) and LMP (18, 30 and 19 patients in data set I, II and IV, respectively) EOCs. 
Additional file 3. Table reporting IL6-correlated genes in serous advanced stage and LMP EOCs 
from data set I. 
Additional file 4. Table reporting the networks identified by IPA software. 
Additional file 5. Table reporting IL6-correlated genes included in each the gene sets selected by 
GSEA.  
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Table 1. List of EOC data sets of gene expression analyzed in the present study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data set ( ) Platform Array 
No. of 
probes 
N. of serous EOC patients 
Advanced 
stage 
LMP 
I [36] Affymetrix HG-U133 Plus 2 54675 204 18 
II [37] Affymetrix HG-U133 Plus 2 54675 60 30 
III [22] Affymetrix HG-U133A 22283 132 0 
IV [42] Affymetrix HG-U133A 22283 40 19 
V [39] Affymetrix HG-U133A 22283 118 0 
VI [40] Affymetrix HT_HG-U133A 22277 598 0 
VII [41] Agilent G4112A 41000 110 0 
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Table 2. Biological functions of the IL6-correlated genes. 
Gene Symbol Name 
Biological 
Function
a
 
IL6 interleukin-6   Inflammation 
CXCL2 chemokine (C-X-C motif) ligand 2 Inflammation 
HBEGF heparin-binding epidermal growth factor  Proliferation 
SERPINE1 plasminogen activator inhibitor 1  Motility/Adhesion 
DUSP1 dual specificity protein phosphatase 1   Proliferation 
ZFP36 tristetraprolin, zinc finger protein ZFP-36 Proliferation 
IER3 immediate early response 3  Proliferation 
FOSB AP-1 , fosB Proliferation 
NR4A1 TR3 orphan receptor, growth factor-inducible nuclear protein N10  Proliferation 
SOCS3 suppressor of cytokine signaling 3, cytokine-inducible SH2 protein 3  Inflammation 
EGR2 early growth response protein 2   Proliferation 
EGR3 early growth response protein 3   Proliferation 
SLC2A3 solute carrier family 2 (facilitated glucose transporter), member 3    Metabolism 
MMP19 matrix metalloproteinase-19   Motility/Adhesion 
KLF4 Krueppel-like factor 4  Proliferation 
ATF3 cyclic AMP-dependent transcription factor ATF-3  Proliferation 
RGS2 cell growth-inhibiting protein 31 , regulator of G-protein signaling 2   Proliferation 
EGR1 early growth response protein 1  Proliferation 
SOD2 manganese-containing superoxide dismutase, mitocondrial   Metabolism 
CYR61 cysteine-rich, angiogenic inducer, 61 ,  IGF-binding protein 10   Metabolism 
IL8 interleukin 8  Inflammation 
DUSP5 dual specificity protein phosphatase 5  Proliferation 
GADD45B growth arrest and DNA damage-inducible protein GADD45 beta  
Cell cycle 
control/Apoptosis 
TNFAIP3 tumor necrosis factor, alpha-induced protein 3 Inflammation 
FPR1 formyl peptide receptor 1, N-formylpeptide chemoattractant receptor  Inflammation 
CCL3 chemokine (C-C motif) ligand 3  Inflammation 
GFPT2 hexosephosphate aminotransferase 2   Metabolism 
NAMPT 
nicotinamide phosphoribosyltransferase, pre-B-cell colony-enhancing 
factor 1  
Metabolism 
NR4A3 
Mitogen-induced nuclear orphan receptor,  Nuclear hormone receptor 
NOR-1   
Proliferation 
GEM RAS-like protein KIR, GTP-binding mitogen-induced T-cell protein  Proliferation 
FOS AP-1, c-fos   Proliferation 
PPP1R15A growth arrest and DNA-damage-inducible 34  
Cell cycle 
control/Apoptosis 
CEBPD CCAAT/enhancer-binding protein delta,  Nuclear factor NF-IL6-beta  Inflammation 
THBD thrombomodulin  Motility/Adhesion 
KLF6 Krueppel-like factor 6  Proliferation 
RHOB rho-related GTP-binding protein RhoB   Proliferation 
KLF2 Krueppel-like factor 2   Proliferation 
IL1B interleukin 1, beta  Inflammation 
G0S2 G0/G1 switch regulatory protein 2   
Cell cycle 
control/Apoptosis 
C5AR1 complement component 5 receptor 1   Motility/Adhesion 
MCL1 bcl-2-like protein 3  
Cell cycle 
control/Apoptosis 
a Biological functions were defined using GeneALaCart tool [43].  
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Table 3. Significant IL6 correlated gene sets identified by GSEA analysis. 
 
NES, normalized enrichment score; FDR, false discovery rate. 
 
 
NES FDR q-val NES FDR q-val NES FDR q-val NES FDR q-val NES FDR q-val NES FDR q-val NES FDR q-val
AMIT_EGF_RESPONSE_120
_HELA
2,31 0,00 1,99 0,02 2,06 0,00 1,92 0,04 2,06 0,00 2,26 0,00 1,78 0,04
AMIT_EGF_RESPONSE_60_
HELA
2,35 0,00 1,96 0,02 2,08 0,00 2,15 0,01 2,21 0,00 2,31 0,00 1,89 0,03
BILD_HRAS_ONCOGENIC_
SIGNATURE
2,53 0,00 2,04 0,01 2,25 0,00 1,92 0,04 2,36 0,00 2,51 0,00 2,17 0,02
DAUER_STAT3_TARGETS_UP 2,28 0,00 2,06 0,01 2,18 0,00 2,10 0,02 2,18 0,00 2,36 0,00 2,02 0,01
DAZARD_RESPONSE_TO_UV
_NHEK_UP
2,34 0,00 2,06 0,01 2,22 0,00 1,95 0,03 2,50 0,00 2,40 0,00 1,92 0,02
DIRMEIER_LMP1_RESPONSE
_EARLY
2,39 0,00 2,29 0,00 2,36 0,00 1,97 0,03 2,24 0,00 2,30 0,00 2,12 0,02
GERY_CEBP_TARGETS 2,38 0,00 1,92 0,03 2,35 0,00 1,88 0,04 2,41 0,00 2,56 0,00 2,08 0,01
GRAHAM_CML_QUIESCENT_
VS_NORMAL_DIVIDING_UP
2,43 0,00 2,05 0,01 2,21 0,00 1,98 0,03 2,24 0,00 2,47 0,00 2,03 0,01
HALMOS_CEBPA_TARGETS_
UP
2,35 0,00 1,91 0,03 2,14 0,00 1,89 0,04 2,05 0,00 2,34 0,00 1,92 0,02
KIM_WT1_TARGETS_8HR_UP 2,28 0,00 1,88 0,04 2,23 0,00 2,00 0,03 2,26 0,00 2,25 0,00 1,96 0,02
KIM_WT1_TARGETS_UP 2,38 0,00 1,93 0,03 2,26 0,00 1,93 0,04 2,40 0,00 2,51 0,00 2,04 0,01
MARZEC_IL2_SIGNALING_U
P
2,34 0,00 2,16 0,01 2,03 0,01 1,60 0,15 1,88 0,02 2,28 0,00 2,03 0,01
NAGASHIMA_NRG1_SIGNA
LING_UP
2,47 0,00 2,04 0,01 2,54 0,00 2,21 0,01 2,54 0,00 2,54 0,00 2,15 0,02
OSWALD_HEMATOPOIETIC_
STEM_CELL_IN_COLLAGEN_
GEL_DN
2,65 0,00 2,20 0,00 2,55 0,00 2,10 0,02 2,52 0,00 2,77 0,00 2,32 0,00
OSWALD_HEMATOPOIETIC_
STEM_CELL_IN_COLLAGEN_
GEL_UP
2,65 0,00 2,20 0,00 2,55 0,00 2,10 0,02 2,52 0,00 2,77 0,00 2,32 0,01
PICCALUGA_ANGIOIMMUNO
BLASTIC_LYMPHOMA_DN
2,47 0,00 1,94 0,03 2,12 0,00 1,95 0,03 2,28 0,00 2,25 0,00 2,00 0,02
SENESE_HDAC1_AND_HDAC
2_TARGETS_UP
2,41 0,00 1,88 0,04 2,04 0,01 2,00 0,03 2,07 0,00 2,62 0,00 2,16 0,02
SMIRNOV_CIRCULATING_EN
DOTHELIOCYTES_IN_CANCE
R_UP
2,30 0,00 2,03 0,01 2,45 0,00 2,13 0,02 2,26 0,00 2,43 0,00 1,96 0,02
THEILGAARD_NEUTROPHIL_
AT_SKIN_WOUND_UP
2,45 0,00 2,02 0,01 2,24 0,00 1,96 0,03 2,16 0,00 2,26 0,00 1,91 0,02
VART_KSHV_INFECTION_AN
GIOGENIC_MARKERS_UP
2,36 0,00 1,93 0,03 2,20 0,00 1,78 0,07 2,19 0,00 2,63 0,00 1,99 0,02
ZHANG_RESPONSE_TO_IKK_
INHIBITOR_AND_TNF_UP
2,27 0,00 2,13 0,01 2,22 0,00 1,87 0,04 2,21 0,00 2,37 0,00 1,96 0,02
GENESETS
VIII II III IV V VI
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IL6 7 205207_at 205207_at 205207_at A_23_P71037
CXCL2 7 209774_x_at 209774_x_at 209774_x_at A_23_P315364
HBEGF 7 203821_at 203821_at 203821_at A_24_P140608
SERPINE1 7 202628_s_at 202628_s_at 202628_s_at A_24_P158089
DUSP1 7 201041_s_at 201041_s_at 201044_x_at A_23_P110712
ZFP36 7 201531_at 201531_at 201531_at A_23_P39237
IER3 7 201631_s_at 201631_s_at 201631_s_at A_23_P42257
FOSB 6 202768_at 202768_at 202768_at A_23_P429998
NR4A1 6 202340_x_at 202340_x_at 202340_x_at A_23_P128230
SOCS3 6 206359_at 206359_at 206359_at A_23_P207058
EGR2 6 205249_at 205249_at 205249_at A_23_P46936
EGR3 6 206115_at 206115_at 206115_at A_23_P216225
SLC2A3 6 202499_s_at 202499_s_at 202499_s_at A_24_P81900
MMP19 6 204575_s_at 204575_s_at 204575_s_at A_24_P184445
KLF4 6 221841_s_at 220266_s_at 221841_s_at A_23_P32233
ATF3 5 202672_s_at 202672_s_at 202672_s_at A_23_P34915
RGS2 5 202388_at 202388_at 202388_at A_23_P114947
EGR1 5 201693_s_at 201694_s_at 201693_s_at A_23_P214080
SOD2 5 215078_at 215078_at 215078_at A_24_P935819
CYR61 5 210764_s_at 201289_at 210764_s_at A_23_P46426
IL8 5 202859_x_at 202859_x_at 202859_x_at A_32_P87013
DUSP5 5 209457_at 209457_at 209457_at A_23_P150018
GADD45B 5 207574_s_at 207574_s_at 209305_s_at A_24_P239606
TNFAIP3 5 202644_s_at 202644_s_at 202643_s_at A_24_P157926
FPR1 5 205119_s_at 205119_s_at 205119_s_at A_23_P38795
CCL3 4 205114_s_at 205114_s_at 205114_s_at A_23_P373017
GFPT2 5 205100_at 205100_at 205100_at A_23_P144916
NAMPT 4 217739_s_at 243296_at 217739_s_at NA
a
NR4A3 4 209959_at 209959_at 209959_at A_23_P398566
GEM 4 204472_at 204472_at 204472_at A_23_P257043
FOS 4 209189_at 209189_at 209189_at A_23_P106194
PPP1R15A 4 37028_at 37028_at 37028_at A_23_P90172
CEBPD 4 213006_at 213006_at 213006_at A_23_P31810
THBD 4 203887_s_at 203887_s_at 203887_s_at A_23_P91390
KLF6 4 208961_s_at 224606_at 208960_s_at A_23_P63798
RHOB 4 212099_at 212099_at 212099_at A_23_P51136
KLF2 4 219371_s_at 219371_s_at 219371_s_at A_23_P119196
IL1B 4 39402_at 39402_at 39402_at A_23_P79518
G0S2 4 213524_s_at 213524_s_at 213524_s_at A_23_P74609
C5AR1 4 220088_at 220088_at 220088_at A_23_P153562
MCL1 4 200797_s_at 214056_at 214056_at A_24_P336754
III, IV, V I, II VI VII
Additional file 1a. Selected probe sets for each platform.
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Data set I Data set II
Data set IV
Additional file2
r p value r p value
IL6 7 1 0 1 0
CXCL2 7 0,644456742 0 0,697061814 0,001304437
HBEGF 7 0,633236241 0 0,746049768 0,000377708
SERPINE1 7 0,617885675 0 0,727385502 0,000624219
DUSP1 7 0,616057037 0 0,675458685 0,002095758
ZFP36 7 0,602872198 0 0,804934823 5,60E-05
IER3 7 0,457370363 6,11E-12 0,615046491 0,006595854
FOSB 6 0,612878984 0 0,694288987 0,001389343
NR4A1 6 0,608438009 0 0,78682387 0,000107134
SOCS3 6 0,602119838 0 0,694178984 0,001392803
EGR2 6 0,589618707 0 0,800376807 6,63E-05
EGR3 6 0,545444523 0 0,733305623 0,000534605
SLC2A3 6 0,532251177 2,22E-16 0,696150061 0,001331866
MMP19
 a 6 0,486497665 1,62E-13 0,286460466 0,249135082
KLF4 6 0,460453533 4,23E-12 0,760981555 0,000244923
ATF3 5 0,59109885 0 0,705256847 0,001078276
RGS2 5 0,523498505 8,88E-16 0,496895958 0,035920545
EGR1 5 0,500293907 2,55E-14 0,624864798 0,005561011
SOD2 5 0,491615639 8,24E-14 0,627796331 0,005279035
CYR61 5 0,483189771 2,49E-13 0,682254573 0,001812845
IL8 5 0,478566297 4,50E-13 0,342656402 0,163931736
DUSP5 5 0,470635954 1,22E-12 0,740398416 0,000441677
GADD45B 5 0,450745623 1,33E-11 0,826460171 2,36E-05
TNFAIP3 5 0,426642256 1,98E-10 0,414811504 0,086958934
FPR1 5 0,419782692 4,11E-10 0,011874577 0,962701286
CCL3 5 0,410205953 1,11E-09 0,6581332 0,00298543
GFPT2
 b 5 0,388844059 9,06E-09 0,194385482 0,439570915
NAMPT 4 0,635895421 0 0,793260281 8,57E-05
NR4A3 4 0,578948177 0 0,67169717 0,002267398
GEM 4 0,523546652 8,88E-16 0,65882084 0,00294502
FOS 4 0,51419416 3,55E-15 0,627368969 0,005319402
PPP1R15A 4 0,500620422 2,44E-14 0,717907297 0,000793704
CEBPD 4 0,500141632 2,60E-14 0,870239801 2,67E-06
THBD 4 0,485757602 1,78E-13 0,161729988 0,521428838
KLF6 4 0,464399685 2,62E-12 0,751280185 0,000325625
RHOB 4 0,45930097 4,86E-12 0,72703803 0,000629847
KLF2 4 0,4672555 1,85E-12 0,359700306 0,142615452
IL1B 4 0,451260825 1,26E-11 0,509916869 0,030629039
G0S2 4 0,436132869 7,01E-11 -0,24941141 0,318237531
C5AR1 4 0,411525245 9,67E-10 0,323428665 0,19046521
MCL1 4 0,347545245 0,000000352 0,599949083 0,008486538
aGenes specifically correlated in advanced stage EOCs are in bold. bGFPT2 gene correlated to IL6 in data sets III-VII.
Additional file 3. Comparison of IL6-correlated genes in serous and LMP EOCs in data set I.
Gene Symbol Common to:
Serous EOC
Advanced Stage LMP
ID Molecules in Network Score
Focus 
Molecules
Top Functions
N
b
1
CCL3, CXCL2, DUSP5, EGR1 ,elastase, ETS, Fcer1, G0S2, 
GADD45B, GFPT2, HLA-DR, IER3, Ifn gamma, JINK1/2, 
KLF2, lymphotoxin-alpha1-beta2, N-cor, NAMPT, NFAT 
(complex), Nfat (family), NFkB (complex), NFkB (family), Nos, 
Notch, Nr1h, Pdgf Ab, PDGF BB, PEPCK, Rar, RHOB, Rxr, 
Serine Protease, Sod, TCR, THBD
24 12
Cell Death, Cellular Function 
and Maintenance, 
Hematological System 
Development and Function
N2
Alp, ATF3, Cebp, CEBPD, Collagen(s), cyclooxygenase, 
DUSP1, ERK1/2, Fc gamma receptor, Fcgr3, Fibrin, FOSB, 
Gm-csf, GOT, Growth hormone, hexokinase, IFN Beta, IgG1, 
IgG, IL1, IL8, IL12 (complex), Immunoglobulin, KLF4, LDL, 
MHC Class II (complex), PPP1R15A, SAA, SERPINE1, 
SLC2A3, SOCS3, SOD2, Tlr, TNFAIP3, TSH
24 12
Cell Death, Cellular 
Development, Cellular 
Growth and Proliferation
ID Molecules in Network Score
Focus 
Molecules
Top Functions
N1
1,4-glucan, Akt ,BPI, C5AR1, Egfr-Erbb2, ERK1/2, Focal 
adhesion kinase, FPR1, FPR, G protein, G0S2, hCG, HTR7, 
IL1, IL8, IL12 (complex), IL36G, KLF2, lauric acid, LPAR2, 
LPAR3, Mapk, MMP19, NFkB (complex), NTSR1, P2RY6, 
PI3K (complex), PLC, PROK1, SENP6, THBD, Tlr11, Tlr12, 
Vegf, ZNF300
21 7
Cell Morphology, Cellular 
Function and Maintenance, 
Cardiovascular Disease
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Additional file 5. IL6-correlated genes included in each the gene sets selected by GSEA.
